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ABSTRACT
The purpose of this project was to examine and optimise the 
production and application of bispecific antibodies. A bispecific antibody is 
an im m unoglobulin-derived molecule which binds monovalently to two 
distinct antigens. It can be produced using somatic cell fusion techniques or 
by chemical m anipulation of the parental immunoglobulin molecules.
Bispecific antibodies were produced from two different species of 
im m unoglobulin, hum an im m unoglobulin and mouse im m unoglobulin 
or rabbit immunoglobulin and mouse immunoglobulin. These were 
characterised using high performance liquid chromatography, poly­
acrylamide gel electrophoresis and enzyme-linked immunosorbent assays 
based on both parental species differences and double antigen specificity. 
The bispecific antibody was produced at 70% of total potential yield. 
Antigen specificity was retained but binding affinity was reduced by 30-50% 
compared to parental molecules.
A rabbit, polyclonal anti-alkaline phosphatase antibody was 
produced. This antibody was used, in conjunction with a murine, 
monoclonal anti-chronic lymphocytic leukaemia antibody (G12), to produce 
a bispecific antibody. The bispecific antibody was characterised, as before, 
following purification by double affinity chromatography. The bispecific 
antibody was used to develop a suspension and a plate enzyme-linked 
immunosorbent assay for the detection of the hum an leukaemic cell line, 
K562. These assays were used to detect chronic lymphocytic leukaemic cells 
in patient blood samples. A positive diagnosis was made in 80-90% of 
known chronic lymphocytic leukaemic patients. The same anti-chronic 
lymphocytic leukaemia X anti-alkaline phosphatase bispecific antibody was 
used in immunocytochemical studies of the same patients blood samples, 
with a positive response of 75-85%.
A second bispecific antibody was produced from the rabbit, polyclonal 
anti-alkaline phosphatase antibody and a rabbit, polyclonal anti-7-hydroxy 
coumarin antibody. This was characterised, as before, following 
purification by double affinity chromatography. The anti-7-hydroxy 
coumarin X anti-alkaline phosphatase bispecific antibody was used, with 
limited success, to develop an enzyme-linked immunosorbent assay for the 
quantitation of 7-hydroxy coumarin.
Studies on the Production and Applications of Bispecific Antibodies
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1.1 ANTIBODIES
1.1.1 The Immune Response:
When an animal encounters an antigen (Ag) either by infection or by 
deliberate injection, antibodies (Ab) are produced which appear in the 
serum. They are produced by the B-lymphocytes, primarily in the spleen. 
Structurally, Ab are proteins of the globulin class and, hence, are often 
referred to as immunoglobulins (Ig). In man, five classes of Ig have been 
identified on the basis of structural differences, not related to their 
specificity to Ag. These are; IgA, IgD, IgE, IgG and IgM (Table 1.1.1). After 
exposure to Ag, a period of 7-10 days elapses before specific Abs appear in 
the serum, reaching a peak at 14-21 days, after which levels fall. This 
response to the Ag is called the primary response, the Abs produced are 
generally of the IgM class. Following a second exposure to Ag, the levels of 
Ab in the serum begin to rise in 2-3 days and subsequently reach levels in 
excess of those achieved in the prim ary response. This accelerated response, 
termed the secondary response, is the result of stimulation of the Ab- 
forming cells of the immune system which had been sensitised by prior 
exposure to Ag. The Ab produced in the secondary response is generally 
IgG. IgG is quantitatively the most important serum Ig (Table 1.1.1) and its 
major function is to neutralize toxins, viruses and to bind to and opsonize 
bacteria (Steward, 1984; Abbas et al., 1991).
The basic structure of the Ab consists of two light chains and two 
heavy chains and has a relative molecular mass of 150-160kDa (Fig. 1.1.1). 
Ab binds to Ag at a binding site located at the -NH2 region of the light and 
heavy chains. Both heavy and light chains can be divided into variable and 
constant regions. Within the variable region there are certain areas which 
are highly conserved and provide a backbone for the structure. There are 
also hyper-variable areas called complementarity determining regions 
(CDR) which are involved in defining the binding specificity of the Ab. Ab 
fragments, e.g. F(ab')2  and Fab', may be produced by enzymatic cleavage and 
by genetic engineering (Fig. 1.1.1). These can have advantages over the 
whole molecule in certain applications, particularly where reduced 
immunogenicity is important. The constant regions (Fc) of the Ab are 
involved in binding to cell surface receptors. They contain carbohydrates 
and have important physiological roles (Steward, 1984; Abbas et al, 1991).
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Antibody Type Antibody
Subtypes
% Total Serum 
Antibody
Molecular 
Weight (kDa)
IgA IgAl 16 150, 300 or 400
IgA2 3 150, 300 or 400
IgD N one Trace 180
IgE N one Trace 190
IgG IgGl 47 150
IgG2 16 150
IgG3 5 150
IgG4 3 150
IgM N one 8 950
Table 1.1.1:
Hum an antibody isotypes: the five classes of immunoglobulin and 
their relevant sub-classes, based on structural differences. The relative 
amount of each sub-class found in hum an serum is quoted as a percentage 
of total serum immunoglobulin. The molecular weight of the secretory 
form is also noted. (Multimeric forms of IgA exist which are associated via 
the tail piece region of the heavy chain.)
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Figure 1.1.1:
The basic structure of an antibody. An antibody consists of heavy and 
light chains which are joined by disulphide linkages. The antibody can be 
further divided into variable (V) and constant (C) regions. CHi, CH2, CH3 
and CH4 refer to various constant domains. The com plim entarity
determ ining regions (CDR) are the hyper-variable regions within the 
variable regions and are primarily responsible for antigen binding. The 
antibody can be broken down into fragments by treatment with the 
enzymes pepsin and papain. Two antigen binding fragments (Fab) of the 
IgG, containing one antigen binding site each, and one crystallisable
fragment (Fc) are produced by papain digestion of the IgG. The antigen 
binding fragment (F(ab')2 ) of the IgG, containing two antigen binding sites, 
is obtained by pepsin digestion of the IgG. The heavy chain fragments
remaining after pepsin digestion are called Fc' fragments.
1 3
1.1.2 Antibody Production:
Ab of defined specificity can be produced by injecting an animal with 
the Ag of interest and subsequently collecting the blood. A molecule is 
defined as being immunogenic if it elicits a complete immune response in 
the host. Immunisation with a single Ag yields polyclonal antiserum, i.e. 
serum containing high titres of Ab specific to the Ag, but being produced by 
a number of B-cell clones. Some Ags fail to elicit a response and a particular 
Ag may provoke a much greater response than would another Ag. This is 
referred to as the antigenicity of the molecule. Proteins and large molecules 
are capable of eliciting good immune responses, with the aid of adjuvants 
(immune stimulants), but small peptides and other molecules with a 
relative molecular mass of less than 5kDa (often called haptens) are often 
too small to be immunogenic. Carrier proteins are frequently bound to 
these small molecules to increase their immunogenicity. Carrier proteins 
used include bovine serum albumin (BSA), keyhole limpet haemocyanin, 
thyroglobulin and many others. The use of adjuvants is often necessary in 
order to maximise the immune response to immunisation. Adjuvants 
non-specifically stimulate an immune response by causing local irritation 
leading to an inflammatory response. Large numbers of immune effector 
cells are attracted to the site of the injection. The Ag, which is emulsified in 
the adjuvant, is released slowly to give a prolonged exposure to the 
immune system, allowing a strong immune response to be generated. The 
most commonly used adjuvants are Freund's complete and incom plete 
adjuvants, (Foster, 1982; Steward, 1984; Abbas et al., 1991; O'Kennedy et 
al., 1994).
Although a number of species have been used, New Zealand white 
rabbits are probably the best animals to use for polyclonal Ab production. 
They are cheap, easy to handle for immunisation and bleeding purposes, 
and the housing required is a lot less than for larger animals. In general, 
the amount of Ag required to elicit an immune response is quite small. 
Typically an animal is immunised with 1 ml of a 0.1-4 m g/m l solution of 
Ag, made up in adjuvant, at intervals of 2-4 weeks. Ag may be injected at 
several sites; subcutaneously (sc), intram uscularly (im), intravenously (iv) 
or intradermally (id). Multi-site injections offer the advantage, over single­
site injections, of presenting the Ag at several sites. Two weeks after the 
second immunisation the animal can be bled and the antiserum Ab levels 
measured. Antiserum Ab levels can be detected quantitatively by enzyme 
linked immunosorbent assay (ELISA) or qualitatively by immuno-histo- 
chemistry, im m uno-diffusion and immuno-electrophoresis. If a 
satisfactory immune response has been obtained, the serum may be purified
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for the specific Ab. Purification can be carried out in a number of ways, e.g. 
on affinity chromatography columns to which the Ag has been coupled. 
Milligram quantities of purified Ab may be obtained from a small volume 
(20ml) of serum. Polyclonal Ab production is often the most practical 
means of obtaining large quantities of Ab. They can be synthesised quickly 
and relatively cheaply and do not require the amount of time and level of 
expertise associated with the production of monoclonal antibodies, (Foster, 
1982; Steward, 1984; Abbas et al, 1991; O'Kennedy et al, 1994).
1.1.3 Monoclonal Antibodies:
The technique of producing unlimited quantities of a single Ab 
specific for a particular antigenic determinant has revolutionised 
immunology. This technique is based on the fact that Ab from a given 13- 
cell are homogenous in structure, specificity and affinity. Therefore, a 
monoclonal tumour derived from a B lymphocyte, called a myeloma, will 
produce only one Ab. Myeloma-derived homogenous Abs have proved 
invaluable in elucidating the structure of Ig proteins. However, most 
myelomas secrete Abs of unknow n antigenic specificities, because these 
tum ours arise spontaneously and it is not possible to predict me specificity 
of any randomly transformed clone of B-cells. Many attempts have been 
made to produce homogenous or monoclonal Abs of known specificity. 
Since normal B lymphocytes cannot grow indefinitely in culture, such 
attempts have focused on immortalising B-cells that produce a specific Ab. 
The first, and now generally used, technique for doing this was described by 
Kohler and Milstein in 1975. The method involves cell fusion, or somatic 
cell hybridisation between a normal Ab-producing B-cell and a non-Ab- 
secreting myeloma cell line. These cells can be fused using polyethylene 
glycol or by electrical methods. This is followed by selection of fused cells 
which secrete Ab of the desired specificity derived from the normal B-cell. 
Such fusion-derived, immortalized, Ab-producing cell lines are called 
hybridomas, and the Ab they produce are monoclonal antibodies (MAb), 
(Foster, 1982; Steward, 1984; Abbas et al, 1991).
MAbs produced in this m anner can be analysed and characterised in 
ways not possible with polyclonal Abs. Both heavy and light chains can be 
classified and sequenced, the nature and function of each of the variable 
and constant regions can be determined. Ag binding occurs at the point 
where the variable region of the heavy chain (Vh ) lies adjacent to the 
variable region of the light chain (Vl ). The actual Ag binding site is 
thought to be a cleft in the three-dimensional structure of the Ab lined by
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loops of amino acid residues which form the hypervariable regions or 
complimentarity determining regions (CDR). X-ray crystallographic 
evidence suggests a canonical structural model for the CDRs. This model 
suggests that there exists a small repertoire of main-frame conformations, 
determined by a few residues in the amino acid sequence. Changes in the 
sequence at a few specific sites causes a shift in the loops, with respect to 
each other, by small but significant amounts. Each sequence change, or 
combination of changes, creates a different main-frame conformation, of 
which a limited number exist. Sequence changes at other sites cause 
variations in loop length and conformation. Differing patterns of loop 
sizes, combining with the effect of sequence diversity, alter the topography 
of the variable regions and generate a multitude of Ag specificities (Chotia 
et al, 1989; Thornton, 1990; Williams et al, 1990; Abbas et al.,1991; Roitt et 
a l, 1993).
Thus, while the framework residues are essential for the correct 
folding of the V region and the maintenance of the integrity of the binding 
site, only a small number of residues (10-12) actually interact with the Ag. 
CDRs form the Ag contact site and the chemical nature of the amino acids 
involved is citical in determining binding strength and specificity. Binding 
occurs with the formation of multiple non-covalent bonds, primarily 
hydrophobic interactions, but also hydrogen bonding, electrostatic 
attractions and Van der Waals forces. These bonds are w eak individually, 
but can combine to give high energy binding. The strength of the bond 
formed is determined by the bond type and the distance between the amino 
acid residues involved. An Ag is said to be complimentary to an Ab if it has 
the correct 'shape', i.e. amino acid grouping, to fit the binding site. A high 
level of complimentarity would imply that a large num ber of non-covalent 
bonds form at once. These are then strong enough to overcome the steric 
repulsion created by the electron clouds around the two molecules. 
Variation from the ideal shape does not mean that binding cannot occur. 
Recent evidence suggests that Abs show conformational changes in  
response to Ag binding. This can occur through rearrangement of the side 
chains or CDR loops or through changes in the disposition of the V h  and 
V l  domains with respect to each other. X-ray crystallography of Fab 
fragments, both free and Ag bound, indicate a relative displacement of the 
variable domains on binding to Ag. It is thought that the flexible,linker 
region between the variable and constant domains can rotate to improve 
the 'fit' of the Ag at the binding site (Bhat et al, 1990; Roitt et al, 1993; 
Stanfield et al, 1993).
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The physico-chem ical characteristics of the A b-A g in teraction can be 
determ ined  once a dynam ic equilibrium  has been  established. The reaction 
of the Ab w ith  A g to produce a com plex (Ab-Ag) can be represen ted  as 
follow s:
ka
Ab + A g ■' ■ ■ — Ab-Ag 
kd
w here  ka rep resen ts the association constan t (or attractive forces) an d  kd 
represen ts the dissociation constan t (or repulsive forces). The tendency of 
an  Ab to form  stable com plexes w ith  A g is called the affinity. The streng th  
of this in teraction is the sum  of all the attractive an d  repulsive forces acting 
at the b ind ing  site, i.e. k a + kd- At low  concentrations of Ab the form ation  
of A b-A g com plexes depends o n  the  concentration  of A g and  the s tren g th  of 
the interaction. The m olar concen tra tion  of A g w hich  allow s half the  Ab 
co n cen tra tio n  to com plex is tak en  as a m easure  of the affinity of the 
interaction. The low er the concen tra tion  of A g requ ired  to reach  half­
m axim um  occupancy of the Ab, the h igher the affin ity  of the Ab for the Ag. 
The affinity constan t is no rm ally  in  the  range 10"^M to 10" ^ M . This holds 
true  for single b in d in g  sites. H ow ever, w ith  m ultip le  b ind ing  sites, the 
s treng th  of the in teraction  increases geom etrically  w ith  each b ind ing  site. A 
low  affinity m olecule m ay  b in d  tightly  to a m ultivalen t Ab since m ultiple, 
low  affinity in teractions can com bine to p roduce  a single h ig h  s tre n g th  
bond. This is called the av id ity  of the in teraction. (Abbas et a l, 1991; Roitt et 
al., 1993) Thus, an  exact m easu rem en t of Ab affinity  is no t alw ays possible. 
H ow ever, m easu rem en t of the am o u n t of A g b o u n d  to Ab a t equilibrium  
can give an  index on  w hich  to com pare the b in d in g  s treng th  of a num b er of 
sim ilar Abs. This can be particu larly  usefu l w h en  screening a num b er of 
M Abs o r M Ab conjugates fo r use  in  im m uno-d iagnostics , im m uno- 
th e rap eu tics  o r im m u n o -assay  developm en t.
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1.1.2 Bispecific Antibodies:
M urine, h u m an  and  chim eric M Abs are cu rren tly  being  used  for the 
trea tm en t of au to im m une disease, graft rejection, infectious diseases, 
clotting d isorders and  cancer. M urine  M Abs have b een  useful, bu t h a v e  
been  show n  to have several draw backs, particu larly  in  the area of 
im m u n o th erap y  (R eading & Bator, 1988). One of the m ain  lim iting factors 
encoun tered  w ith  the use of M A bs in  th e rap y  is the developm ent of 
h u m an  anti-m ouse Ab (HAM A) responses. A num b er of attem pts h a v e  
been  m ade to alleviate this problem . H u m an  M Abs have been  produced 
u sing  h u m an  B-cells (Carroll et ah, 1990). Genetic eng ineering  techniques 
have b een  u sed  to develop chim eric M Abs, Abs hav in g  a m u rin e  variab le  
reg ion  an d  a h u m an  constan t region, and  h u m an ised  M Ab fragm ents 
w hich  m ay  also have therapeu tic  po tentia l (O 'K ennedy & Roben, 1991). 
The H A M A  response is n o t com pletely  eradicated , how ever, since anti- 
idiotypic and  anti-allotypic responses are still possible. As toxin- and  
rad ionuclide- im m u n ocon jugates  (Fig. 1.1.2A), these M Abs have 
considerable potential, b u t p rob lem s associated w ith  the ir toxicity have 
slow ed their clinical app lications (Songsivilia & Lachm ann, 1990). 
U nconjugated  M Abs have few er side effects, b u t generally  less biological 
activity in vivo, p robab ly  because m ost M Abs do n o t efficiently initiate host 
cellular or hum oral effector m echanism s. For a M Ab to be an  effective 
therapeu tic  agent, it m u st b rin g  to g e th er m olecules or cells th a t m ediate the 
desired  biological effect. This m igh t include facilitating the action of an  
enzym e such  as p lasm inogen  activator on its substrate , activating the 
h u m a n  co m p lem en t system  to cause cell lysis o r triggering  m olecules on 
leucocytes th a t are responsible for phagocytosis o r cytolytic killing of a ta rget 
cell. It has been  suggested  th a t this m ay  be achieved, and  m any  of the 
problem s of M Abs overcom e, by  the  use of a bispecific, m onovalent Ab, i.e. 
a bispecific Ab (BAb). (R eading & Bator, 1988; Songsivilia & Lachm ann, 
1990; Fanger et a l, 1992; N o lan  & O 'Kennedy, 1992)
BAbs are an tibody-derived  m olecules capable of m onovalen tly  
b in d in g  to  tw o  distinct Ags. BAbs use the  specificity of M Abs to  join 
together the m olecules o r cells th a t m ediate the desired  effect. Such 
m olecules can b ind  enzym es, therapeu tic  agents o r radioactive labels to a 
ta rget w ith o u t the need  for chem ical m odification (Fig. 1.1.2B). This is 
advan tageous since the  affin ity  an d  activity of b o th  M Ab an d  active agent 
m ay  be a ltered  b y  the  chem ical m odifications req u ired  for conjugation. 
This concept w as first in tro d u ced  in  1961 (N isonoff & Rivers, 1961) w h en  
polyclonal Abs w ere  u sed  to p roduce  a fu lly  functional BAb. The potential 
of BAbs w en t unnoticed  for n early  tw en ty  years.
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A.
Tumour Cell
Tumour-  
Associated 
Antigen
Drug
Figure 1.1.2:
A n illustration of strateg ies for the use of antibodies in tum our 
targeting , (a) M onoclonal an tibodies (i.e. b ivalent IgG m olecules specific 
for a tu m o u r associated antigen) can be covalently  bound  to a d ru g  
m olecule, and subsequently  used  to b ring  the d ru g  into direct contact w ith  
the tu m o u r cell, (b) Bispecific antibodies (i.e. IgG molecules w hich 
m onovalen tly  bind to tw o distinct an tigens) can be u sed  to b ring  a tum our- 
associated antigen and a d ru g  m olecule into close contact, w ithout chem ical 
m odification of either the d ru g  or BAb m olecules.
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The adven t of m yelom a technology  (Kohler & M ilstein, 1975) led to the 
p roduction  of hybrid -hybridom as (Reading, 1981). These provided  a 
con tinuous source of BAbs of p re-determ ined  specificity. Such BAbs could 
be isolated, tested  an d  used  for a varie ty  of purposes, m ost particu larly  the 
im m unotherapy  of cancer. The toxicity associated w ith  m any  M A b-drug 
conjugates can be reduced . BAbs can be adm inistered, and  allow ed to 
localize a t the desired  site, p rio r to  adm in istra tion  of the active agent. This 
allow s the BAbs to w ash  ou t from  non-specific b in d in g  sites, w here it b inds 
less strongly, so th a t the active ag en t is localised only  at the  desired site. 
These m ethods have an  add itional benefit. B oth BAb an d  active agent are 
sm aller th an  m ost im m uno-con jugates, th is m akes them  less 
im m unogenic and  increases pen etra tio n  of these m olecules to the desired 
site (R eading & Bator, 1988). BAbs can also be u sed  to b ind  to trigger 
m olecules on leucocytes such  as T-cell receptors (TcR), thus focusing 
no rm al cellular im m une defence m echanism s specifically to the  tu m o u r 
cell o r infectious agent. For exam ple, in  an tibody-dependent cellular 
cytotoxicity (ADCC), k illing of the  ta rge t cell is triggered  w h en  the Fc 
receptors for IgG (FcyR) on  effector cells are cross-linked, leading  to the 
d irected release of cytotoxic m olecules from  the  effector cell. H ow ever, 
m any  po tentially  usefu l M Abs are n o t of the ap p rop ria te  isotype to m ediate 
these effects and  are  inactive du e  to their inability  to activate h u m an  
com plem ent a n d /o r  trigger FcyR on  h u m an  cells. A BAb could be 
constructed  to link  a ta rget cell to the  FcyR on effector cells, thus triggering  
an  ADCC response (Fanger et a l, 1992).
The potential applications of BAbs are n o t lim ited to im m u n o -  
therapeutics. R adionuclides can be localised for diagnosis as w ell as 
tre a tm e n t (S o m asu n d aram  et a l, 1993). Enzym es an d  p ro -d ru g s can be 
localized and  activated  in situ  to reduce non-specific or system ic action 
(B ranscom e et al., 1990; Fanger et al., 1992). A range of novel en zy m e  
im m unoassays have b een  suggested  w hich  re ly  on  the  u n iq u e  properties of 
BAbs (Paulus, 1985). BAbs n o w  rep resen t a po ten tia lly  pow erfu l n ew  
therapeu tic  and  diagnostic tool. In  the  follow ing pages the full potential of 
BAbs w ill be exam ined in  m ore detail. In  addition, the various m ethods fo r 
the p roduction  of BAbs will be  discussed.
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1.2 PRODUCTION OF BISPECIFIC ANTIBODIES
Since their inception, a num b er of m ethods have been  used to 
produce BAbs, w ith  v a ry in g  degrees of success. BAbs have been  created by  
fusion  of A b-producing  cells, by  chem ical cross-linking or by  m olecular 
genetic approaches. Each of these approaches has lim itations, and a m a jo r 
problem  in  establishing clinical trials w ith  BAbs is the p rocurem ent of 
sufficient am ounts of clinical-grade m aterial necessary  to carry  ou t studies 
in  their entirety. Thus, from  a clinical standpoin t, econom ical large-scale 
p roduction  of BAbs is vital to p rogress in  th is field.
1.2.1 Biological Production of Bispecific Antibodies:
The biological p roduction  of BAbs is based  on  the principles of 
som atic cell hybrid ization , first developed by  C otton an d  M ilstein (1973). 
They dem onstrated  th a t the fusion  of tw o  Ig-secreting cell lines produces 
hybrid  cells w h ich  secrete Ig  of bo th  p aren ta l types and  of a hybrid  type. 
This w as of lim ited usefulness since the  antigenic specificity of the Ab w as 
unknow n. This p rob lem  w as overcom e in  1975 w hen  K ohler and  M ilstein 
fused  an tibody-producing  lym phocytes w ith  a m yelom a cell line producing  
Abs specific to a g iven  Ag. The po tentia l of these developm ents w as 
recognised b y  R ead ing  1980 (U.S. Patent: 4 474 893) and  repo rted  in 1981. 
BAbs w ere sh o w n  to arise via the fusion  of tw o hybridom as to p roduce one 
quadrom a, derived  from  four p aren ta l cells (Reading, 1981; M artinis et ah, 
1982). A slightly  d iferen t approach  w as u sed  w hen  a hybridom a w ith  
specificity for one A g  w as fused  w ith  sp leen  cells from  an anim al 
im m unised  w ith  the second A g (M ilstein & Cuello, 1984). These som atic 
hybrids are refe rred  to as triom as since they  derive from  three  paren tal cells.
O riginal p roduction  m ethods for BAbs are based  largely on 
conventional hybridom a technology (Fig. 1.2.1). M A b-producing 
hybridom as are p roduced  in  the u su al m anner. M yelom a cell m utan ts 
lacking the enzym e hypoxan th ine  guanine phosphoribosy l transferase  
(HGPRT) w ere  used. These fail to g ro w  in  m ed iu m  contain ing  
hypoxan th ine , am in o p te rin  an d  thym idine (HAT), since b o th  D N A  
biosynthetic p a th w ay s are blocked. Spleen cells contain HGPRT, b u t are 
incapable of con tinuous division. Thus, only  hybridom as w ill su rv ive  in  
HAT m edium , since th ey  are fo rm ed  b y  the fusion  of a m yelom a cell and a 
spleen cell an d  so p roduce  HGPRT. Such cell lines are te rm ed  HAT- 
resistant. These hybridom as are com m only back  selected for HAT 
sensitiv ity  p rio r to fu rth er fusion.
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Figure 1.2.1:
A flow d iag ram  illu stra ting  the protocols u sed  in the biological 
p ro d u c tio n  of bispecific antibodies. H ybridom as are p roduced  by som atic 
cell fu sion  and  back selected, b y  g ro w th  in 8-azaguan ine, for H ypoxanthine- 
A m inop terin -T hym id ine  m ed iu m  (HAT) sensitivity. A triom a can then  be 
p ro d u ced  from  the h yb ridom a an d  a splenocyte, using  the sam e fusion and  
selection procedures. A lternatively, the hybridom a is selected for ouabain  
resistance, b y  add ing  ouabain  to the g row th  m edium . This is then  fused to 
a H A T -resis tan t/ouaba in -sensitive  hybridom a. The quadrom a so produced 
is selected b y  g ro w th  in  m ed ium  containing bo th  HAT and  ouabain, (-r = 
resistan t; -s = sensitive)
HAT sensitivity  is readily  in duced  by  g row ing  the cells in  increasing 
concentrations of 8-azaguanine in  com plete g row th  m edium , thus in d u c in g  
HGPRT deficiency. HAT sensitiv ity  can sim ilarly be induced  using  brom o- 
deoxyurid ine to induce thym id ine k inase deficiency (Wong & Colvin, 1987; 
U rnov itz  et a l, 1988). These back-selected hybridom as can be fused  to Ab- 
secreting spleen cells from  an  an im al im m unised  w ith  a second A g in  the  
sam e m an n er as for hybridom as. Yield of BAb b y  this m ethod  has been  
sh o w n  to be approxim ately  34% of total Ig  p ro d u c tio n  (W ong & Colvin, 
1987; Tada et a l, 1989).
A lthough  there  have b een  successes u s ing  triom as, m any  w orkers 
have concentrated  on  quadrom a production . It is po tentially  easier to w ork  
w ith  a popu la tion  of cells p ro d u c in g  Abs of defined  A g specificity and  
affinity, th an  w ith  a he terogenous popu la tion  of sp leen  cells p ro d u c in g  
uncharacterised  Abs. M ost w orkers  use one h y b rid o m a line m ain ta ined  
w ith  HAT resistance. The o th er hybridom a is back-selected for HAT 
sensitivity, and  is fu rth er m odified  for resistance to biological inhibitors or 
cytotoxic drugs. Of these, o u abain  app ears  to be the m ost p o p u la r (Staerz & 
Bevan, 1986; T iebout et a l, 1987; R eading  & Bator, 1988), b u t the  use of 
em etine (Suresh et a l, 1986), actinom ycin  (C hervonsky et a l, 1988) and 
neom ycin  (DeLau et a l, 1989) has also been  reported . Thus, w hen  a H A T - 
res is tan t-o u ab a in -sen s itiv e  hybridom a is fused  w ith  a HAT-sensitive- 
ouabain-resistan t hybridom a, quad ro m as are p roduced  w hich  are b o th  HAT 
and  ouabain  resistan t (Fig. 1.2.1). U p  to 90% of su p ern a tan ts  from  grow th- 
positive wells, so produced , w ere  show n  to contain  b o th  Ab activities. It 
w as estim ated th a t the actual y ield  of the desired  hybrid  w as betw een  12.5% 
an d  50% of total Ig p roduction  (Staerz & Bevan, 1986). A nother possibility 
is to fuse tw o single m u tan t hybridom as, bo th  of w hich  are HAT sensitive - 
one due to HGPRT deficiency, the o ther due to tyrosine k inase deficiency 
(W ong & Colvin, 1987; U rnov itz  et a l, 1988).
A n alternative m ethod  fo r inducing  resistance to  com pounds has 
been  suggested. In  certain  instances, genom ic m arkers are available for 
transfer in to  cell lines, so inducing  resistance. M ost of these revolve 
a ro u n d  the induction  of resistance to geneticin. This gene, o rig inating  fro m  
Escherichia coli, w ou ld  b ehave  as a true  dom inan t m arker after 
in troduction , independen t of the  degree of p lo idy  of the hybridom a 
involved. R etroviral tran sd u ctio n  w as found  to be the  m ost efficient 
m ethod  of gene transfer in to  cells g row ing  in  suspension  (DeLau et a l, 
1989). Sim ilar techniques w ere  u sed  to induce hybridom a resistance to  
geneticin  an d  ouabain  (R eading & Bator, 1988) o r to  geneticin  and
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m ycophenolic acid (Xiang et a l, 1992). Q uadrom as can th en  be selected for 
in  m edium  containing bo th  drugs.
Selection of quadrom as initially d epended  en tirely  on the use of 
m u tan t phenotypes an d  biochem ical selection. The isolation of these 
m u tan t phenotypes is tim e consum ing an d  the  add ition  of biochem ical 
inhibitors m ay no t be conducive to o u tg ro w th  of quadrom as. A m ethod 
has been  developed invo lv ing  the use of Percoll density  g radient 
cen trifugation  an d  fluorescence-activated  cell so rting  (FACS), w hich  largely 
avoid  in terference in  cell b iochem istry  (Koolwijk et al., 1988). In  Percoll 
density  g radient cen trifugation  cells pass th ro u g h  layered  solutions of 
increasing  density. Cells of different s iz e /d e n s ity  stop a t different so lu tio n  
density  interfaces. W hen  th is w as carried  ou t follow ing a fusion, 
p roduction  of quadrom as w as increased eight-fold in  cells taken  from  the 
1.082-1.075 g /m l density  fraction. W hen  FACS w as used , hybridom as w ere  
labelled w ith  e ither fluorescein  isothiocyanate (FITC) or tetram ethyl- 
rh o d am in e  iso th iocyanate (TRITC) v ia  the  m em brane m arker 
octadecylam ine. Cells w ere  fused  to p roduce  quad rom as labelled w ith  bo th  
FITC and  TRITC. A double-gated  flow  cy tom etry  system  w as set up. The 
first gate separa ted  cells on  the  basis of axial light loss, o r size, and  righ t 
angle scatter, or in te rna l struc tu re . The second gates sim ultaneously  
detected  green  (FITC) an d  red  (TRITC) fluorescence, sepera ting  out d o u b le ­
positive cells. A single cell deposition  system  can be used  to seed the 
double-positive cells in to  96-well plates. This system  appears to  offer a fast 
efficient m ethod  of quad rom a isolation w ith  the  resu lts of the fusion 
(percentage of fused  cells) im m ediately  available. In  addition, quadrom as 
are m ain tained  in  optim al g ro w th  conditions after fusion. It w as found, 
how ever, tha t so rting  m u st be carried  ou t w ith in  six hou rs after fusion. 
A fter this tim e the  m ark er dyes begin  to random ly  exchange betw een  no n ­
fused  p aren t hybridom as in  suspension  together, (K araw ajew  et al., 1987; 
K oolw ijk et a l, 1988; Jantscheff et a l, 1993).
Before use, qu ad ro m a p roducts  m u st first be isolated from  the g ro w th  
m edium  and  characterised . The first s tep  fo llow ing fusion is the 
de term ination  of an tibody  secretion in  g row th-positive  wells. D etection of 
BAb has, thus far, d ep en d ed  on  the use  of double an tigen  enzym e-linked 
im m u n o so rb e n t assay  (ELISA) (Tiebout et a l, 1987; Takahashi & Fuller, 
1988; Tada et a l, 1989) o r affinity ch rom atog raphy  w ith  each specific A g 
(C orvalan & Smith, 1987). In  1984, M ilstein an d  C uello analysed the  Ab 
m ixture. Since A b-producing  cells have  V an d  C regions of each chain 
attached  to a single transcrip tional unit, the expression  of each chain is no t 
altered. H ow ever, the  ind iv idua l light an d  h eav y  chains are th em se lv es  on
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separate transcrip tional units. D u rin g  transcrip tion, chains are synthesised 
th ro u g h  the m em brane of the ro u g h  endoplasm ic re ticu lum  an d  released 
into the cisternal space w here  they  are assem bled. The expected m olecular 
species resu lting  from  random  association of the tw o heavy  an d  tw o light 
chains are show n  (Fig. 1.2.2). It is difficult to p redict the concentrations of 
each m olecular species p roduced  due  to the differential ra te  of synthesis of 
the different chains, and  the p referen tia l association of hom ologous vs. 
heterologous pairs. In  vitro  s tud ies have  sh o w n  that u n d e r com petitive 
re-association the  hom ologous ligh t-heavy  chain  prevails in  80% of cases. 
In  addition, there  appears to be a hom ologous heav y -h eav y  chain  b ind ing  
preference, resu lting  in  a  70% prevalance of this com bination (M ilstein & 
Cuello, 1984). This w o u ld  indicate th a t hybrids of a single sub-class have an  
advantage in  th a t th ey  are m ost likely to give best yields. H ow ever, the 
difference in  electrophoretic or chrom atographic  behav iour of assym etric 
hybrids is advan tageous for the fractionation  of different m olecular species 
and  m ay  com pensate for the low er y ield  of bispecific hybrids (Xiang et a l, 
1992).
Suitable quadrom as are clonally expanded, either in  cu lture or, m ore 
generally, as an  ascitic tum our. R ecently  it has b een  suggested  tha t the use 
of hollow  fibre b ioreactors could grea tly  increase yields (G orter et a l, 1993). 
Ig  can be purified  from  ascites flu id  b y  dialysis against phosphate  buffered 
saline (PBS) a t p H  7.4 (Staerz & Bevan, 1986; Takahashi & Fuller, 1988), or by 
p rec ip ita tion  w ith  50% (w /v )  sa tu ra ted  am m onium  su lphate  (Tada et a l,
1989). The Ab so lu tion  can then  be passed  th ro u g h  a p ro te in  A -S epharose  
colum n, an d  the Igs elu ted  w ith  acetate or citrate buffer in  a p H  gradient 
from  p H  3.0-5.0. BAbs have been  sh o w n  to elute in  the fraction  p H  4.0-4.5 
(K uppen et a l, 1993). The Ig  can also be separa ted  on  a  hydroxyl-appatite  
co lum n  b y  h igh  perform ance liquid  ch rom atography  (HPLC), using  
increasing  concentrations of sod ium  phosphate  buffer (10-350 m M ) (Staerz 
& Bevan, 1986; B arr et a l, 1989). Q uadrom as can be expected to p ro d u ce  
th ree  m ain  types of functional Ig: the  tw o  paren ta l Ab an d  the hybrid  BAb, 
w hich  elute  in  th ree  separate  fractions follow ing HPLC. The degree of 
separa tion  varies. H ybrids fo rm ed  b y  Abs of d ifferent sub-class (e.g. IgG l & 
IgG2b) are easier to separa te  th an  those form ed by  Abs of the sam e sub-class. 
The isolated Abs can be fu rth er characterised  u sing  iso-electric focusing or 
sodium  dodecyl su lphate  polyacry lam ide gel electrophoresis (SDS-PAGE), 
(M ilstein & Cuello, 1984).
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Figure 1.2.2:
A ntibody p roduction  by  q u ad rom as and  triom as. The expected 
m olecular species aris ing  from  the ran d o m  association of heavy  and  light 
chains. N ative heavy-light com binations will p roduce  the best three- 
dim ensional configuration  for h igh  affinity binding. O ther heavy-light 
chain  com binations w ill have reduced  affinity for the antigen.
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1.2.2 Chemical Production of Bispecific Antibodies:
O ne of the m ajor problem s associated w ith  the use of BAbs is the 
p rocurem ent of large quantities of the purified  product. W ith biological 
p roduction  a m ixture  of b o th  paren tal and  bispecific Abs is produced, from  
w hich the  BAb m ust be purified . For th is reason  several w orkers have u sed  
chem ical m eans of production . These m ethods, w ith  purified  parental Abs 
as the starting  m aterial, are designed  so th a t BAb form s the sole p ro d u c t 
w hich  can be extracted in  one step  purification  procedures. Such m e th o d s  
w ere first discussed as early  as 1961 b y  N isonoff and  Rivers. Polyclonal 
rabbit A bs w ere  digested  w ith  pepsin  an d  m ildly reduced  to yield tw o 
un ivalen t fragm ents (Fab' fragm ents). The u n iv a len t su bun its  w ere  
com bined to give good yields of BAb by  oxidation of the disulphide bonds. 
W hen  a m ixture of approxim ately  equal am ounts of Ab of tw o different 
specificities w as used , the  recom bined  p ro d u c t w as precip ita ted  only in  th e  
presence of an  appropria te  m ixture of the  tw o  Ags. This suggested the 
presence of a la rge  po rtion  of Ab of d u a l specificity. F urther w ork  
confirm ed the presence of bispecific A b fragm ents (N isonoff & M andy, 
1962).
These m ethods w ere  u sed  b y  B rennan  et al. (1985) in  an  a ttem pt to 
create BAbs from  tw o  m urine  M A bs (Fig. 1.2.3). L im ited pepsin  hydrolysis 
w as u sed  to  p roduce  F(ab ')2 fragm ents w ith  an  80% yield. Com plete 
reduction  of the F(ab ')2 to  Fab' w as obtained u s in g  2 -m ercap to -e th y lam in e  
(1 mM ) in  sod ium  phosphate  (0.1 M), w ith  EDTA (1 mM). A ttem pts to 
regenerate  F (ab ')2 fragm ents gave poor resu lts  com pared  to those achieved 
w ith  rabbit Abs. This is p robab ly  re la ted  to the  th ree  d isu lphide bonds that 
b ridge the heav y  chains in  m ouse IgG (only one exists in  rabbit IgG), 
resu lting  in  the fo rm ation  of in tra-chain  d isu lph ide bonds. M odifications 
to  the p rocedu re  w ere  m ade to  p rev en t th is recurring . Firstly, F(ab ')2 
fragm ents w ere  reduced  in  the presence of the di-thiol com plexing agen t 
sodium  arsenite, th u s  im p ed in g  in tra-m o lecu lar d isu lp h id e  bond  
fo rm ation  (B rennan et ah, 1985). The successful use  of d ith io th re ito l in  this 
step has also be rep o rted  (N itta et ah, 1989). In  the  second step, the thiols 
w ere  stabilised as the  d ith io -n itro -benzoate  (dTNB) derivative. One of th e  
Fab'-TNB derivatives w as th en  converted  to the Fab'-SH by  reduction  w ith  
2 -m ercaptoethylam ine an d  w as m ixed w ith  an  equim olar am oun t of the 
o ther Fab'-TNB derivative  to fo rm  the hyb rid  (Fig. 1.2.4). The absence of 
hybrid  d im er form ation , w h en  either of the  reaction  p artn e rs  w as absent, 
suggested  th a t the  d im er fo rm ed  in  the com plete m ix ture  rep resen ted  p u re  
BAb. Follow ing h igh-perfo rm ance gel exclusion chrom atography , the  yield 
of bispecific F (ab ')2 fragm en ts  w as 50-70% of to tal po ten tia l yield.
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Figure 1.2.3:
Chem ical p roduction  of bispecific antibodies. U sing this m ethod, the 
p aren ta l IgG are first subjected to a pepsin  digestion to  p roduce F(ab ')2 
fragm ents. The d isu lph ide b o nds are reduced  to the Fab' fragm ents, u s in g
2-m ercaptoethylam ine, in  the  presence of sodium  arsenite and  Ellm an's 
reagen t. The tw o different Fab' are m ixed in  an  equim olar ratio  and 
recom bined under app rop ria te  conditions to produce the hybrid  F(ab ')2 
m olecule (after B rennan  et a l, 1985).
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A nother im portan t consideration  w as p roduct quality. W hen  an  
enzym e-linked im m unoassay  w as u sed  to  com pare th e  im m unoreactiv ity  
of the original an d  the reconstitu ted  F(ab')2, no significant difference w as 
found. H ow ever, 0.1-0.2 m oles of residual free thiol per m ole of F(ab ')2 w as 
detected, ind icating  tha t n o t all d isu lphides w ere  com pletely reform ed. 
These observations and  o thers suggested  th a t the p rocedure  led to some 
reduc tion  and  incom plete re-ox idation  of the d isu lphide bond  betw een 
heavy  an d  light chains, w ith o u t significantly  affecting the  in tegrity  of the 
A g-binding  site. The bispecific n a tu re  of the F(ab ')2 fragm ents w as 
illustra ted  b y  double an tigen  ELISA (B rennan et al., 1985).
O ther m ethods have b een  tried  in  w hich heterod im ers of rabbit and 
m ouse Abs have b een  p ro duced  (G lennie et al., 1987). The protocol for this 
p rep ara tio n  falls in to  th ree m ain  steps. Firstly, F(ab ')2 fragm ents w ere 
p rep a red  an d  reduced  for b o th  A b p artn e rs  to  give h ig h  yields of Fab'-SH 
fragm ents. Subsequently, all of the  available thiol g roups on  one of the Ab 
w ere m aleim idated  w ith  the  b ifunctional cross-linking reagent, o- 
pheny lene  dim aleim ide (o-PDM ). This step  w as carried  ou t in  a large m o la r 
excess of o-PDM  to avoid possible in term olecu lar linking. Finally, the Fab'- 
SH and  the Fab'-m al w ere  com bined u n d e r conditions favouring  -SH and 
m aleim ide reaction  w hile m in im izing  the re-oxidation  of -SH groups, 
th ro u g h  low  pH  an d  the p resence of EDTA. The final p roducts w ere 
reduced  and  alkylated, p rio r to gel filtration  to rem ove an y  F(ab ')2 w hich 
m ay  have form ed by  re-ox idation  of h inge reg ion  -SH groups. The tw o Ab 
com binations tried , m ouse-m ouse a n d  m ouse-rabbit, gave sim ilar products, 
w ith  the  requ ired  F(ab ')2 species constitu ting  50-70% of the  recovered 
m aterial. D ifferential pre-labelling  w ith  radioactive isotopes show ed that 
the purified  F(ab ')2 contained a lm ost equal am ounts of the tw o Ab species, 
a resu lt consistent w ith  a 1:1 union . The n a tu re  of the  linkage betw een  the 
Fab' Ab p artn e rs  w as investigated  u sin g  SDS-PAGE. In  m ost m olecules it 
appears  th a t the heav y  chain  segm ents of the tw o Fab' fragm ents w ere 
coupled, p robab ly  as a resu lt of th io -e th e r linkage be tw een  the hinge region 
-SH groups. The p roposed  typical s tru c tu re  is show n  (Fig. 1.2.5). O nly 0.84 
m aleim ide g roups p e r Fab' w ere  detected. This suggested  th a t tw o of the 
three h inge  reg ion  SH g ro u p s p re sen t in  the m ouse Fab' are cross-linked 
in tra-m olecu larly  d u rin g  m aleim idation , so tha t ju s t one is available to the 
rabb it o r m ouse Fab'-SH. Functionally, the BAb m olecules w ere  tested  in  
th ree  d ifferen t system s, in  w h ich  they  behaved  as w o u ld  be p red ic ted  
assum ing  th a t bo th  Abs b o u n d  to the ir respective Ags sim ultaneously.
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Figure 1.2.5:
Bispecific F (ab ')2  fragm ent, the  p roposed  typical structure , form ed by 
the recom bination  of Fab' fragm ents u sing  o-phenylene dim aleim ide as a 
cross-linking agent, according to the  m ethods of G lennie et al. (1987).
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The protocols of b o th  B rennan  et a l  (1985) and  G lennie et a l (1987) 
describe rap id  an d  efficient m ethods for the p repara tion  of BAbs. Of the  
tw o, the  form er appears to offer the  advantage of hav ing  the  BAb as the sole 
p roduct, rem oving  the need  for separa tion  and  purification  of the products. 
Functional studies have dem onstra ted  th a t bispecific F(ab ')2 he terod im ers 
behave in  a sim ilar m anner to th a t described for bispecific IgG, and  m ay 
offer a num ber of advantages, b o th  in  their p rep ara tio n  and in  their 
perform ance. The m ajor advan tage  over bispecific IgG secreted from  
quadrom as is the ease w ith  w h ich  they  can be p roduced  an d  the eventual 
good yield  of useful products.
1.2.3 Genetic Engineering of Bispecific Antibodies:
M olecular b iology techn iques have advanced to the po in t w here 
designer genes are regu larly  transfected  into E. coli an d  hybridom as in 
o rder to p roduce Ab libraries specific to a given A g (O 'K ennedy & Roben,
1991). T here is no reason  w h y  th is technology cannot be taken a step 
fu rth e r in  o rder to p roduce BAbs. The double transfection  of D N A  
constructs of m urine  IgG genes in to  p roducer hybridom a cells has been  
carried  ou t successfully (Songsivilai et a t,  1989; Lenz & W eidle, 1990). The 
p roducts  of th is hybridom a w ill be  m urine, bispecific IgG. Because of the 
im m unogenicity  of the IgG m olecule, w h en  used  in  im m u n o th e rap y , th e re  
has b een  a m ove aw ay  from  the use  of m urine  IgG. It is now  possible to 
p roduce  h u m an ised /ch im eric  M Abs. These are constructed  w h en  the  gene 
of the variable reg ion  of a m urine  IgG an d  the gene for the  constant region 
of a h u m an  IgG  are co-transfected  in to  the sam e cell. The genes for tw o  of 
these m olecules have been  transfected  in to  SP2 hybridom as, the  p roducts of 
w hich  w ere  found  to be 10-20% bispecific IgG (Phelps et al., 1990). Such 
m olecules have been  u sed  in  tw o  phase rad io -im m uno therapy  w ith o u t 
inducing  the im m une response th a t occured w ith  m urine  M Abs (B ruynck 
et a l,  1993).
A n  alternative to transfection  of the  w hole gene has b een  to  use only 
th a t p a rt w h ich  codes for the Fab' fragm ent. The gene coding for a m urine, 
hypervariab le  reg ion  has been  transfected  in to  E. coli a long  w ith  the gene 
coding for h u m an  Fab1. This la tte r gene can be ad justed  so tha t the Fab' 
p ro duced  contains only one free th iol g roup , thus p rev en tin g  in tra-chain  
d isu lph ide  b o n d  form ation. The secreted  Fab' can be purified  from  the 
g ro w th  m ed ium  an d  chem ically cross-linked to p roduce  an  active bispecific 
F (ab ')2 m olecule (Rodrigues et a l, 1992; Shalaby et a l, 1992). As an  
alternative to chem ical cross-linking, a m olecular app roach  has been  used  
to fo rm  BAbs th ro u g h  the use of "leucine zippers" (Kostelny et a l, 1992).
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Leucine z ippers are a-helices, approxim ately  30 am ino acids long, w ith 
leucine every  seven th  residue. The leucine residues align on  the outside of 
the helix an d  are available for b in d in g  w ith  sim ilar constructs. The leucine 
z ipper reg ion  of transcrip tion  factor Jun  or Fos w ere  genetically fused to the 
genes for each Fab' m olecule, an d  transfected  in to  SP2 hybridom a cells. 
Effective BAbs w ere  then  created  b y  m ixing bo th  constructs together. This 
m ethod  has the  advan tage of a  g rea ter tendency  to  p roduce the 
heterod im ers of in terest ra th e r th a n  u n w a n ted  hom o-dim ers. Such 
protocols could w ell be the  m ethods of choice in  the fu tu re  of bispecific 
an tibod ies.
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1.3 ANTIBODY APPLICATIONS
O ne of the p rim ary  objectives of im m unotherap ists  over the last 
decade has been  to im prove the therapeu tic  ratio  of cytotoxic agents in  
cancer patients b y  using  the specificity inheren t in  M Abs. The 
adm inistra tion  of m urine  M Abs to  h u m ans has generated  w idely vary ing  
results, w ith  rare  "cures" and, in  general, no  firm  conclusions as to their 
m ost efficacious use. It w as initially  envisaged th a t a BAb could be u sed  to 
im prove the efficacy of such  treatm ents. The BAb w ould  b ind  univalen tly  
to bo th  the ta rge t cell an d  the  therapeu tic  agent, th u s  localising large 
quantities of d ru g  at the ta rg e t site and  increasing  the effectiveness of the 
therapy. Since then , a  w ide varie ty  of o ther uses have been  postu lated  and  
tested  for bo th  M Abs and  BAbs.
1.3.1 Chemotherapy:
M ost of the  therapeu tic  d ru g s  available for trea tm en t of cancer rely 
on up take  b y  rap id ly  d iv id ing  cells, a poor basis for selectivity since it will 
resu lt in  significant dam age to norm al cells. Tum our cells, though , differ 
not only  in  freedom  from  norm al g ro w th  constrain ts, b u t also in  an  altered 
spectrum  of gene expression. W here this resu lts  in  expression of tum our- 
specific or tum our-associated  Ags (TAA) a t the cell surface, Abs recognising 
these m ay  be considered for use  as therapeu tic  agents. If tum our-specific 
M Abs are chem icaly linked to suitable d rugs, toxins or radionuclides, th e n  
cytotoxic agents w ith  a h igh  degree of selectivity are form ed. These im m n o -  
conjugates b ind  the  tu m o u r cells an d  are in ternalised  an d  degraded  by  the 
lysosom es to release the active agen t w h ich  th en  acts on the ta rget - a 
particu la r enzym e, D N A  or RNA. A num ber of TAAs have been  identified  
and  M Abs p roduced  for these (Teh et ah, 1985). Several d rugs (Pietersz,
1990), toxins (Spooner & Lord, 1990) and  rad ionuclides (Britton et a l, 1991) 
have been  a ttached  to M Abs an d  their effects in  vitro  as w ell as in  v ivo  in 
m ice an d  hum ans have  b een  studied.
O ne of the  m ost form idable obstacles in  the p roduction  and  
u tiliza tio n  of im m u n o -co n ju g a tes  is the effect of chem ical reactions on the 
activities of bo th  the active agen t an d  the M Ab. A ttem pts to m axim ise the 
num b er of d ru g /to x in  m olecules conjugate p e r M Ab m olecule resu lt in  
significant decreases in  p ro te in  recovery  due  to precipitation. The b in d in g  
activity of the M Ab an d  the effectiveness of the active agent can b o th  be 
drastically  reduced . D espite these  factors, initial in vitro  studies w ere  
encouraging. H ow ever, in  v ivo  testing  show ed  m ixed results. The failure
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of im m uno-conjugates, so far, to fulfill their potential m ay be attribu ted  to a 
num ber of causes (Spooner & Lord, 1990). These include:
failure of large conjugates (180kDa) to  penetrate  solid tum ours;
circulation of shed A g com peting  for im m uno-conjugate;
escape of A g-negative tu m o u r varian ts;
the n a tu re  and  density  of ta rge t Ag;
non-specific b ind ing  of the constant reg ion  of the Ab to non-target 
cells, resu lting  in  system ic toxicity;
neu tra lization  of therapeu tic  m olecules b y  patien ts w ho  are not 
sev ere ly  im m u n o -su p p ressed ;
the developm ent of h u m an  an ti-m ouse Ab responses lim its the 
num b er of treatm ents possible for a patient;
the appearance of side effects no t p red ic ted  b y  anim al m odels, e.g.
flu id  re ten tio n  and  m uscu lar pain.
A n alternative  app roach  for the localization of agents is the use of BAbs. 
These m olecules have  the potential to overcom e som e of the problem s 
associated w ith  im m uno-conjugates. The bispecific F(ab ')2 [BF(ab')2]
m olecule is as effective as the w hole m olecule, b u t its sm aller size m akes it 
less im m unogenic an d  increases pen e tra tio n  of the m olecule to solid and
inaccessable tum ours. The m onovalen t b in d in g  of the BAb increases the
density  of Ab and, hence, active ag en t on  the  cell surface. The BAb can be 
adm in istered  p rio r to the active ag en t and  allow ed to localize to the target 
tissue. N on-specifically  b o u n d  BAb will w ash  ou t quicker th an  specifically 
b o u n d  BAb; active agen t adm in istered  after this w ill localize to the tum our 
site only. A num b er of BAbs have been  p roduced  and  tested  and  their 
effectiveness com pared  to the p a ren ta l M Abs and  im m uno-conjugates.
Several i?i v itro  studies have  been  carried  ou t u sing  BAbs to ta rget 
ricin, a toxin  derived  from  the castor bean , to tu m o u r cells. This 
com pound, w hich  consists of an  A- an d  B-chain, is toxic only in  the dim eric 
form . The B -chain is requ ired  to b ind  the  complex to  the galactose 
determ inan ts  on  the cell surface. O nly  w h en  it is in  such  close association 
w ith  the cell surface does the A -chain en ter the cell, re su ltin g  in  
inactivation  of the ribosom es and  sh u t d o w n  of p ro te in  synthesis. The A- 
chain alone is non-toxic and  can be adm in istered  in  v ivo  w ith o u t effect. 
U sing  triom a technology, a BAb w as p roduced  w hich  b o u n d  ric in  A -chain  
(RAC) and  a prosta te-restricted  A g (Webb et ah, 1985). The BAb b rings the
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RAC into  sufficiently close contact w ith  the cell to allow  it to en ter and  act 
in  the usual m anner (Fig. 1.3.1).
BAbs w ere also p roduced  b y  chem ically linking Fab' fragm ents from  
rabbit anti-RAC Ab and  rabb it an ti-h u m an  IgG Ab (Raso & Griffin, 1981). 
This in troduced  an  anti-g lobulin  step  w here  the toxin is directed only 
tow ards those cells w hich ca rry  cell surface hum an  IgG. This approach  has 
the d isadvantage of be ing  blocked b y  free IgG. The Abs w ere tested in vitro  
w ith  RAC, h u m an  IgG  and  cancer cells and  w ere  sh o w n  to have retained  
bo th  affinity and  biological ac tiv ity  There w as som e indication that 
un ivalen t b ind ing  b y  the Abs increases the cell surface satu ration  w ith  BAbs 
and, hence, increases cell k illing b y  the toxin. U nivalent b ind ing  of BAbs to 
tu m o u r cells m ay  also reduce m odu la tion  of the A g at the cell surface (e.g. 
reduc ing  levels of in ternalisation), leav ing  the A g accessible for fu r th e r  
trea tm en ts  (Webb et ah, 1985). In  addition, in  vitro  tests show ed that 
p ro te in  synthesis w as inhib ited  in  B A b-bound cells a t considerably  low er 
ricin concentrations th an  in  non-B A b-bound cells (Raso & Griffin, 1981). 
There w as a 50% reduction  of p ro te in  synthesis (m easured  b y  14c_iabelled 
am ino acid uptake) in  those cells trea ted  w ith  BAb an d  RAC com pared to 
controls (Webb et al., 1985). These investigators also p roduced  a BAb 
recognising  a prosta te-restricted  A g and  pokew eed  an ti-v ira l p ro tein , w hich  
w as equally  effective in  sim ilar cytotoxicity tests (Webb, 1988; Webb et ah, 
1988).
M ore extensive BAb testing  w as perfo rm ed  u sin g  an  anti-carcino- 
em bryonic A g (C E A )/an ti-v inca alkaloid BAb (C orvalan et ah, 1987a&b; 
C orvalan  et ah, 1988). BAbs selectively targeted  v inblastine to CEA -bearing 
cells as sh o w n  by  exam ination  of histological sections of h u m an  colorectal 
cancer. A n in  v ivo  tu m o u r m odel w as set u p  u s in g  n u d e  mice bearing  
established MAWI h u m an  tu m o u r xenografts. Tritiated (3H )-v inb lastine  
d is trib u tio n  w as m easu red  in  tum our, visceral o rgans and  plasm a 
follow ing adm in istra tion  of the  BAb (day 0) and  the radio-labelled  d ru g  (day 
14). R esults ind icated  a ten-fo ld  h igher concentration  of radio-labelled 
vinblastine  in  the tu m o u r fo llow ing BAb adm in istra tion  (C orvalan et ah, 
1987a). The efficacy of the  d ru g  ta rg e ted  w ith  BAb w as estim ated in  the 
sam e m odel u sing  tu m o u r vo lum e, tu m o u r w e ig h t and  subsequen t 
h isto logy as guidelines. These tests show ed  th a t B A b-targeted d ru g  is 
available in  the active fo rm  and , for a g iven dose, is m ore effective at 
tu m o u r supression  th an  free d ru g , p robably  due to  the  increase in  local 
concentration, m ediated  via the  BAb (C orvalan et ah, 1987b). The d ru g  w as 
found  to be m ost effective w h en  adm in istered  sim ultaneously  w ith  the 
BAb (C orvalan  et ah, 1988).
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Figure 1.3.1:
Ricin chem otherapy. (A) A dm inistration  of the ricin com plex leads 
to  b ind ing  of the cell by  the B-chain, the A -chain enters resu lting  in  
ribosom e inactivation. (B) A dm inistration of the ricin A -chain has no 
cytotoxic effect as it cannot en ter the cell. (C) A dm inistration of ricin A- 
chain  and  a bispecific an tibody  leads to b ind ing  of the cell and  the A-chain 
b y  the  bispecific antibody, the A -chain en ters the cell resu lting  in ribosom e 
in a c tiv a tio n .
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This m odel also illustrates the efficiency of BAbs in  a m ore realistic 
cancer m odel system . Both BAbs w ith  d ru g  and  M A b-drug  conjugates 
caused tu m o u r suppression  in  fresh ly  im plan ted  tu m o u r xenografts. 
H ow ever, in  well established xenografts (3 w eeks) significant suppression  
w as obtained  only  follow ing trea tm en t w ith  BAb and  v in b las tin e  (C orvalan  
et ah, 1987b). These MAWI h u m a n  tu m o u r xenografts, im planted  in 
n u /n u  mice, w ere  in  the exponential g row th  phase and  constitu ted 2 % of 
body  w eight. M axim um  cytostasis w as achieved on ly  follow ing the 
establishm ent of the  op tim um  drug:B A b ratios. In  v ivo  tu m o u r  
suppression  w as susta ined  for tw o  m onths after w ithd raw al of treatm ent. 
H istological exam ination indicated a  reduction  in the cellularity, b u t not 
size, of these tum ours. In  addition, it w as show n that those tu m o u r cells 
rem ain ing  after a tw o m onth  lapse in  trea tm en t still express CEA on  the 
cell surface. This w ou ld  indicate the  po ten tia l succcess of re-challenge w ith  
the  sam e trea tm en t protocol (Sm ith et ah, 1990).
BAbs to  several o ther tu m o u r and  d ru g  types h ave  b een  p ro d u ced  
from  quadrom as. These antibodies have  been  tested  b o th  in vitro  and  in  
v iv o .  A BAb w as p roduced  w h ich  b o u n d  to  b o th  an  osteosarcom a cell line 
and  a  carrier p ro te in  (Pim m  et ah, 1990). M ethotrexate (MTX) w as 
conjugated to the carrier protein . This resu lted  in  a fo rty  fold increase in 
MTX concentration  at the cell su rface  w h en  targeted  w ith  BAb, com pared to 
a MTX-MAb conjugate. N o t all this extra MTX is available or active, 
how ever, since sim ilar ra tes of cell death  w ere  recorded  in  in vitro assays 
com paring  BAb ta rge ting  w ith  MTX-MAb conjugate targeting.
A BAb reacting  w ith  b o th  a  ra t hepatom a cell line and  the  
anthracycline d rugs w as p ro duced  (Tsukada et ah, 1989). The cell line w as 
grafted  in to  D o n ry u  ra ts  to set u p  a tu m o u r m odel w ith  m icrom etastases. 
This m odel w as used  to com pare the  therapeu tic  effectiveness of th is BAb 
w ith  th a t of a M A b-drug  conjugate an d  controls. It w as fo u n d  that, in  o rder 
to p roduce  the sam e surv ival ra tes  (60 days), one and  a  half tim es m ore  
d ru g  w as req u ired  w ith  the M A b -d rug  conjugate th an  w h en  the d ru g  w as 
ad m in is te red  and  ta rge ted  w ith  the  BAb. Blood a -fe to p ro te in  (AFP) levels 
w ere  also low er fo llow ing  BAb therapy, ind icating  p referentia l activity of 
the BAb an d  d ru g  over the M A b-d rug  conjugate.
Saporin , the  ribosom e-inactivating  pro tein , has been  targeted  to 
lym phom a cells b y  the  use  of BAbs (French et ah, 1991). It w as found  tha t 
the  use of polyclonal an ti-saporin  A b in  the p roduction  of BAbs, increased  
the po tency  of a g iven  dose 10- to 20-fold. Best resu lts w ere  obtained  w hen  
several an ti-saporin  M Abs w ere  u sed  synergistically  in  con junction  w ith  an  
anti-CD 22 M Ab to  p roduce  several BAbs w ith  sim ilar affinities. (C lusters of
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D ifferentiation (CD) are Ags on m em brane proteins of h u m an  blood cells 
tha t define stages of d ifferentiation of these cells.) Targeting via the CD22 
increased in ternalisation  of the d ru g  and, hence, cytotoxicity b y  u p  to 1,000 
tim es com pared to targeting  via CD19 or CD37. Use of pairs of BAbs w ith
affinity for different epitopes on  the  sam e A g gave a 10-fold increase in
cytotoxicity com pared  to using  a single BAb (Bonardi et al., 1992; Bonardi et 
al., 1993). This type of the rap y  has also been  show n to be successful using  
BAbs targeted  against CD7 and  CD38 on  the cell surface (Flavell et al., 1992). 
It w ou ld  appear th a t m ultiple cell surface A g ta rge ting  alleviates the 
p roblem  of sm all num bers of cells w ith in  the  diseased population  not 
expressing the ta rg e t Ag. Such cells w ou ld  no t be ta rge ted  and  destroyed if 
only  one BAb w as used. It also serves to increase the d ru g  concentration at 
the ta rge t site.
1.3.2 Effector Cell Retargeting:
The adm in istra tion  of m u rin e  anti-TAA M Abs alone to hum ans has 
generated  w idely  v a ry in g  results. In  cases in  w hich M Ab adm inistration  
resu lted  in  elim ination of tu m o u r cells, the m ost likely m echanism s for the  
destruction  have been:
reg u la to ry  - as in  anti-id iotype trea tm en t of lym phom as;
re su ltin g  from  im m unisa tion  - an ti-an ti-id io type  h u m a n  Ab
production , th o u g h t to recognise the original tu m o u r epitope;
ind irect - based  on  A b-dependen t cell-m ediated cytotoxicity (ADCC);
directly  - s tim ula ting  com plem ent fixation th a t resu lts in  cell lysis.
U nfortunate ly , onco logy  p a tien ts ' im m une system s are often  com prom ised 
from  p rio r therapy, tu m o u r bu rd en , o r both. Thus, the patien t m ay  be 
unable to benefit from  M Ab th e rap y  via these m echanism s. A lth o u g h  
som e rem issions have  been  observed , there  is no convincing evidence of 
any  cancer b e in g  cu red  exclusively b y  adm in istra tion  of M A bs (Reading & 
Bator, 1988). A m ore  successful m eans of s tim u la tin g  the  p a tien ts  im m une 
response to a tu m o u r has been  achieved th ro u g h  the  use of BAbs. In  
d irected o r red irected  cytotoxicity, BAbs b ind  b o th  to ta rge t cells (pathogens 
or tum ours) an d  to cytotoxic trigger m olecules on  leucocytes such  as TcR or 
FcyR. BAbs can th u s  be u sed  to focus no rm al cellular im m une defence 
m echanism s specifically to the tu m o u r cell or infectious ag en t (Fig. 1.3.2). 
In  the likely even t th a t the patien t's  im m une system  has b een  depleted  by 
disease o r trea tm en t, the  cellular defence m echanism s can be augm ented  by  
the extra-system ic stim ulation, an d  subsequen t reinfusion, of effector cells.
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Figure 1.3.2:
Effector cell re-targeting. A bispecific antibody, w hich  binds to a triggering  
m olecule (CD3) on a cytotoxic T-cell and  a tu m o u r associated antigen, is 
u sed  as a bridging  agen t to b rin g  a cytotoxic T-cell in close contact w ith  a 
tu m o u r cell. Stim ulation of the T-cell resu lts in cytolysis of the tu m o u r 
cell.
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1.3.2a THE COM PONENTS OF TH E SYSTEM:
It has b een  suggested  th a t T-cells w ou ld  be the m ost efficient cells to 
redirect w ith  BAbs (Ferrini et a l, 1989a&b). These cells represen t a 
hom ogenous cytolytic popu la tion  and  the ir h igh  m otility  and unique 
hom ing properties increase th e ir ability  to reach  target cells. The prim ary  
cytotoxic trigger com plex on  T-cells is the TcR complex, w hich  consists of a 
n on-covalen t association  of Ti heterod im ers (a /p  o r  y/6) w ith  the CD3 
m olecular complex. The TcR is no rm ally  Ag-specific and  m ajor histo- 
com patability  com plex (M H C)-restricted. H ow ever, BAbs can react w ith  th is  
com plex an d  in itiate cytotoxicity th a t is no t M H C -restricted, and  can thus 
red irect the cytolytic action of v irtu a lly  all available T-cells to  the A g of 
choice (Perez et a l, 1985). CD2 can also initiate T-cell m ediated  cytotoxicity. 
H ow ever, the engagem ent of tw o  d ifferent epitopes on  th is m olecule may, 
u n d e r som e conditions, be req u ired  for in itiation of cytotoxicity (Scott et a l, 
1988). CD28, in  conjunction w ith  CD2 or CD3, p rovides a co -s tim u la to ry  
signal th a t plays a m ajor role in  T-cell activation. In teraction  of CD28 w ith  
its ligand prov ides an  A g derived  co-stim ulato ry  signal resu lting  in 
in terleukin-2 (11-2) p roduction  b y  h u m an  T-cells (Ferrini et al., 1992). O ther 
T-cell surface Ags th a t have b een  u sed  in  effector cell re targeting  include 
CD4, CD gf(W ong et al., 1989; G orter et a l, 1992) and  CD16 (W einer et a l, 
1993a&b).
O ther effector cells of the  im m une system  have also been  re targeted  
u sin g  BAbs. FcyRs appear to be the  only  m olecules on  h u m an  m yeloid cells 
capable of m ed ia ting  ADCC of tum ours. The on ly  requ irem en t for 
triggering  of FcyR function  app ears  to be receptor cross-linking. There are 
three  s tructu ra lly  an d  functionally  distinct classes of FcyR. FcyRI (CD64) is 
h ighly  expressed only  on m onocytes and  m acrophages, and  is a potent 
cytotoxic trigger on  these cells. It has been  u sed  successfully as a target 
m olecule in  B A b-m ediated effector cell re ta rge ting  (Chokri et a l, 1992; 
D eram o u n t et a l, 1992). FcyRII (CD32) is a trigger m olecule on  m onocytes, 
m acrophages and  eosinophils th a t can m ediate  ta rg e t cell lysis a n d /o r  
phagocytosis w h en  used  in  conjunction  w ith  BAbs (G reenm an et al., 1991). 
It is also expressed on  platelets an d  can trigger p latelet aggregation, thus 
b locking BAbs from  b in d in g  to  p o ten t effector cells. FcyRIII (CD16) is 
p resen t on  m acrophages and  the  n a tu ra l killer (NK) ce ll/la rg e  g ra n u la r  
lym phocyte (LGL) popu la tion  and  can act as a cytotoxic trigger m olecule for 
these cells. R esting cells ta rgeted , v ia this m olecule an d  a  BAb, to tu m o u r  
cells have  b een  stim ula ted  to active cytolysis of the ta rge t cells (DePalazzo et 
al., 1990; Ferrini et a l, 1991; D ePalazzo et a l,  1992a&b; G reenm an et a l, 
1992; H sieh-m a et a l, 1992; Ferrini et a l, 1993).
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C irculating lym phocytes from  healthy  donors are typically in  a 
resting  state and  m ust be activated before they  w ill perform  cytolytic 
functions. Similarly, op tim al cytotoxicity b y  BAbs m ay  also require 
activation of the effector cells b y  im m une cytokines, in  addition  to specific 
trigger m olecules. The p redom inan t cytokines involved are 11-2 and  
g am m a-in te rfe ro n  (IFN -y). C ultu re  of effector cells in  11-2 conditioned 
m edium  for u p  to five w eeks prio r to trea tm en t w as show n to g reatly  
enhance their cytolytic effect follow ing targeting  w ith  BAbs (N itta et a l, 
1991; C hen et a l, 1992; H aagen  et a l, 1992). In  addition, in  v ivo  studies in 
im m uno-com peten t mice, w ith  tu m o u r im plan ts, show ed  tha t w hen  BAb 
and  effector cells alone w ere  adm in istered  75% m ortality  occurred. 
H ow ever, w hen  11-2 w as adm in istered  along w ith  the effector cells and  BAb 
m ortality  fell to 18% (Weiner, 1992). P re-treatm ent of tu m o u r cells w ith  
IFN-y w as show n to  induce expression of in tercellu lar adhesion  m olecule 1. 
This, in  tu rn , enhances BA b-directed N K  cell cytotoxicity (A zum a et al.,
1992). Cytotoxicity triggered  b y  BAbs m ay  also include the release of 
cytokines th a t are toxic to the  ta rge t cell. This effect has b een  show n to have 
a significant role in  cytolysis of ta rge t cells, as triggered  b y  BAb binding, and 
m ay  aid  in  the destruction  of bystander, A g-negative tu m o u r cells (p ia n  et 
al., 1991; Segal et al., 1991).
1.3.2b IN  VITRO  STUDIES:
BAbs have been  extrem ely  usefu l in  p rob ing  the  functional 
properties of cell surface m olecules and  in  defin ing  the  ability of the 
d ifferent FcyR to m ediate  cytotoxicity b y  the  various effector cells, as w ell as 
the effect of cytokines on  these activities. Overall, these studies indicate 
th a t the  d ifferent classes of FcR have d ifferent capabilities for d irecting 
cellular cytotoxicity, and  th a t th e ir function  seem s to be dictated b y  the  
isoform  of the  receptor, the cell type on w hich  it is d isp layed  and  the state of 
activation of the cell. BAbs have  been  used  to s tu d y  T-cell signalling 
pathw ays. A nti-C D 3/an ti-C D 8 BAbs w ere  sh o w n  to cause Il-2-dependent 
proliferation  of these cells (DeLau et a l, 1992). It is speculated th a t A g 
stim ulation  causes CD3 and  C D 8 to be expressed in  close proxim ity, as 
m im icked by  the BAb, w h ich  in  tu rn  facilitates Il-2 -d ep en d en t p ro liferation . 
Sim ilar studies have been  carried  o u t on  the  11-2 recep tor (I1-2R). A BAb 
b in d in g  to bo th  a -  and  p-chains of the I1-2R can com pletely block 11-2 
stim ula tion  of T-cell p ro liferation  (Francois et al., 1993a&b). This has 
therapeutic  potentia l in  the p reven tion  of a llograft rejection.
The earliest in vitro studies exam ined the  potentia l for th e rap y  of 
BA b-directed effector cell re targeting , h u m an  T-cells w ere  ta rge ted  to
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tu m o u r cell lines causing  h ig h  levels of cytolysis (Lanzavecchia & 
Scheidegger, 1987; C lark  et a l, 1988). Effector cell re ta rge ting  w as also carried  
ou t u sing  an  anti-g lobulin  step. M urine M Abs w ere b o u n d  to the tum our 
cells, a BAb w as applied  w hich  w as specific for m ouse IgG and  a T-cell Ag. 
This extra step increases the  range  of tu m ours to  w hich  a single BAb m ay  be 
applied  (Gilliland et a l, 1988). Subsequently, BAbs have been  used  to target 
cytotoxic cells to a  num b er of cell lines, these include; m u rin e  B-cell 
ly m phom as (C lark & W ald m an, 1987; D eM anet et al., 1992), ovarian  
carcinom a (C anevari et al., 1988; vanR avensw ay-C lassen  et al., 1993), m ulti­
d ru g  resistan t tu m o u r cells (vanD ijk et al., 1989) an d  h u m an  im m uno­
deficiency v iru s (H lV )-infected cells (O kada et al., 1992). Finally, BAbs have 
b een  used  to detect the  presence of activated T-cells, those expressing CD3 
a n d /o r  I1-2R, and  to target cytotoxic or N K  cells to  destroy  them  (Kaneko et 
al., 1992; M acLean et al., 1993). This has therapeu tic  potential in  cases of 
g ran u la r lym phocyte pro liferative d isorders, au to -im m une disease and  
graft rejection w here  im m une-suppression  th e rap y  is indicated.
1.3.2c IN  VIVO  STUDIES:
BAb ta rge ting  of T-cell cytotoxicity has show n  prom ise in  several 
ro d en t m odel system s. These in  vitro  and  anim al m odel studies have 
prov ided  direction fo r the  in itiation  of h u m an  clinical trials. BF(ab ')2 
m olecules w ere u sed  to s tu d y  ta rge ting  of T-cells to m urine  lym phom a cells 
g ro w n  as ascitic tu m ours in  mice (C lark et al., 1989). It w as later show n  that 
BAb and  effector cells adm in istered  nine days after the tu m o u r had  been  
established, could initiate a  com plete cure, w ith  no  rem issions recorded  at 
day  150 (Brissinck et al., 1991). This m odel also show ed  th a t T-cell to target 
cell b ind ing  w as essential for activation of the  T-cell, an  im portan t 
consideration  if system ic activation of T-cells is to be avoided. A sim ilar 
m odel w as set up  in  im m une-com peten t m ice (W einer & H illstrom , 1991). 
This m odel illustra ted  th a t T-cells w ere m ore effective th an  m acrophages, 
hence it is the BAb and  n o t the Fc portion  of the Ab th a t is responsible for 
ta rge t cell lysis. A subcu taneous xenograft of a solid tum our, hum an  renal 
cell carcinom a, w as exam ined b y  vanD ijk  et al. (1991). In  this m odel the 
paren tal IgG and  F(ab ')2 w ere  com pared to the  BF(ab ')2 for their ability to 
localize to the tum our. The low ered  affinity of the BF(ab ')2 for the target, 
w ith  respect to the  paren ta l m olecules, h ad  v e ry  little effect on  the quantity  
of Ab localized to th e  tum our. A BF(ab')2, w h ich  has a sim ilar size to a 
F (ab ')2 m olecule, w as show n to have a h igher tum our:non-tum our b in d in g  
ratio  th an  the larger IgG. This w ould  indicate th a t localization to solid 
tu m ours depends m ore on  size th an  affinity. Recently, a ra t co lon
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carcinom a m odel has been  developed w hich  m ore closely resem bles the 
h u m a n  s itua tion  (Beun et al., 1992; B eun et a l, 1993a&b). H ere, the 
tum o u r-h o st re la tionsh ip  is w eak ly  o r non-im m unogenic , liver m etastases 
are com m on and  spontaneous regression  does n o t occur. The m urine Abs 
u sed  in  th e rap y  are xenogenic, w hich  also m im ics the  clinical application. 
Significant lysis of the tu m o u r w as sh o w n  to  occur following 
adm in istra tion  of effector T-lym phocytes, w h ich  h ad  b een  pre-treated  w ith  
an  anti-T -cell/anti-colon carcinom a BAb. Some activation of resting T-cells 
b y  the BAb w as also evident.
A m urine m odel has b een  developed in  w hich  ovarian  carcinom a 
im plants w ere  established in  athym ic mice (M ezzanzanica et al., 1991a&b; 
W u n d erlich  et a l, 1992). This m odel show ed th a t no rm al or activated 
lym phocytes adm inistered, a long  w ith  BAb, four days after the tu m o u r cells 
w ere  established, caused a significant reduction  in  tu m o u r g row th  rates and 
doubled  the host su rv ival tim e. This m odel w as developed for use in  
clinical trials u sing  BAb an d  activated  T-cells to  trea t patients w ith  
advanced  ovarian  carcinom a w ith  som e success (Pupa et al., 1988; 
M ezzanzanica et al., 1991a&b). A m ulticentre s tudy  of this tre a tm e n t 
show ed th a t significant tu m o u r regression  w as accom panied, in  some cases, 
b y  a m arked  local in flam m atory  response. In  addition, som e patients 
developed a H A M A  reaction  (Bolhuis et al.r 1992). A separate  clinical s tudy  
w as carried  ou t u s in g  a  less specific BAbs, anti-C D 3/anti-TA A  (K roesen et 
al., 1993). This BAb w ill b ind  to  cytotoxic T-cells and  to a num ber of tu m o u r  
types. The patien ts chosen for the  trial all suffered  from  m alignan t ascitic 
tum ours, arising from  several p rim ary  tu m o u r types. Lym phocytes w ere 
activated w ith  11-2 an d  adm in istered  at the tu m o u r site along w ith  the BAb 
(i.e. by  in tra-peritoneal injection (i.p.)). This trea tm en t resu lted  in  a 
significant local reduction  in  tu m o u r load, accom panied by  a strong 
in flam m atory  response. Since the inflam m atory  reaction does no t occur in  
the  absence of BAb, it is th o u g h t th a t T-cell to  tu m o u r cell cross-linking 
triggers local cytokine release, resu lting  in  granulocyte influxes and  
in f la m m a tio n .
1.3.3 Fibrinolytic Agents:
Plasm inogen activators (PA) trigger the  conversion of plasm inogen 
to the fibrinolytic enzym e plasm in, w hich  causes dissolution of fibrin- 
contain ing  throm bi. These agents are u sed  clinically follow ing acute 
m yocardial infarction, b u t in  am ounts th a t m ay  resu lt in  severe b leeding  as 
a side effect. It has been  suggested  that, if PAs could be focused to  fibrin- 
con tain ing  clots w id esp read  fibrinolysis, an d  the resu ltan t haem orrhagic
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side effects, could be prevented. BAbs w ere  produced, b y  som atic cell fusion 
and  b y  chem ical coupling of Fab' fragm ents, w hich  b o u n d  to fibrin  and 
tissue p lasm inogen  activator (tPA). In  a solid phase  assay, the BAb
produced  b y  cell fusion  caused a 5-10-fold increase in  tPA activity w hen  they  
w ere app lied  together, com pared to  the  tPA applied  alone. This sam e BAb 
enhanced clot lysis in v iv o  approx im ately  2-fold in  the  rabb it jugu lar vein 
m odel of throm bolysis (Branscom b et al., 1990). Sim ilar resu lts w ere 
obtained u sing  chem ically p ro d u ced  BF(ab')2s, w hich  caused  10-fold m ore 
fibrinolysis in vitro th an  tPA alone. The sm aller BF(ab ')2 m olecule m ay
have the  advan tage  in  in  v ivo  stud ies due  to its increased diffusibility and 
reduced  im m unogenicity. O ther studies have explored the  use of BAbs to 
target u rokinase-type p lasm inogen activator (uPA). The presence of BAb 
has increased the  po tency  of tPA an d  uPA 10-20-fold in  an  in vitro assay, 
w hen  com pared  to tPA or uPA alone (Bos & N ieuw enhu izen , 1991). In  an 
in vivo ham ster m odel of p u lm o n a ry  em bolism , the  throm bolytic  po tency  
of recom binant uPA w as enhanced  13-17-fold relative to th a t of uPA alone 
and  4-fold in  the rabbit ju g u la r ve in  throm bosis m odel (K urokaw a et al.,
1991). N either of these m odels show ed  any  m ajor system ic activation of 
fibrinolysis or haem orrhagic side effects. The use of BAbs in  this area has 
recently  been  rev iew ed  (Bos & N ieuenhu izen , 1992).
1.3.4 Radioimmunoscintigraphy & Radioimmunoassay:
R adiolabelled M Abs have been  u sed  successfully in  the im aging and
trea tm en t of som e solid tum ours. Im m unotherapy  depends on the
absolute am oun t of Ab taken  u p  b y  an d  rem ain ing  on  or in  the tum our, 
w h e th er the  Ab is linked to  a toxin, rad io n u c lid e  o r chem otherapeu tic  
agent. For rad io im m unoscin tig raphy  it does n o t m atter if on ly  a fraction of 
the cells in  a tu m o u r m ass b in d  the  Ab. For rad io im m u n o -th erap y , 
depend ing  on  the  radionuclide, the  m ajority  of all the viable tu m o u r cells 
m ust b in d  the Ab. Lack of a  requ irem en t for in ternalization  and  the 
beneficial effects of cross-irrad iation  are advan tages of rad io­
im m u n o th erap y  over o ther im m uno-conjugates. Access to the  tum our site 
m ay  be a lim iting factor. For rad io im m unoscin tig raphy  it does no t m atter 
if on ly  the  ou te r cells of the  tu m o u r m ass take u p  the radiolabelled Ab 
because a  signal is still ob tained  from  the tum our. For ra d io im m u n o -  
th e rap y  penetra tion  th ro u g h o u t the  tu m o u r is required. This is one of the 
reasons w h y  rad io im m uno therapy  requ ires a large am ount of Ab (approx. 
40mg) w hereas rad io im m unoscin tig raphy  is generally  successful w ith  lesser 
am oun ts (approxim ately 0.2-2mg). The requ irem en t fo r tu m o u r 
p en e tra tio n  is all the  m ore critical w h en  radio-sensitiv ity  is considered.
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Tum our tha t is less w ell oxygenated  is less radio-sensitive so the deeper 
parts  of large tum ours n o t on ly  receive less radiolabelled  Ab b u t the 
rad ia tion  they  receive is less effective. (Haller, 1988; B ritton et a l, 1991)
It has been  suggested  th a t d iagnosis and  trea tm en t could be im p ro v ed  
b y  the use of BAbs. A BAb has been  p roduced  w hich  b inds CEA and  
BLEDTA IV, an  ^ I n - b e n z y l  EDTA derivative (G ridley et a l, 1988; K ing et 
al., 1988). The ability of th is BAb to localise BLEDTA IV in  T380 hum an  
tu m o u r xenografts in  nude  mice has been  established (King et a l, 1988). 
U sing the sam e m odel, it w as sh o w n  tha t h y p e rth e rm ia  enhances 
localisation of BLEDTA IV to  the  BAb in  the xenograft (G ridley et al., 1991b). 
One day  after BAb adm inistra tion , the anim als w ere  heated  to 41.5°C for 
45min. A fter a  fu rth er tw o  hou rs the BLEDTA IV w as adm inistered. Of the 
adm inistered  dose, 4.46% p e r g ram  of tu m o u r w as localised to this tum our 
in  the  hypertherm ic mice, w hereas only  1.44% p e r g ram  of tu m o u r w as 
found  in  the xenografts of non-hypertherm ic  mice (m easured by  au to ­
rad io g rap h y  and radioactiv ity  read ings of the excised tum ours).
In  clinical studies, pa tien ts  w ith  colorectal carcinom a or m elanom a 
w ere injected first w ith  BAb, th en  w ith  radiolabelled hapten . This system  
allow ed the  BAb to accum ulate in  the  tu m o u r w ith  "w ash  out" from  other 
tissues before adm in istra tion  of the  labelled h ap ten  (G ridley et a l, 1988; 
LeD oussal et a l, 1990; Stickney et a l, 1991; LeD oussal et a l, 1992; 
S o m asu n d aram  et a l, 1993). T um our w as detected, w ith in  the  liver and  at 
o ther locations, u sing  gam m a(y)-cam era and  im m u n o sc in tig ra p h y . 
Targeting of k n o w n  lesions w as 84%, and  new  lesions w ere d iscovered  
(G ridley et a l, 1988). A lthough  localisation of radiolabel w as reduced, the 
tum ourrtarget cell ratio  w as increased, resu lting  in  a three-fold  increase in  
im aging  efficiency w hen  com pared  to labelled M Ab (LeD oussal et a l, 1992). 
The BAb had  a faster b lood clearance an d  there  w as less up take  b y  the bone 
m arro w  and  liver th an  the p a ren t M Ab, thus reduc ing  side effects and  n on­
specific b in d in g  (S om asundaram  et a l,  1993). This w ou ld  be advantageous, 
particu larly  in  the even t of this system  being  used  for ra d io ­
im m unotherapy. A side effect of such trea tm en ts is the im m uno- 
m odula tion  of leucocyte popu la tions fo llow ing BAb and  rad ioactive  h ap ten  
ad m in is tra tio n . The responsiveness of the patien t's  lym phocytes is 
m arked ly  reduced. Conversely, the  cytotoxic activity  of NK-cells, including 
oxygen radical production , is increased  (G ridley et al., 1991a).
Therapeutic  doses of ta rg e ted  radiolabelled  h ap ten  m ust be h igher 
th an  those u sed  for diagnostic purposes, since deep  penetra tion  of solid 
tum ours is required . The long  half-life of labelled Ab resu lts in  h igh  levels 
of irrad ia tion  of no rm al tissues. W ith BAb the radiolabelled  hapten , w hich
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is rap id ly  cleared by  the kidneys, can be injected after the BAb has been  
localised in  the tum our, so reducing  dam age to norm al tissues (Britton et 
al., 1991). A lternatively, the  specificity of radiolabelled Abs could be 
im proved. It has b een  show n  th a t BAbs d irected  tow ards tw o diferent Ags 
on  the ta rget cell surface w ill increase the  specificity of the  BAb to  tha t cell 
w hen  com pared w ith  M Abs, w h ich  b ivalen tly  b ind  one A g (Wong & 
Colvin, 1987).
1.3.5 Immunochemistry & Enzyme Immunoassay:
Traditionally, cell types an d  certain  horm ones and  peptides have 
been  visualised b y  the use of conventional im m u n o ch em is try  o r ELISA. 
The practice of im m unochem istry  orig inated  w ith  A lbert H. Coons and  his 
colleagues (Coons et a l, 1941 & 1955) w ho  w ere  the  first to  label an  Ab w ith  
a fluorescent dye, an d  use it to iden tify  an  A g in  tissue sections. As a resu lt 
of the  absolute specificity of the  A b-A g reaction, positive identification of 
tissue constituents w as achieved and  m uch  of the  uncerta in ty  w as rem oved  
from  som e aspects of histopathology. The first fluorescent dye to  be 
a ttached  to an  an tibody  w as fluorescein isocyanate, b u t fluorescein 
isothiocyanate (FITC) soon becam e the label o f choice because the m olecule 
is m uch  easier to conjugate to the  Ab. These com pounds fluoresce w h en  
excited a t a w aveleng th  of 490nm  and  are easily  visible against a non- 
fluorescent background . The first enzym e to be u sed  w as peroxidase 
(A vram eas & Uriel, 1966; N ak an e  & Pierce, 1966), o ther enzym es include 
alkaline p h o sphatase  (M ason & Sam m ons, 1978) and  glucose oxidase 
(Suffin et a l, 1979). The developm ent of the  enzym e-substrate  colour 
reaction  identifies the  Ab b in d in g  site. Enzym e-labelled Abs have the 
advan tage  tha t an  o rd in a ry  transm itted-ligh t m icroscope can be u sed  and  
the p reparations are perm anen t. The developm ent of the enzym e reaction 
is progressive and  can be m onito red  and  stopped  w h e n  the  'signal-to -no ise ' 
ratio  is adequate . The label:Ab ra tio  used  in  conjugation m ust be carefully  
calculated. Ab activ ity  m ay  be altered  b y  an  excess of label and  u n ­
conjugated label m u st be rem oved  by  dialysis o r colum n chrom atography  
before the Ab can be used. All Ab m olecules m u st be labelled as an y  u n ­
labelled A b p resen t w ill com pete for b ind ing  sites w ith  the  labelled Ab and  
reduce the  visibility  of the final reaction.
In  his original m ethod  C oons (Coons & K aplan, 1950) u sed  a one-step 
(direct) s ta in ing  m ethod  in  w hich  the specific Ab w as conjugated to FITC. 
The conjugated  an tiserum , d ilu ted  in  PBS, w as allow ed to react w ith  a 
tissue section and  the  u n b o u n d  Ab w as th en  w ashed  off w ith  PBS. The 
section w as exam ined in  an  ultra-violet m icroscope and  the site of
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attachm ent of the Ab fluoresced apple green. The direct labelling m ethod 
w as subsequently  ad ap ted  to the  in d irec t im m unofluo rescence  techn ique 
(Coons et a t, 1955) w hich  is still w idely  used. In  this m ethod  the p rim ary  
Ab is no t conjugated, b u t a second layer is ad d ed  w hich consists of an  Ab 
ra ised  to the Ig of the species w hich  d o nated  the  first Ab, e.g. goat anti-rabbit 
Ig, w hich  is conjugated to FITC. The p rim ary  Ab, rabbit anti-Ag, w hich  is 
bound  to antigenic sites in  the  tissue section, then  acts as an  A g for the 
second fluorescent Ab. The indirect m ethod  often produces an  am plified 
signal, since tw o labelled anti-Ig  m olecules can b ind  to each p rim ary  Ab 
m olecule. In  addition, conjugation of a  label to  the  p rim ary  Ab is en tire ly  
avoided, along w ith  the  dam age to its reactiv ity  w hich  tha t entailed. The 
incubation  tim e req u ired  to allow  ad eq u a te  b ind ing  of p rim ary  and  
secondary  Ab ranges from  1 to 48 hou rs , dep en d in g  on  the activity and  
d ilu tion  of the  Ab. Sim ilar m ethods are  app lied  w ith  enzym e-labelled Ab. 
O ther m ethods involved  the  use of a second A g (hapten) as a label, 
v isualised b y  a second Ab, the  exploitation of the  s trong  attraction  betw een  
avid in  and  biotin, an d  num ero u s w ays of im prov ing  the  specificity and  
in tensity  of the  final reaction  an d  of carry in g  ou t m ultiple staining, (Polak 
& v anN oorden , 1987). ft
Im m unochem istry  is applied  only  to  tissue com ponents, and  so is 
lim ited in  application  to histological an d  histo-pathological in v es tig a tio n s . 
The developm ent of enzym e im m unoassays occurred  w ith  the realisa tion  
th a t A g or Ab could  be im m obilised onto solid supports  w ith  re ten tion  of 
the ir im m unological reactivity. This gave rise to  the enzym e-linked 
im m unosorben t assay  (ELISA), for the quan tita tive  m easurem ent of A g 
(Engvall & Perlm ann, 1971; Van W eem en & Schurs, 1971). As a resu lt, the 
possible applications of enzym e-labelled  Ab w ere  g reatly  increased. In  its 
sim plest form , ELISA technique closely resem bles im m unochem istry . The 
first step is the im m obilisation of A g to a solid phase, m ost com m only a 
polysty rene plate  w ith  96 w ells, each ho ld ing  150-250 [xl. N on-specific 
b in d in g  sites are  b locked u sing  a h igh  m olecular w eigh t pro tein  (e.g. BSA). 
The second step  is the  b in d in g  of the p rim ary  Ab. This can be enzym e- 
labelled (direct m ethod) o r un-labelled  (indirect m ethod). U nbound  Ab is 
w ashed  aw ay  w ith  PBS. Secondary  o r labelled Ab is th en  applied  for the 
indirect m ethod. This is often  the p re fe rred  m ethod, since one labelled Ab 
can be u sed  in  a n u m b er of d ifferen t assays. In  all cases, the  am o u n t of 
enzym e activity is detected  b y  its conversion  of a colourless substrate  to a 
h igh ly  co loured  p ro d u c t th a t can be v isually  or spectrophotom etrically  
determ ined . D esp ite  m echanisation  a n d  o ther im provem ents, th is  
p rocedure  can take from  six to tw en ty  fo u r hours, dep en d in g  on  the
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conditions and  reagents in use. The use of BAbs could considerably 
shortened  these procedures. Once the p late has been  coated and  blocked, 
BAb and  enzym e can be added  sim ultaneously, and  the plate developed in 
the usual m anner. Such techniques reduce the tim e for the assay w ith o u t 
loss of specificity for Ag. O ne possible d isadvantage of th is technique is the 
loss of the am plification step available w ith  the indirect m ethod. This 
problem  is less re levan t in  im m unochem istry  th an  in  ELISA. BAbs also 
allow  for the developm ent of novel assay  techniques not possible w ith  
labelled M Abs (Paulus, 1985; N o lan  & O 'Kennedy, 1993).
H am m erlin g  et a l  (1968) u sed  chem ically p roduced  BAbs, w ith  anti- 
IgG and  an ti-ferritin  specificities, to locate surface Ags b y  electron 
microscopy. Biologically p roduced  BAbs have been  applied  successfully to 
the  im m uno-chem ical analysis of som atostatin  an d  substance P, one a rm  of 
the  Ab reacting  w ith  the  pep tide  the o ther b in d in g  horse-rad ish  peroxidase 
(HRP) (Suresh et a l, 1986). These sam e principles have  been  applied  to 
ELISAs. K araw ajew  et al. (1988) have u sed  BAbs as b ridg ing  reagents for 
ELISAs for h u m an  chorionic gonado troph in  (hCG) an d  AFP A MAb, 
ra ised  against hCG  or AFP is labelled w ith  FITC. The BAb b inds bo th  the 
FTTC-labeHed M Ab an d  H R P an d  the ELISA is developed u sing  an y  HRP 
substrate." The sensitiv ity  w as fo u n d  to be sim ilar to conventional ELISAs. 
A n an ti-hC G /an ti-a lkaline  phosphatase  IgM -like Ab has also been  used  to 
develop an  assay  for hCG w ith  sufficient sensitiv ity  to  use  in a p regnancy  
test (Behrsing et a l, 1992). A u rease-based  im m unoassay  for hCG  has also 
been  described w hich  utilises BAb b in d in g  b o th  u rease  and  hCG. This assay 
system  could  detect 25 m lU /m l hCG  (Takahashi & Fuller, 1988). Some 
BAbs have been  show n  to  have g rea tly  increased  sensitiv ity  com pared  w ith  
conventional system s. A BAb w as p roduced  reactive against bo th  p- 
galactosidase an d  lu te in ising  horm one (Bugari et a l, 1990). This had  low  
reactiv ity  w ith  hCG  w h ich  com m only  in te rfe res  w ith  lu te in is in g  h o rm one  
asays. W hen  used  in  an  ELISA, the BAb detected concentrations as low  as
0.8 IU /m l. This com pared  w ell w ith  conventional ELISA (2.0 IU /m l), 
rad io -im m unoassay  (1.5 IU /m l) and  im m uno-rad iom etric  assays (0.5 
IU /m l). O ther BAbs resu lt in  reduced  sensitiv ity  com pared w ith  
co n v en tio n a l system s. A n  an ti-Il-2 /an ti-H R P  BAb w as u sed  to  develop an  
ELISA w hich  could  detect 11-2 in  the range 1.5-4.0 n g /m l. This com pared 
u n-favourab ly  w ith  s tan d ard  m ethods w hich  w ere  capable of detecting  0.2 
n g /m l  (S tratieva-T aneeva et a l, 1993). The use of BAbs in  ELISA should  
still be considered, how ever, since the  sim ultaneous addition  of reag en ts  
elim inates unnecessary  w ash ings an d  additions, thus red u c in g  tim e 
requ ired  and  increasing  the  reproducib ility  of the assay.
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A part from  basing  assays on  conventional system s, there  are m any  
p o ten tia l novel im m unoassay  form ats. BAbs have  been  used  to develop a 
hom ogeneous enzym e im m unoassay  system  (G orog et ah, 1989). Anti- 
C E A /an ti-p -galactosidase BAbs w ere p roduced  w hich  w ere capable of 
p ro tecting  the enzym e from  therm al denatu ration . H av ing  incubated CEA 
and  (3-galactosidase in  the presence of BAb, heatin g  the solution to 62°C  for 
1 h o u r destroyed the  free enzym e. U nder approp ria te  conditions, heat- 
resistan t enzym e activity  w as sh o w n  to be p roportional to the co n cen tra tio n  
of CEA in  the range  u p  to 75 n g /m l, the range  likely to be of clinical 
significance. O ther assays have been  postu la ted  b u t few  so far have been  
achieved (Paulus, 1985). E nzym e im m obilisation to a solid m atrix, or 
m ulti-enzym e im m obilization, b y  BAb has the potentia l to greatly  enhance 
responses in  enzym e-dependen t assays. Similarly, w ith  enzym e electrodes, 
the reaction tim e can be speeded  up  by  u sin g  BAb to link  the enzym es 
directly  to  the perm eable m em brane covering  th e  electrode. M ulti-enzym e 
sequences can be u sed  to increase the  analytical reperto ire  of the 
im m unoassays and  enzym e electrodes. W ith a p ro te in  analyte as a bridge, a 
pair of BAbs directed  against d ifferent epitopes on  an  analyte can b rin g  tw o 
indicator proteins in to  close proxim ity  and  thereby  generate  a m easurable 
signal. A gain a  v a rie ty  of de tection  system s are possible.
1.3.6 Summary:
Several M Abs have been  p roduced  and  used , w ith  v a ry in g  degrees of 
success, in  im m uno-therapy  an d  im m uno-diagnosis. Their use has been  
curtailed, particu larly  in  im m uno-therapy, b y  problem s w hich  include the 
im m unogenicity  of the  im m uno-conjugate  an d  loss of activity  resu lting  
from  conjugation. Some of these problem s m ay  be overcom e b y  the use of 
BAbs. BAbs are m onovalent, bispecific, A b-derived m olecules. BAbs can be 
p roduced  by  b o th  biological an d  chemical m eans and  can be used  to b ind  
tw o separate  Ags sim ultaneously. P roduction  m ethods h a v e  im p ro v ed  
greatly  in  recent years. BAbs have  been  tested  b o th  in vitro and  in  v ivo  
an d  found  to efficiently destroy  targe ted  tu m o u r cells. In  m any  instances 
BAbs w ere found  to  have g rea ter efficacy th an  the corresponding  M Ab 
conjugate. As w ell as tu m o u r cells, o ther d iseased tissues can be targeted  by  
BAbs for therapy. The area  of im m uno-d iagnostics has no t b een  developed 
to the  sam e extent as im m uno-therapeutics. This project sets ou t to look at 
the  chem ical p roduction  of BAb. In  particular, the  use of BAbs in  im m u n o ­
assays w ill be exam ined. It w ill be  som e tim e, how ever, before the full 
po tentia l of BAbs as a  pow erfu l tool in  b o th  im m uno-diagnostics and  
im m u n o -th erap eu tic s  is realised .
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1.4 LEUKAEMIA
T um ours of haem opoietic tissue m ay  involve lym phoid  cells, 
m yeloid cells or ery th ro id  cells. They are m ostly  m alignant sarcom ata. 
Those arising from  tissues th a t form  leukocytes are called leukaem ias and  
m ay be m yeloid, lym phatic  or m onocytic. Each of these m ay arise in  the 
chronic or the acute form . H u m an  leukaem ias w ere first recognised about 
165 years ago, b u t a cen tu ry  passed  before acu te /ch ro n ic  lym phocytic  
leukaem ia  and  acu te /ch ro n ic  m yelogenous leukaem ia w ere clinically 
differentiated. The clonal n a tu re  of each of these d isorders has since been 
established, (Bow m an & R and, 1984).
1.4.1 Acute Leukaemia:
Acute leukaem ia is a  general te rm  for a g ro u p  of m alignan t d isorders 
of blood leukocytes. A ge a t onset of disease an d  certain  m orphological 
characteristics have significant im plications for pa tien t su rv iv a l and  
responsiveness to chem otherapy. Acute lym phocytic leukaem ia (ALL) is 
the  p redom inan t form  of leukaem ia in  ch ildhood  and  the m ost com m on 
fo rm  of cancer in  children. The u su al cell of o rig in  appears to be a  "null" 
lym phocyte. These ch ildren  have  a relatively  good prognosis. A subset of 
patien ts w ith  a poor prognosis have neoplastic disease expressing surface 
antigenic features of T-lym phocytes. A cytoplasm ic enzym e expressed by  
norm al thym ocytes, te rm ina l deoxycytidyl transferase , is also expressed in  
m any  cases of ALL. T-cell ALL also express h ig h  levels of the enzym e, 
adenosine deam inase. Cell m ed ia ted  im m unity  to ALL can be 
dem onstrated  m ost read ily  w hen  the patien t en ters rem ission. The m ed ian  
surv ival in ch ildhood acute  leukaem ia is n o w  approach ing  four years. 
Acute leukaem ia in  adu lts  is p redom inan tly  of the myelocytic variety, 
a lthough  som e cases of lym phoblastic leukaem ia are also seen. Acute 
m yelogenous leukaem ia  has been  quite dificult to  treat, w ith  the m edian  
su rv ival tim es in  the range  of th ree  m onths. (K atzung, 1987)
1.4.2 Chronic Myelogenous Leukaemia:
Chronic m yelogenous leukaem ia (CML) is rare  in  childhood in  
w este rn  populations, b u t a sm all p eak  in  incidence has been  observed 
in ternationally  in  w hite  m ales u n d er age five. Incidence of the adu lt type 
CML begins to rise in  adolescence am ong  b o th  sexes and  increases steadily  
w ith  age. A n u m b er of env ironm en ta l factors, p a rticu la rly  rad ia tion  
exposure, have been  asociated w ith  CML developm ent. CML arises from  a 
chrom osom ally  abnorm al hem atopoietic stem  cell. The P h i  ch rom osom e
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associated w ith  CML w as the first leukaem ia chrom osom al abnorm ality  to 
be identified. The Ph^ chrom osom e is a chrom osom e 22 th a t has lost its 
long a rm  due to a reciprocal translocation  w ith  chrom osom e 9. This 
com bination produces a chim aeric m essenger RNA, w hich  translates into a 
larger p ro te in  than  norm al w ith  in  vitro  tyrosine kinase activity. Several 
g ro w th  factor receptors are ty rosine k inase-linked an d  it is recognised that 
this abnorm al p ro te in  can confer g ro w th  factor independence to several cell 
lines. Presence of the  Ph^ chrom osom e is indicative b u t no t diagnostic of 
CML. D iagnosis of CML is generally  no t difficult to establish. H ow ever, 
m is-classification has been  estim ated  to occur in  approxim ately  10-15% of 
patients w ith  this disorder. Some patien ts are incorrectly  diagnosed as 
hav ing  one of the closely re la ted  m yeloproliferative diseases such  as 
polycytaem ia vera, especially if th ey  are am ong the 10% w ith  P h i 
chrom osom e-negative CML. Survival in  CML is extrem ely variable b u t on 
average m edian  surv ival is in  the  range 40-47 m onths, (Finch & Linet,
1992).
1.4.3 Chronic Lymphocytic Leukaemia:
C hronic lym phocytic leukaem ia  (CLL) is rare  in  persons u n d er 30 
years, b u t incidence increases dram atically  w ith  age for bo th  sexes. CLL is 
the leukaem ia type w ith  the  h ighest incidence am ong persons aged  50-55 
years and  older. A bout 95% of persons w ith  CLL have the m atu re  B-cell 
type, less th an  5% have adu lt T-cell leukaem ia an  aggressive varian t of CLL 
caused b y  the  h u m an  T-cell lym photropic  v iru s  type 1 (HTLV-I), w hile less 
th an  2% have h a iry  cell leukaem ia. CLL has been  linked to exposure to 
acid-containing chemicals, a liphatic  an d  chlorinated  hydrocarbons and  
certain  organic solvents. L inks to o th e r en v iro n m en ta l facto rs rem ain  
ten u o u s and  pu ta tive  causative agents are no t w ell established. Familial 
aggregation  of CLL has b een  reported . A n u n d erly ing  inherited  
chrom osom e abnorm ality  (e.g. of chrom osom e 12) o r a h ig h  frequency  of 
chrom atid  exchange figures could  p red ispose  to CLL, (Finch & Linet, 1992).
B-cell CLL is characterised  by  susta ined  lym phocytosis of g reater than  
10*0/1  in  periphera l blood w ith  m atu re  appearing  lym phocytes and  bone 
m arro w  lym phocytosis of at least 30% in  bone m arro w  aspirates. In  typical 
cases of CLL the  cells are sm all w ith  a n a rro w  rim  of cytoplasm . The 
nuclear chrom atin  is dense an d  nucleoli are no t visible. M orphologically 
th ey  resem ble sm all resting  B-cells. CLL cells express surface m em brane Ig 
(Smlg), C 3dr com plem ent recep tors an d  receptors for the Fc fraction of Ig. 
Sm lg are  constantly  restric ted  to a single light chain, and  frequently  express 
IgM  or b o th  IgM  an d  IgD. CLL B-cells also express several Ags, including
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D -related h u m an  leukocyte A g an d  Ags re la ted  to B-cells. M ost cases of B- 
cell CLL appear to  react w ith  anti-CD19, CD20, CD24, CD37 and  CD21 MAbs. 
A bout 60% of CLL are positive for CD23, w hereas m em brane positiv ity  w ith  
CD22 is infrequent. CLL B-cells have been  show n  to express a 69 kD a 
glycoprotein th a t is n o t expressed b y  norm al blood T and B lym phocytes, 
thym ocy te-cu ltu red  T- an d  B-cell lym phoblasto id  cell lines, or acute 
lym phoblastic leukaem ia cells (D ighiero et a l, 1991). The G12 Ab, p roduced 
in  ou r laboratory, has been  sh o w n  to b ind  to a  CLL specific, cell surface Ag 
of m olecular w eigh t 69.2 kDa, This Ab w as show n to d istinguish  CLL cells 
from  a range of o ther leukaem ias an d  m yelo-proliferative disorders 
(L annon et a l, 1988). The G12 Ab w as u sed  in  this project to develop a 
range of diagnostic tests for CLL w hich  are quicker and  requ ire  less expertise 
th an  trad itional histopathological exam ination. It is p roposed  th a t these 
could form  p a rt of a b a tte ry  of tests to de term ine  the diagnosis and  progress 
of the disease.
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1.5 COUMARIN
C oum arin  is a n a tu ra lly  occuring constituent of m any  plants and 
essential oils. It derives its n am e from  the p lan t C oum arouna  odorata. 
C oum arin  is a m em ber of a class of com pounds called benzopyrones. These 
consist of fused benzene and  a -p y ro n e  rings. C oum arin  has a m olecular 
w eigh t of 146.15 D a and  exists as colourless, glistening, sm all plates w ith  a 
p leasan t and  characteristic odour. It often occurs as an  odourless complex 
conjugated to sugars and  acids, from  w hich it is released b y  the action of 
enzym es, acids or u ltrav io let rad iation .
1.5.1 The Action & Applications of Coumarin:
C oum arin  com pounds have  been  u sed  to trea t su ch  diverse ailm ents 
as cancer, bu rns, brucellosis an d  rheum atic  disease, and  have been  used as 
anti-spasm odics. C oum arin  has a w ide varie ty  of uses in  industry, m ainly  
due  to  its s trong  frag ran t odour. C oum arin  has a num ber of na tu ra l and  
synthetic derivatives, b u t on ly  a few  are of econom ic im portance. These 
inc lude :
3,4-dihydroxycoum arin, u sed  m ainly  in  the perfum e m inistry.
6-m ethylcoum arin , u sed  as a flavour enhancer. W
7-am ino-4-m ethylcoum arin , u sed  as a laser dye.
4-hydroxycoum arin , a p recu rso r of d icoum arol and  w arfarin .
am ino-m ethy lcoum arin  acetic acid, a fluorescent label,
7-hydroxycoum arin , u sed  in  sunscreen  and  fluorescent brighteners.
D erivatives of 7-hydroxy coum arin  (7-OHC) are also used  as fluorigenic 
enzym e substrates (Cohen, 1979; K haflan et al., 1986; Egan et al., 1990).
C oum arin  is m etabolised initially by  a specific cytochrom e P-450- 
linked m ono-oxygenase enzym e system  in  liver m icrosom es, resu lting  in 
hydroxylation  to fo rm  7-OHC. The levels of th is enzym e have been  show n 
to be v e ry  h igh  in  h u m an  liver m icrosom es, a lthough  there exists a large 
in ter-indiv idual variab ility  in  the  activity of th is enzym e (Pelkonen et al., 
1985). The ra te  of 7-O H C fo rm ation  d u rin g  the first tw o  hours after 
co u m arin  ad m in is tra tio n  sh o w s in te r-in d iv id u a l variability, b u t is stable 
an d  reproducib le for a g iven  ind iv idual (Rautio et al., 1992). C oum arin , 
hav in g  been  m etabolised to fo rm  7-OHC, undergoes g lucuron idation  p rio r  
to  excretion. B etw een 30% an d  100% of an  oral dose of coum arin  w as 
recovered  w ith in  fou r h o u rs  of adm inistration , as 7-O H C in  the u rine  of 
vo lu n tee rs  (Rautio et al., 1992). C oum arin  is often  considered a p ro -d ru g  
due  to its rap id  m etabolism  to  7-O H C. This th eo ry  is partia lly  substantiated , 
since coum arin  has a  sh o rt half-life and  low  bioavailability. Various in
55
vitro  and  in  v ivo  studies have suggested  th a t 7-O H C and  not coum arin  is 
the pharm acologically active agent. It has been  show n that 7-OHC is a m ore 
po ten t cytostatic agent than  coum arin. These effects are reversible 
(M arshall et al., 1993). In vitro  studies suggest tha t 7-OHC, and  not 
coum arin, significantly increase the phagocytic activity of h um an  
n eu tro p h il granulocytes, w hile reducing  the  m otility  of carcinom a cells, so 
reducing  the possibility of m etastasis (Rosskopf et al., 1992; Z anker et a l,
1993). In  clinical trials coum arin  has b een  effective in  the treatm ent of 
cancers, particu larly  m elanom a and  renal cell carcinom a. Significant 
p ro longation  of progression-free in tervals and  survival, w ith  m in im a l 
toxicity, has been  repo rted  (review ed by  M arshall & M ohler, 1993). These 
trials are to be continued.
1.5.2 Detection of Coumarin & Coumarin Derivatives:
The ability to quickly and  easily m easure  levels of coum arin  an d  7- 
O H C  in  a varie ty  of sam ples is im portan t for m etabolic and  activity studies 
of these drugs. A v e ry  w ide  range of techniques have been  used  to analyse 
coum arin  and  coum arin-related  com pounds. Two of the  m ost co m m o n ly  
u sed  techniques are H PLC an d  spectrofluorim etry. Less com m only used  
techn ique! include: p ap er chrom atography, th in  layer chrom atography, gas 
chrom atography , rad io-labelling , po la rog raphy , lum inescence and  
vo ltam m etry  (review ed by  Egan et al., 1990). These techniques have been 
developed quan tita tively  and  qualita tively  for the determ in tion  of 
coum arin  and  coum arin  derivatives. They have  been  applied  to a varie ty  
of sam ples including: u rine, p lasm a, serum , blood, tissue honogenates, and  
p lan t m aterial. M any  of these m ethods requ ire  significant sam ple 
p rep ara tio n  p rio r to analysis. M any  of these ex traction  procedures are time- 
consum ing an d  cum bersom e and, hence, p rohib itive  w h en  hand ling  large 
n u m bers of sam ples. A recently  developed H PLC m ethod provides a 
sim plified m ethod for the ro u tin e  analysis of coum arin, 7-O H C and  7-OHC- 
glucuronide. The m eth o d  involves a single so lven t extraction procedure 
an d  utilises an  in te rn a l s tandard . The m ethod  is accurate in  the range 0.5- 
100 pig/m l and  has been  u sed  successfully to m onito r the  u rin a ry  excretion 
of these com pounds (Egan, 1993). A spectrophotofluorim etric  m ethod w as 
also developed w ith  the sam e linear range. This h ad  the advantages of not 
need ing  p rio r so lvent extraction of the sam ples, u s in g  v e ry  sm all sam ple 
v o lu m es  and  a llow ing  for the  sim ultaneous determ ination  of large 
n u m bers of sam ples, th ro u g h  the use of 96-well m icrotitre plates. The 
m ethod  had  the  d isadvan tages of only  m easu rin g  7-O H C an d  7-OHC- 
g lucuronide, an d  n eed ing  a  fluorescence spectrom eter w ith  m icrotitre plate
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capacity, an  instrum ent no t alw ays readily  available (Egan, 1993). A n u m b e r  
of Ab based  assays have recently  b een  developed. A com petitive ELISA w as 
developed w hich  could  detect 7 -0 HC, in  the  range 5-lOOng/ml, in  u n ­
extracted urine. The resu lts obtained w ere  show n  to be consistent w ith  
those obtained b y  HPLC. The polyclonal Abs u sed  w ere  show n  to be specific 
for a num ber of coum arin  derivatives. These Abs w ere  also used  in  the 
developm ent of A b-based electrochem ical assays. The first is a non­
com petitive assay and  requires solvent extraction of the u rine  sam ples. T he 
Ab is b o u n d  to a glassy carbon electrode. In teraction  of the Ab an d  7-OHC 
causes m easureable fluctuations in  the cu rren t passing  th ro u g h  the 
electrode. The second is a com petitive assay  in  w hich  7-O H C is b o u n d  to 
the electrode. The 7-O H C in  the  sam ple m u st com pete w ith  the b o u n d  7- 
OHC for b ind ing  of the Ab. A lterations in  the cu rren t th ro u g h  the 
electrode, caused b y  Ab binding , allow  the  m easurem ent of 7-OHC levels in  
the sam ple (Egan et al., 1994). The need  still exists for a rapid , sim ple assay, 
w ith  m in im um  sam ple p rep a ra tio n  and  h igh  sam ple capacity, for th e  
rou tine  determ ination  of coum arin , 7-O H C and  7-O H C -glucuronide in  
patien t sam ples. It is th o u g h t th a t an  A b-based app roach  w ill provide the 
answ er to this problem , and  th a t BAbs have potential in  this area. ,
?■
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1.6 PROJECT OUTLINE
This project w as set u p  to  exam ine the  chem ical p roduction  and  
diagnostic application of bispecific antibodies. A num ber of bispecific 
antibodies w ere p roduced  an d  tested , p rio r to the developm ent of detection 
system s for chronic lym phocytic leukaem ia and  7-hydroxy-coum arin. This 
involved  a four-fold approach:
1. The technology for the  chem ical p roduction  of bispecific antibodies 
b y  tw o  separate  m ethods (B rennan et al., 1985; G lennie et al., 1987) w as set 
up . It w as show n, u sing  H PLC, th a t bo th  of these resu lted  in  the desired 
p roduct. These m ethods w ere  com pared for ease of use and  level of 
p roduction  of bispecific antibody.
2. The bispecific antibodies p roduced  b y  bo th  m ethods w ere  tested  by  a 
series of ELISAs. These w ere  carried  o u t to show  th a t the molecules 
p roduced  w ere h yb rid  m olecules, w hich  h ad  re ta ined  the ir b ind ing  
specificity. A second series of ELISAs w as u sed  to exam ine the extent to 
w hich  the affinities of the bispecific antibodies w ere  re ta ined  com pared to 
the  paren ta l IgG and  F(ab ')2 m olecules.
3. A rabbit polyclonal anti-alkaline phosphatase  an tibody  w as produced  
an d  used , along w ith  the m u rin e  m onoclonal an ti-ch ron ic  lym phocytic  
leukaem ia an tibody (G12), to p roduce  a bispecific antibody. This bispecific 
an tibody  w as tested  for specificity an d  affinity by  ELISA. M ethods for the 
detection of chronic lym phocytic leukaem ia cells w ere  developed using  the 
G12 X anti-alkaline phosphatase  antibody. The first m ethod w as a 
conventional ELISA system , u sin g  a 96-well po lystyrene plate  as a solid 
support. The second m ethod  w as a suspension  ELISA, th is w as carried  out 
in  1.8 m l conical centrifuge tubes. A n im m unohistochem ical m ethod w as 
also developed .
4. The polyclonal an ti-alkaline phosphatase  an tibody  w as used  along 
w ith  a polyclonal anti-7-hydroxy-coum arin  an tibody  to p roduce a bispecific 
antibody. This bispecific an tibody  w as tested  for specificity and  affinity by  
ELISA. A com petitive ELISA w as set up  for the quan tita tive  detection of 7- 
h y d ro x y -co u m arin .
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CHAPTER 2 
MATERIALS
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2.1 REAGENTS
The follow ing reagen ts w ere  supplied  b y  Sigm a Chem ical Co., Poole, 
D orset, England; alkaline ph o sp h atase  (bovine in testinal m ucosa, affinity 
pu rified ), am m o n iu m  su lphate , bov ine  se ru m  album in , 5-brom o-4-chloro-
3-indolyl phosphate , d i-m ethyl-su lphoxide, E llm an's reagen t, e th y len e- 
diam ine-tetra-acetic acid (EDTA), F reund 's  incom plete adjuvant, L- 
g lu taraldehyde, glycerol, glycine, horse  rad ish  peroxidase (affinity purified), 
m ercap to -e thy lam ine , m ethy lene-b is-acry lam ide , pepsin , o -phenylene 
diam ine, o -pheny lene  d im aleim ide, poly-L -lysine, pristane, sodium  acetate, 
sodium  carbonate, sod ium  hy d ro g en  carbonate an d  all antibodies no t 
p roduced  in  house.
The follow ing reagents w ere  supplied  b y  Riedel de H aen  AG, 
H annover, G erm any: acetic acid, am m o n iu m  p e r  su lp h a te , b ro m o p h en o l 
b lue, citric acid, d i-sod ium  h y d ro g en  phosphate , glycerine, hydrochloric 
acid, iodoacetic acid, m ercaptoethanol, po tassium  d i-h y d ro g en  phosphate , 
sod ium  chloride, sod ium  d i-hyd rogen  phosphate , tris[hydroxym ethyl] 
am inom ethane  & Tw een 20.
The follow ing reagen ts w ere  supplied  b y  BDH Chem icals Ltd., Poole, 
D orset, England: acrylam ide, hy d ro g en  peroxide 30% (w /v), po tassium
chloride, sodium  azide, sodium  dodecyl su lphate  & tetra-m ethyl ethlyene 
d i-am ine (TEMED).
The follow ing w ere  supplied  b y  Pierce Chem icals, 3747 N o rth  M eridian 
Road, EO. Box 117, Rockford, II 61105, USA: Bicinchoninic acid assay kit,
IODOGEN, Pro tein  A colum n kit.
The follow ing w ere supp lied  b y  Pharm acia  Fine Chem icals AB, P.O. 
Box 175, S-75104 U ppsala 1, Sw eden: CN Br-Sepharose 4B, Sephacryl S-200, 
Sephadex G-25, G-75, G -100.
All organic solvents w ere  of HPLC grade an d  w ere supplied  by  
LabScan, U nit T26, Stillorgan Industria l Park, Co. D ublin. These w ere: 
acetic acid, acetone, am inom ethyl p ropanol, chloroform , d im e th y l 
fo rm am ide, e thanol, iso p ro p an o l & m ethanol.
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All cell cu lture m edia, supplem ents, sera and  disposable plastic-w are 
w ere supplied  b y  Flow  L aboratories, W oodcock Hill, H arefield, H erts., 
England.
Stains u sed  in  cytocentrifuge preparations fo r histological 
exam ination w ere  purchased  from  D iagnostic D evelopm ents, U nit 2-4, 50A 
E verton  Road, Berkdale, S outhport, England.
2.2 EQ U IPM EN T
Item Manufacturer Supplier
B alance O H au 's  B rainw eigh B-100 1
C en trifuge  H eraeus, Labofuge GL 2
C ytosp in  H eraeus, Sepatech 2
H o m o g e n ise r  U ltra  Turrax, K ika-W erk 1
H PLC system  Beckm an, System  G old 3
Incubators (CO2 ) Leec 4
Lam inar flow  cabinets In terM ed, M icroflow  p a th fin d er 4
M agnetic s tirre r Ikam ag  RCT 1
M icroscopes;
F luorescence  Leitz Labrolux 2
L igh t N ik o n  SE 2
Phase contrast N ik o n  SE 2
M ini-gel E lec trophoresis  LKB 5
Peristaltic p u m p  P-l P h a rm ac ia  5
p H  m eter B eckm an, Z erom atic  SS-3 1
P la te-R eader T ite rtek  T w in read erp lu s  2
S p ec tro p h o to m e te r U V /V isib le, UV-160A, S h im adzu  4
S uperspeed  C entrifuge Sorvall RC-5B, R efrigerated  4
W ate rb a th  C linicon, P rec itherm  PFV 1
Suppliers:
1. Lennox, John F. K ennedy Dr., N aas Rd., D ub lin  12.
2. M edlabs, U nit lc , S tillorgan Industria l Pk., Stillorgan, D ublin  4.
3. B.M. B row nes Ltd., Sandyford  Industria l Est., Sandyford, Co. D ublin.
4. M edical Supply  Co., U nit 9, S an try  Industria l Est., Santry, D ublin  9.
5. U nited  D ru g  PLC., B elgard Rd., D ublin  24.
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3.1 CELL CULTURE METHODS
Four cell lines w ere  u sed  in  this project: K562 is a h u m an  ery thro- 
leukaem ic cell line w ith  a non -ad h eren t g ro w th  pa tte rn . NSO is a m urine 
m yelom a cell line w ith  a non -ad h eren t g ro w th  pattern . G12 is a  m urine 
hybridom a cell line, w hich  secretes antibodies reactive w ith  PBLs from  
patients suffering  from  chronic lym phocytic leukaem ia and  the cell line 
K562. G12 has a non -ad h eren t g ro w th  pa tte rn . N RK  is a cell line derived  
from  norm al ra t k idney  cells, w hich  has an  ad h eren t g row th  pattern .
3.1.1 Storage of Cell Lines:
Long term  storage of cell lines w as in  cryotubes, in  liquid  n itrogen  at 
-186°C. T haw ing  of cells w as accom plished b y  im m ersion of the cryotube in  
a  37°C w aterbath  for 2 m in. The cells w ere  w ashed  w ith  D ulbecco 's 
M odification of Eagle's M edium  (DMEM) an d  centrifuged  at 2,000 rp m  for 
10 min. The pelletted  cells w ere  resu sp en d ed  in  DM EM  supplem ented  w ith  
50% (v /v ) H am 's F-12 m edium , 10% (v /v )  foetal calf serum  (FCS), 2% 
(w /v )  H epe's buffer (1 M, p H  7.2), 1% (v /v )  L -glutam ine (200 mM) an d  2% 
(v /v )  penicillin (5000 IU /m l)/s tre p to m y c in  (5,000 pig/ml). These w ere 
transferred  to a 25 cm^ sterile tissue cu ltu re  flask, w hich  w as sealed and 
placed in  an  incubator at 37°C.
Cells to be frozen  w ere  suspended  in  the g ro w th  m edium  b y  gentle 
ag itation  of the cu ltu re  flask. The cell suspension  w as decanted in to  a 30 m l 
sterile centrifuge tube  an d  centrifuged  a t 2,000 rp m  for 10 min. The cells 
from  a 25 cm^ flask  w ere  resu sp en d ed  in  1.5 m l of FCS, supplem ented  w ith  
7.5% (v /v )  d im ethylsu lphoxide (DMSO), an d  tran sferred  to  a cryotube u s in g  
a sterile p asteu r p ipette. The cryotubes w ere  low ered  into a  container of 
liqu id  n itrogen  so th a t the tem pera tu re  of the cells w as reduced  at a  ra te  of 
l° C /m in  to -186°C. The cryotubes w ere  th en  subm erged  in  liqu id  n itrogen  
for long  te rm  storage.
3.1.2 Expansion of Cell Lines In Vitro :
All cell lines u sed  w ere g ro w n  in  e ither D M EM  su p p lem en ted  w ith  
10% (v /v ) FCS, 2% (v /v )  H epes bu ffer (1 M , p H  7.2), 2% (v /v )  penicillin 
(5,000 IU /m l) /  s trep tom ycin  (5,000 n g /m l) and  1% (v /v ) L-glutam ine (200 
m M ) (DM EM .Sio) o r DM EM  supp lem ented  w ith  5% (v /v ) FCS, 2% (v /v ) 
H epes buffer (1 M, p H  7.2), 2% (v /v )  penicillin (5,000 IU /m l) /  streptom ycin 
(5,000 ¡wg/ml) an d  1% (v /v )  L -glutam ine (200 mM ) (DMEM.S5). The 
m edium  w as changed w henever the  p H  fell be low  p H  7, this w as indicated 
b y  the change in  colour of the phenol red  indicator in  the m edium  from
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r e d /p in k  to  o range/yellow . For those cell lines w hich  are  non-adherent, 
the cells w ere suspended  w ith in  the  flask  b y  gentle agitation. The cell 
suspension  w as decanted  into a  30 m l sterile centrifuge tube  an d  cen trifuged  
for 10 m in at 1,500 rpm . For ad h eren t cell lines, the old m edium  w as 
p o ured  off, the cells w ere then  exposed  to trypsin  (0.25% (w /v )  in  EDTA (0.2 
m g /m l)) for 5-15 m in  at 37°C. The cells w ere  suspended  w ith in  the flask 
an d  centrifuged  as above. The old m edium , o r trypsin  solution, w as p o u re d  
off and  the cells resuspended  in  fresh  m ed iu m  (DMEM.Sio or DMEM.S5). 
The cell suspension  w as re tu rn ed  to  sterile tissue culture flasks, w hich w ere 
sealed an d  placed in  an  incubator a t 37°C.
3.1.3 Expansion of Cell Lines In Vivo :
M any m urine  cell lines can be g ro w n  as an  ascitic tum or in  the 
abdom inal cavity of a m ouse. In  the  case of hybridom as the  resu ltan t ascitic 
fluid is rich  in  antibody, secreted b y  the g row ing  cells. Ascitic fluid 
p roduction  is g rea tly  increased if an  ad juvan t is u sed  to prim e the mice 
p rio r to  injection of the cells. P ristane (2,6,10,14 - te traethyl-pentadecane) 
can be u sed  for p rim ing  the mice. The mice w ere  injected w ith  0.5 m l of 
p ristane, i.p.. Seven o r eight days la te r the  mice w ere injected w ith  10^ cells
i.p.. A n alternative  to Pristane is F reund 's incom plete ad juvant, 0.5 m l of 
w hich  w ere adm inistered  i.p.. Tw enty four h ou rs  la te r the  mice w ere 
injected w ith  10^ cells i.p.. The anim als w ere left u n til abd o m in a l 
d istension  occurred. Tapping can  th en  be carried  ou t if desired, i.e. ascitic 
fluid is rem oved from  the abdom inal cavity u sing  a syringe. The a n im a ls  
w ere  again  left un til abdom nal d istension  occurred, a t th is tim e the a n im a ls  
w ere  sacrificed b y  cervical dislocation. The sacrificed an im al w as w ashed 
w ith  alcohol an d  the  ascitic flu id  rem oved u n d er sterile conditions and  
placed in  a 30 m l sterile centrifuge tube. This w as then  centrifuged  a t 2,000 
rp m  for 10 min. The fa tty  layer w as rem oved using  a sterile pasteu r pipette 
an d  discarded. The antibody-con tain ing  su p ern a tan t w as p o u red  into 
sterile vials and  sto red  at -20°C . The pelletted  cells w ere w ash ed  and  grow n 
as described previously.
3.1.4 Cell Counts & Viability Testing:
Cell counts w ere  p e rfo rm ed  on an  im proved N eu b au e r H em o- 
cytom eter slide. T rypan b lue  w as used  rou tinely  to determ ine cell 
v iabilities (W ilson, 1986). O ne volum e of cell suspension  w as added  to an  
equal volum e of stain  (0.25%, w / v  in  PBS), left for one m inu te  and  
exam ined w ith in  five m inutes b y  ligh t microscopy, using  a  phase contrast 
setting. L onger incubation  periods lead to non-specific up take  of dye and
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inaccurate results. Live cells excluded dye and  rem ained  w hite , w hile dead 
cells stained  blue.
3.1.5 Mycoplasma Detection - Hoechst 33258 Fluorescence Assay:
Cell lines w ere  reg u la rly  screened  fo r co n tam ination  w ith  
m ycoplasm a u sing  NRK cells an d  the  D N A  chelating agen t bisbenzim id 
(H oechst 33528). A vial of m ycoplasm a-free N RK  w as g ro w n  in antibiotic- 
free m e d iu m  (DM EM .S5) for a t least tw o  passages. C ultures w ere then  
established on  sterile glass coverslips in  sterile petrie  dishes a t 10^ ce lls /m l 
and  g ro w n  overn igh t in  antibiotic-free DMEM.S5 at 37° C, in  a n  a tm osphere  
m ain tained  a t 5% CO2 . S up ern a tan t from  cultures to be screened w as 
applied  to  the  p rep ared  petrie  d ish  an d  incubated  for three  days at 37°C, in  
an  a tm osphere  m ain ta ined  a t 5% CO2 . D uplicate N RK  cultures w ere  fed 
w ith  fresh  m edium  and  used  as a negative  control. The coverslips w ere 
w ashed  th ree  tim es in  PBS, keep ing  the  cells upperm ost, an d  fixed for 6 
m in in  m ethanolracetone (1:1), a t -20°C . The coverslip p reparations w ere 
rinsed  th ree  tim es in  PBS and  sta ined  for lOm in in  H oechst 33258 (0.05 
pig/m l in  PBS). The excess s ta in  w as w ashed  from  the  cells and  th e  
coverslips air-dried  and  m o u n ted  on  clean slides. Slides w ere  exam ined 
u n d e r a fluorescence m icroscope (Leitz Labrolux) u s ing  the 100X, oil- 
im m ersion  lens. U ncontam inated  cells fluoresce in  the  nucleus only, 
w hile contam inated  cells show  fluorescence in  the cytoplasm  as w ell as the 
n u c leu s .
3.2 ANTIBODY PRODUCTION
3.2.1 Polyclonal Antibody Production:
Polyclonal antibodies w ere  ra ised  b y  im m unisation  of a  m ature, 
m ale, N ew  Z ealand w hite  rabbit. P rio r to  im m unisation , the  anim al w as 
b led  from  the  m arg inal ear vein, to  p rov ide control serum . To 1 ml of 
F reund 's  incom plete ad juvan t w as added  100 pil alkaline phosphatase  
so lu tion  (10 m g /m l in  PBS). The tw o  layers w ere m ixed to  p roduce an  
em u ls io n  (Kika-Werk, U ltra-Turrax hom ogeniser). A 1 m l sam ple w as 
injected i.d., a t various sites a long  the anim als back. Booster 
im m u n isa tio n s  w ere  given a t 28 day  in tervals. The anim al w as b led  from  
the  m arginal ear ve in  on d ay  12 of each 28 day  cycle. The cycles w ere 
continued  u n til the an tibody titre  w as sufficiently h igh  (i.e. g rea ter than  
1:10,000), as de term ined  b y  ELISA (Section 3.6).
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3.2.2 Ammonium Sulphate Precipitation:
Immunoglobulins were precipitated from ascitic fluid, or culture 
supernatants in 50% saturated ammonium sulphate solution, according to 
the methods of Hudson and Hay (1980).
The ascitic fluid was centrifuged for 20 min at 15,000 rpm, at 4°C  
(Sorvall RC-5B refrigerated superspeed centrifuge). The supernatant was 
then filtered through glass wool. The solution was adjusted to pH 4.75 
using HC1 and left at 4°C for 1 hr. This was then centrifuged for 20 min at
15,000 rpm, at 4°C. The supernatant was adjusted to pH 7 using NaOH. An 
equal volume of saturated ammonium sulphate (pH 7.4, (NH4)2SC>4) was 
added drop wise to the stirring mixture and left at 4°C for 1 hr. The mixture 
was then centrifuged for 20 min at 15,000 rpm, at 4°C. The pellet was 
resuspended in 50% (w /v) (NH4)2SC>4 (pH 7.4) and centrifuged for 20 min 
at 15,000 rpm, at 4°C. The pellet was resuspended in the minimum 
amount of PBS for storage at -20°C.
3.3 AFFINITY CHROMATOGRAPHY
Affinity chromatography is a type of adsorption chromatography in 
which the molecule to be purified is specifically and reversibly adsorbed by a 
complementary binding substance (ligand) immobilised on an insoluble 
support (matrix). Ligands containing primary amino groups are readily 
coupled to polysaccharide matrices which have been activated by cyanogen 
bromide. For this reason CNBr-activated Sepharose is regularly used for 
the immobilisation of ligands, (Axen et at, 1967; Cuatrecasas, et ah, 1968).
3.3.1 Coupling of Ligand:
The required amount of CNBr-activated Sepharose 4B (Pharmacia) 
was weighed out and suspended in 1 mM HC1 (3.5 m l/g). The gel was 
transferred to a scintered glass filter (5 ml Gooch crucible) and washed with 
1 mM HC1 for about 15 min (200 m l/g). The gel was then washed with 
coupling buffer (0.1 M NaHC0 3 , pH 8.3, containing 0.5 M NaCl), 5 ml of 
coupling buffer for every 5 g of gel. The ligand was dissolved in coupling 
buffer (2 m g/m l). The ligand and gel were combined in a stoppered vessel 
and the mixture rotated end-over-end for 2 hr at room temperature. The 
mixture was returned to the scintered glass filter and washed with coupling 
buffer (5 m l/g  gel), to remove any excess ligand. Any remaining active 
groups were blocked by suspending the gel in coupling buffer with glycine, 
0.2 M, and mixing gently for 1 hr at room temperature. The gel was then 
washed with three cycles of alternating pH, in the scintered glass filter. Each
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cycle consisted of a wash with acetate buffer (0.1 M, pH 4), containing NaCl 
(0.5 M), followed by a wash with Tris buffer (0.1 M, pH 8) containing NaCl 
(0.5 M). The gel was suspended in PBS and a column poured in a 1 ml 
syringe, the outlet having been stopped with a plug of glass wool. The 
column was stored at 4-8°C.
3.3.2 Use of Immunoadsorbent:
The column was washed with PBS (0.02 M, pH 7.1) to rem ove  
leached protein. Fractions were collected until the Abs280nm was less than 
0.03. The sample was applied slowly followed by PBS (0.02 M, pH 7.1) and 
the column washed as before, until collected fractions had Abs280nm of less 
than 0.03. The PBS (0.02 M, pH 7.1) was run to the top of the gel before the 
dissociation buffer was applied (glycine/HCl, 0.1 M /0.1 M, pH 2.5). When 1 
ml of dissociation buffer had run onto the column, the outlet was clamped 
for 15 min. The dissociation buffer was used to elute the sample into 1 ml 
fractions, each containing 100 [xl of Tris-HCl (1 M, pH 10.5) to neutralise the 
pH. The fractions were monitored for protein by measuring the 
Abs280nm.- The column was regenerated using three cycles of alternating 
pH, using acetate buffer (0.1 M, pH 4) with 0.5 M NaCl and Tris buffer (0.1 
M, pH 8) with 0.5 M NaCl.
3.3.3 Protein A Chromatography:
Protein A is isolated from Staphylococcus aureus and shows strong, 
specific binding for the Fc part of the IgG molecule (Krovall et a l, 1970; 
Langone et al., 1978). IgG can be purified from solution using Protein A as 
the ligand in affinity chromatography. Pre-packed Protein A Sepharose 
columns are available from a variety of suppliers (column volume of 1 ml 
or 5 ml); a similar protocol can be applied to each. The column was 
equilibrated with at least eight column volumes of binding buffer (Tris-HCl, 
50 mM, pH 8.6). The sample was diluted with an equal volume of binding 
buffer, before being applied to the column. The column was allowed to 
stand for 15 min to allow adsorption of the IgG to the Protein A to occur. 
The column was washed with ten column volumes of binding buffer to 
remove unbound protein. To release the IgG the column was washed with 
five column volumes of elution buffer (Citrate buffer, 0.1 M, pH 4). 
Prepared collection tubes, each containing 50 pil of Tris-HCl (1 M, pH 9) to 
neutralise the elution buffer, were used to collect 1 ml fractions of elution 
buffer. The BCA protein assay was used to identify those fractions 
containing purified protein. These were pooled and stored at -20°C. The
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columns were washed and stored in 20% ethanol. They can be re-used up 
to twelve times.
3.3.4 Affi-T Chromatography:
Affi-T (Kem-en-Tec) is a matrix with an imm obilised thiophilic 
ligand. Most proteins will bind to Affi-T at high concentrations of 
ammonium sulphate and will easily be eluted by gradually lowering the 
concentration of salt in the washing buffer (Lihme & Heegaard, 1991).
The matrix is supplied as a 50% aqueous suspension with 15 mM 
sodium azide. The gel was washed with distilled water and drained under 
vacuum in a scintered glass filter until cracks appeared in the gel bed. The 
dry gel was weighed out (5 g) and suspended in excess (NH4)2S0 4  (0.75 M). 
A 10 cm x 1 cm column was poured and washed with ten column volumes 
of (NH4)2S0 4  (0.75 M). The sample was adjusted to 0.75 M (NH4)2S04  and 
a 3 ml volume applied to the column. The column was washed with the 
same buffer until a baseline was reached (Abs280nm < 0.03). Bound 
immunoglobulins were eluted in 0.05M Tris (pH 9) and 1 ml fractions 
collected. All protein-containing fractions were pooled and stored at -20°C 
for future use. The column was regenerated by washing with distilled 
water followed by 0.01 M sodium hydroxide containing 20% (v /v)
isopropanol, followed by distilled water.
3.4 SIZE EXCLUSION CHROMATOGRAPHY
Size exclusion chromatography is a commonly used method for the 
separation of biological macromolecules (Porath & Flodin, 1959). The 
separation depends on the different abilities of the various sample 
molecules to enter pores in the stationary phase. Large molecules never 
enter the stationary phase and move through the chromatographic bed 
fastest. Smaller molecules, which enter the gel pores, move more slowly 
through the column, since they spend some time in the stationary phase. 
Molecules are, therefore, eluted in order of decreasing molecular size.
3.4.1 Low Pressure Chromatography:
Sephadex (Pharmacia) is a bead-formed gel of cross-linked dextran 
available in a variety of pore sizes and, hence, fractionation ranges. The 
required amount of dry Sephadex, of the desired grade, was weighed out 
and allowed to swell in excess PBS overnight at room temperature. The gel 
was then degassed under vacuum for 15 min. The gel was poured into the 
column (generally 15 cm x 1 cm) and allowed to settle while washing with
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at least five colum n volum es of m obile phase. This w as carried  o u t u sing  a 
peristaltic p u m p  (P-l, Pharm acia) a t a flow  ra te  of 1 m l/m in . The sam ple 
w as applied  in  PBS, in  a volum e less th an  l /1 0 th  th a t of the  colum n, and  
eluted in  1 m l fractions w hich  w ere  m onito red  for protein.
3.4.2 High Performance Liquid Chromatography:
H ig h  perform ance liquid  ch rom atog raphy  (HPLC) w as carried  ou t on 
a Protein-Pak 300SW series colum n (W aters). This w as a 7.5 m m  x 300 m m  
gel filtration  colum n packed w ith  a  rig id  hydrophillic po rous silica gel 
(particle size 10 jxm, pore  size 300A), w ith  a fractionation range of 10,000-
300.000 Da. The colum n w as u sed  in  series w ith  a  7.5 m m  x 50 m m  g u ard  
colum n packed w ith  a sim ilar silica gel (particle size 35jxm, pore  size 125A). 
The g u a rd  colum n w as u sed  to p ro tec t the  analytical colum n from  
becom ing blocked b y  precipitate in  the  analy te so lu tion  o r irreversible 
b ind ing  of analyte com ponents to the  silica. The colum ns w ere  a ttached  to 
a B eckm an System  G old H PLC system . This consisted of; a  Program m able 
Solvent M odule 126, double-headed  pum p , a P rogram m able D etector 
M odule 166, variable w aveleng th  detector fitted  w ith  a  flow  th ro u g h  cell 
and  an  A utosam pler 507. These w ere  controlled  b y  the  System  G old 
(version 4) softw are package, loaded  onto an  IBM sy stem /2  M odel 50 Z 
p e rso n a l com puter.
Sodium  phosphate  buffer (0.1 M, p H  7.4), the  m obile phase, w as 
filtered, u s in g  0.22 pim filters (M illipore), an d  degassed u n d e r vacuum , 
before be ing  p u m p ed  th ro u g h  the  colum n a t 0.5 m l/m in . The sam ple w as 
m ade u p  to a  concentration  of 0.5-1 m g /m l in  the m obile phase. A volum e 
of 20-50 jil w as injected onto the  co lum n either m anually  o r using  the 
autosam pler. The elu tion  of p ro te in  w as detected a t 280nm. D ata  w as 
collected for a m in im um  of 30 m in. The colum n w as sto red  in  s o d iu m  
azide (0.05%, w /v ) ,  filtered  and  degassed  as fo r the  m obile phase. (C arty & 
O 'K ennedy, 1988)
3.5 DETECTION & CONJUGATION METHODS
3.5.1 Bicinchoninic Acid Assay:
Bicinchoninic acid (BCA), in  the  fo rm  of its w ater-soluble sodium  
salt, is a sensitive, stable an d  h igh ly  specific reagen t for the cuprous ion 
(Cu+). P roteins in  alkaline m edium  react w ith  C u++ to fo rm  C u+ . T hu s, 
proteins, particu la rly  the am ino acids cysteine, cystine, try p to p h an  and
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tyrosine, are responsible for colour fo rm ation  in  p ro te in  sam ples w h e n  
com bined w ith  BCA in  alkaline conditions (Sm ith et al.f 1985).
The reagen ts fo r the BCA assay  are available in  k it fo rm  from  v a rio u s  
suppliers (Pierce & Sigma). R eagen t A contains BCA in  buffered, alkaline 
solution, reagen t B contains copper su lphate, (4% w /v ) . The w ork ing  
solution w as p rep ared  b y  m ixing A an d  B in  the  ra tio  - 50:1. A range of 
p ro te in  s tandards (0-1 m g /m l)  w ere  p repared  from  the stock BSA so lu tio n  
(2 m g /m l)  supplied. To 20 p a rts  w ork ing  so lu tion  w as added  1 p a rt 
s tan d ard  or u n k n o w n  sam ple, (eg. 10 pil p ro te in  so lu tion  in  200 (xl w ork ing  
solution in  a m icrotitre plate). The sam ples w ere  m ixed b y  gentle agg ita tion  
an d  incubated  for 30 m in  a t 37°C . The A bs560nm  w as determ ined  on  a 
T itretek  Twin read er Plus p la te  reader. The p ro te in  concentration of the 
sam ple w as determ ined  from  a s tan d a rd  curve.
3.5.2 Periodate Conjugation:
This m ethod  w as u sed  fo r the  chemical conjugation  of BSA to horse 
rad ish  peroxidase (HRP). It is ad ap ted  from  the m ethod  described in  T ijssen 
an d  K urstak  (1984) fo r the coup ling  of glycoproteins, specifically HRP and 
IgG.
The HRP w as activated  b y  the  addition  of N a I0 4 . This oxidises the 
enzym e's carbohydrates p ro ducing  aldehyde and  carboxyl groups. To 0.5 ml 
of H RP solution (1 m g /m l in  0.1 M  NaHCC>3, p H  9.2) w as added  0.5 ml of 8 
m M  N aI0 4 . This w as incubated  a t 20°C  for 2 h r  in  the  dark. C onjugation 
occurs w h en  free, non-p ro tonated , am ino g roups of the  added  BSA form  
Schiff bases w ith  the  a ldehyde g roups of the activated  H RP To the 
activated  HRP w as ad d ed  1 m l of BSA ( lm g /m l in  0.1 M  NaHCC>3, p H  9.2) 
an d  5 m g  Sephadex G-25. The Sephadex beads sw ell rap id ly  causing an  
ap p aren t increase in  p ro te in  concentration, th u s  accelerating the reaction. 
This w as incubated  a t 20° C for 2 h r  in  the  dark . The conjugate w as 
subsequen tly  stabilised b y  reduction  w ith  N aB H 4 . N aB H 4 (0.1 m l of a 5 
m g /m l solution in  0.1 M  N aO H ) w as added  to the  conjugate m ixture, w ith  
gentle aggitation. A fter 30 m in  in  the d a rk  at 20°C  a  fu rth er 0.2 m l of 
N aB H 4 so lution w as added . The m ixture  w as incubated  in  the  d a rk  for 1 h r  
a t 4°C . Excess reagen ts w ere  rem oved  b y  dialysis against PBS a t 4°C  in  the 
dark .
3.5.3 Iodine Labelling:
The co m pound  l,3 ,4 ,6 -te trach lo ro -3a-6a-d ipheny lg lycouril is 
supplied  as a reagen t for the  iod ination  of p ro te ins (IODO-GEN, Pierce). 
V irtually  insoluble in  w ater, IO D O -G EN  m ediates rap id  iodination at the
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solid phase in terface w ith  aqueous solutions of iodide and  pro teins (Fraker 
& Speck, 1978). In  th is m ethod, the  exposed tyrosine residues of the  IgG are 
io d in a ted .
Glass test tubes w ere  w ash ed  an d  rinsed  w ith  a d ry  organic solvent, 
e.g. chloroform , and  allow ed to dry. To each test tube w as added  100 n-1 of 
IODOGEN solu tion  (0.1 m g /m l in  chloroform ). The solvent w as 
evaporated  u n d e r n itrogen  gas. The test tubes w ere covered and  stored 
desiccated overn igh t or un til needed. The test tubes w ere rinsed  w ith  PBS 
to rem ove u n b o u n d  IODOGEN. To each test tube w as added  100 jil of IgG 
solution (1 m g /m l in  PBS). N a l w as added  to  a final concentration of 25 
m M  in  each test tube. The tubes w ere  incubated  for 20 m in  a t room  
tem perature, w ith  gentle aggitation. The reaction  w as term inated  by  
rem o v in g  the p ro te in  solution from  the  test tube. Excess iodine w as 
rem oved b y  extensive dialysis against PBS.
3.5.4 Detection of Cold Iodine:
A m icro-assay  system  based  on  the  effect of the catalytic Sandell- 
Kolthoff reaction  of iodide on the oxidation of arsenic (III) by cerium  (IV) 
w as u sed  to m easure  iodine in  so lu tion  and, hence, iodine conjugated 
com pounds. This rap id  assay  uses sm all quantities of reagents, is suitable 
for use w ith  a photom etric  m icroplate reader, can test m any  sam ples 
sim ultaneously  an d  elim inates problem s associated w ith  the  use of 
radiolabelled  com pounds to  m easu re  iodination , (O 'K ennedy et al., 1989).
S tandards of KI w ere  p rep a red  in  the range 0.001-0.1 pig/m l. To the 
w ells of a 96-w ell plate  w ere  applied  100 jxl of s tan d a rd  or sam ple, 60 |xl of 75 
m M  arsenious acid an d  25 jxl of acidified eerie am m onium  sulphate (0.1 M 
Ce(S0 4 )2 -2 (N H 4)2S0 4 .2H 2 0  :1  M  H N O 3, 1:2.57). The plate w as incubated at 
room  tem peratu re  an d  the  absorbance read  a t 414nm  every  5 m in  for 20 
m in .
3.6 ENZYME-LINKED IMMUNOSORBENT ASSAY
Enzym e-linked im m unosorben t assays (ELISA) are m ethods for 
detecting antigens o r antibodies u tiliz ing  enzym e-substrate  reactions. The 
enzym es are u sually  coupled to antibodies (either to  antibodies specific for 
the an tigen  o r to anti-im m unoglobulin). It is essential th a t b o th  the  
enzym atic activity an d  the  im m unological reactiv ity  of the  conjugate are 
preserved . The am o u n t of enzym e conjugate is detected b y  the  enzym atic 
conversion of a colourless substra te  to a h igh ly  coloured p roduct th a t can be 
v isually  o r photom etrically  determ ined . ELISA's are carried o u t in  96-well
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m icrotitre plates, to  w hich  an tibody  or an tigen  can be adsorbed, 
(O 'Kennedy, 1989).
3.6.1 Adsorption of Cells to ELISA Plates:
The PVC, 96-well m icrotitre p lates (N unc) w ere  w ashed  th ree  tim es 
w ith  PBS, contain ing  5% (w /v )  Tween 20, th en  th ree  tim es w ith  PBS. To 
each w ell w as added  125 jxl of poly-L-lysine, 0.1% (w /v )  in  PBS. The plate 
w as incubated  for 1.5 h rs at 37°C . The plate  w as w ashed  as before. A single 
cell suspension  w as p rep a red  (5 x  10^ cells/m l) from  the  re lev an t source 
m aterial. This w as applied  to the  p late  a t 50 pil/well. The plate w as 
incubated for 1.5 h rs  at 4°C . At th is tim e 150 [xl of L -g lu taraldehyde (0.1% 
w / v  in  PBS) w ere added  to each well. The plate  w as left for a fu rth er 15 
m in  at 4°C . The plate  w as w ash ed  as before. N on-specific b ind ing  sites on 
the plate  w ere  blocked u sing  200 [xl/well of a so lu tion  of 1% (w /v )  BSA in  
PBS, the  plate w as left at 4 °C  overn igh t.
3.6.2 Adsorption of Proteins to ELISA Plates:
The PVC, 96-well m icro-titre p lates (N unc) w ere  w ashed  th ree  times 
w ith  PBS, contain ing  5% (w /v )  Tween 20, th en  th ree  tim es w ith  PBS. A 
solution of p ro te in  (10 n g /m l in  1 M  carbonate /b icarbonate  buffer p H  9.6) 
w as applied  to  the  p late, 100 pil in  each well. The plate  w as incubated for lh r  
at 37°C. The pla te  w as w ashed  as before. N on-specific b ind ing  sites on  the 
plate  w ere  blocked u sin g  200 ^1 /w ell of a so lu tion  of BSA (1% w / v  in  PBS). 
The plate  w as left a t 4°C  overn igh t.
3.6.2 Colour Development in ELISA:
The w ells of a  plate, to w hich  p ro te in  o r cells had  been  adsorbed, 
w ere  w ashed  three tim es w ith  PBS, contain ing  5% (w /v )  Tween 20, then  
three tim es w ith  PBS. The p rim ary  antibody, w ith  affinity for the adsorbed 
cells or protein , w as applied, in  suitable w o rk in g  dilution, a t 100 (xl p e r well. 
This w as incubated  fo r 1 h r  a t 37°C. The pla te  w as w ashed  as before. T he 
secondary, o r enzym e-labelled, an tibody  w as applied, in  suitable w ork ing  
dilution, a t 100 fxl p e r w ell. The m ost com m on enzym e label u sed  w as 
horse rad ish  peroxidase (HRP), b u t alkaline phosphatase  w as also used. T he 
plate  w as incubated  fo r 1 h r  a t 37°C. The pla te  w as w ashed  as before. The 
substrate  for the enzym e-catalysed, co lour-producing  reaction w as p repared  
fresh  every  tim e. For H RP the substrate  u sed  w as o-phenylenediam ine (o- 
PD), 0.2 m g /m l in  citrate buffer (0.1 M , p H  4.5), to w hich  w as added  
hy d rogen  peroxide (0.003%, w /v )  im m ediately before use. This w as applied 
to the plate at 100 pil p e r w ell and  incubated  for 30m in a t 37°C. C olour
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developm ent w as estim ated b y  m easu ring  the  absorbance of the w ells at 
405nm  on  a T itretek  T w inreader P lus p la te  reader. For a lk a lin e  
phosphatase, the substra te  u sed  w as 5-brom o-4-chloro-3-indolyl phosphate  
d isod ium  salt (BCIP), 1 m g /m l in  am ino m ethy l p ropano l buffer (pH  10.25). 
This w as applied a t 100 jxl p e r  w ell and  incubated  a t room  tem peratu re  fo r 
30 m in. Colour developm ent w as estim ated b y  m easu ring  the  absorbance 
of the  w ells a t 620nm  on  a  T itre tek  Tw inreader P lus p late  reader.
3.7 ELECTROPHORESIS
Electrophoresis in  polyacrylam ide gels in  the  presence of the anionic 
detergent, sodium  dodecyl su lphate  (SDS), has p ro v en  to be  a useful tool for 
the  separation  of p ro te in  subun its  and  the  determ ination  of their m o le c u la r  
w eights. The slab gel p rocedure  developed b y  Laem m li (1970) w as u sed  in  a 
LKB m ini-gel system  (Pharm acia).
The m ost com m only u sed  reso lv ing  gels w ere  p rep a red  according to 
Table 3.1, in  Tris-HCl bu ffer (0.4 M, p H  8.8). The tetra-m ethyl-ethylene- 
diam ine (TEMED) w as added  last as th is starts  the  polym erisation reaction. 
The gel w as p o u red  b e tw een  tw o  glass p lates an d  overlayed  w ith  water. T he 
w a te r layer excludes a ir th u s  speed ing  the po lym erisation  process, w hile  the 
surface tension  at the  w a te r /g e l interface ensures a sm ooth  surface to the 
top  of the  gel. W hen  the  gel h ad  set the  w a te r w as p o u red  off. The 
reso lv ing  gel w as th en  overlayed  w ith  the stacking  gel, p rep ared  according  
to  Table 3.1, in  Tris-HCl (0.05 M, p H  6.8). The TEM ED w as added  last. The 
gel w as allow ed to  set a ro u n d  a  "comb". This created  w ells in  the stacking 
gel for application of sam ples. The w ells w ere  w ash ed  o u t w ith  electrode 
bu ffer before use.
Sam ples for e lectrophoresis w ere  p rep ared  b y  heating  a t 100°C for 2 
m in  in  sam ple buffer. This consisted  of SDS (2%, w /v ) ,  glycerol (10%, v /v )  
an d  brom ophenol b lue  (0.05%, w /v )  in  Tris-HCl buffer (0.08 M, p H  6.8). 
The p rep ared  sam ples (10-30 [xl) w ere  applied  to  the  w ells in  the stacking 
gel, u n d e r the electrode buffer. The electrode bu ffer (pH  8.3) w as p repared  
contain ing  Tris (25 m M ), glycine (0.2 M) an d  SDS (0.1%, w /v ) .
E lectrophoresis w as p erfo rm ed  a t constant cu rren t (30 m A p e r m ini­
gel) un til the dye fro n t h ad  traversed  the gel. The dye w as no t allow ed to 
ru n  off the  gel. The gel w as rem oved  from  the  glass p lates and  stained  for 
20 m in  w ith  C oom assie brillian t b lue (5%, w /v )  in  acetic acid : w a ter : 
m ethanol (1:10:8, v / v / v ) .  The sam e solvent m ix ture  w as u sed  to destain  
the  background  u n til on ly  the  p ro te in  ban d s rem ained  stained.
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H ig h  Mol.
W t.
P ro te in s
G enera l
P u rp o se
Low  Mol.
W t.
P ro te in s
S tacking
Gels
Polyacry lam ide
(w /v )
7.5% 10% 15% 3%
M ethy lene-b is- 
acrylam ide (w /v )
0 .2 % 0.27% 0.4% 0.08%
Sodium  dodecyl 
su lphate  (w /v )
0.05% 0.05% 0.05% 0.08%
A m m o n iu m  p e r ­
su lphate  (w /v )
0.05% 0.05% 0.05% 0.07%
TEMED (w /v ) 0 .1% 0 .1% 0 .1% 0.9%
Table 3.1:
The com ponents req u ired  fo r the  p rep ara tio n  of gels for polyacrylam ide 
gel electrophoresis. The reso lv ing  gels, those req u ired  for the separation  of 
general p ro te in  m ixtures o r m ore specific gels for the  separation  of h igh  
m olecular w eigh t p ro te ins o r lo w  m olecular w e ig h t proteins, w ere p repared  
in  Tris-HCl buffer (0.4 M, p H  8.8). The stacking gel w as p repared  in  Tris-HCl 
bu ffer (0.05 M, p H  6.8).
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3.8 BISPECIFIC ANTIBODY PRODUCTION
Bispecific antibodies w ere  p rep a red  b y  the  b reak d o w n  and  chemical 
re-association of purified  antibodies. Two m ethods w ere  used, b o th  of 
w hich  had  the F(ab ')2 fragm ent as the  s tarting  m aterial.
3.8.1 F(ab')2 Fragment Production:
The an tigen  b in d in g  fragm ent (F(ab')2 ) is obtained from  
im m unoglobulins b y  d igestion w ith  the enzym e pepsin  a t p H  4.0-4.5. T he 
F(ab ')2 fragm ent, w h ich  has a m olecular w eigh t of approxim ately  95 kDa, 
retains the an tibody com bining sites of the  p a ren t IgG m olecule. Pepsin 
digests the  IgG h inge reg ion  leaving  the d isu lph ide b ridges intact. The 
heavy  chain  piece rem ain ing  is k n o w n  as Fc'; it m ay  becom e fu rth er 
deg raded  in to  sm aller peptides. Pepsin digestion  w as carried  ou t u n d e r tw o 
different sets of conditions.
In  the first m ethod  (B rennan et a l, 1985), the  IgG  w as suspended  in  
PBS an d  adjusted to a final concentration  of 20 m g /m l. This w as dialysed 
against a 0.1 M  sod ium  acetate so lu tion  for 3 hrs. The dialysate w as 
ad justed  to  p H  4.5 b y  dropw ise  add ition  of acetic acid (glacial). The pepsin  
w as ad d ed  to this to a final concentration  of 2 m g / 100 m g  IgG. The solution 
w as incubated  overn igh t at 37°C. The reaction tubes w ere  centrifuged at 
2,000 rp m  fo r 10 m in  to  rem ove an y  precipitate  th a t m ay  have form ed. The 
so lu tion  w as dialysed extensively against Im M  sodium  phosphate  buffer 
(pH  7.2) to inactivate the enzym e.
In  the  second m ethod  (Runge et al., 1990), the  IgG w as suspended  in  
10 m M  sodium  phosphate  buffer, w ith  0.15 M  sodium  chloride (pH  7.4), to a 
final concentration of 2 m g /m l. To 10 m l of IgG  solution w as added  1 m l of 
pepsin  (3 m g /m l) an d  1 m l of 1M sodium  citrate (pH  2.75). The m ixture 
w as ad justed  to p H  3.5. This w as incubated  for 2 h rs  a t 37°C. Stopping 
so lu tion  w as added, consisting of 1 m l of 3 M  Tris-HCl (pH  8.5). The 
so lu tion  w as dialysed extensively against 1 m M  sodium  phosphate  buffer 
(pH  7.2).
All antibodies and  fragm ents w ere sto red  in  PBS at 4°C  for 
im m ediate use, o r a t -20°C  for long  term  storage. R epeated freezing and  
th aw in g  w as avoided.
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3.8.2 BF(ab')2 Production I:
The first m ethod  exam ined w as th a t of B rennan  et al. (1985). The 
starting  m aterial w as F(ab ')2 fragm ents in  1 m M  sod ium  phosphate  buffer 
(pH  7.2) at a  concentration  of 3 m g /m l. This w as reduced  to the  Fab1 
fragm ent b y  the  add ition  of 1 m M  2-m ercaptoethylam ine, 1 m M  EDTA and  
10 m M  sodium  arsenite. The so lu tion  w as incubated  a t 25°C  o v e rn ig h t. 
Solid 5 ,5 '-dithio-bis(2-nitrobenzoic acid), (dTNB, E llm an's reagent), w as 
added  to  a final concentration of 5 mM . The so lu tion  w as incubated  a t 25° C 
for 3 hrs. Excess dTNB can  be rem oved  b y  extensive dialysis against 1 m M  
sodium  phosphate  (pH  7.2). The rem ain in g  p ro te in  constitu tes Fab’-TNB 
fragm ents. The Fab'-TNB of one specificity w as fu rth er reduced  to  the  Fab'- 
SH fragm ent b y  the add ition  of 10 m M  2-m ercap toethy lam ine, 1 m M  EDTA 
and  10 m M  sodium  arsenite, for 30 m in  at 25°C . Excess reagen ts w ere 
rem oved b y  dialysis as before.
B F(ab ')2 fragm ents w ere  p ro d u ced  b y  com bining equim olar am ounts 
of Fab'-TNB an d  Fab'-SH, in  0.1 M  sod ium  phosphate  buffer w ith  1 m M  
EDTA. This w as incubated  for 16 h rs  a t 25° C. A ddition of solid dTNB, 5 
m M  after th is po in t p reven ts the fo rm ation  of hom ologous pairs. Excess 
reagents w ere  rem oved  b y  extensive dialysis as before. The BF(ab ')2 w as 
purified  b y  double affinity  ch rom atog raphy  and  sto red  a t 4° C in  PBS.
3.8.3 BF(ab')2 Production II:
The second m ethod  exam ined w as th a t of G lennie et al. (1987). The 
starting  m aterial w as F(ab ')2 fragm ents in  0.2 M  Tris-HCl w ith  10 m M  
EDTA at a concentration  of 2 m g /m l. This w as reduced  to the  Fab' 
fragm en t b y  the  add ition  of 20 m M  2-m ercaptoethanol. The solution w as 
incubated  a t 21°C  fo r 30 min. Excess reagen ts w ere  rem oved b y  extensive 
dialysis against 50 m M  sodium  acetate, p H  5.3, w ith  0.5 m M  EDTA a t 4°C .
To the  m urine  Fab'-SH fragm ent w as ad d ed  1 /2  volum e of 12 m M  o-
pheny lene  dim aliem ide in  dim ethyl-form am ide. This w as incubated  at 
4°C  for 30 m in  to  fo rm  the  Fab'-m al fragm ent. Excess reagents w ere 
rem oved b y  dialysis as before.
B F(ab ')2 fragm ents w ere  p ro d u ced  b y  com bining Fab'-SH an d  Fab'- 
m al in  a ratio  of 1:1.3, a t a concentration  of 5 m g /m l. The m ix tu re  w as 
ad justed  to p H  8.0 u sin g  1 M  Tris-HCl an d  incubated  for 18 h rs  a t 4°C . 
H om ologous pairs  w ere  d isru p ted  b y  the  add ition  of 20 m M  2-m ercapto- 
e thano l for 30 m in  a t 30° C, follow ed b y  25 m M  iodoacetam ide. Excess
reagents w ere  rem oved  b y  dialysis against PBS. The BF(ab ')2 w as purified
b y  double affinity  ch rom atog raphy  an d  sto red  a t 4°C  in  PBS.
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3.9 IMMUNOCYTOCHEMISTRY
3.9.1 Isolation of Mononuclear Cells:
M ononuclear cells form  0.06% of all blood cells, 50% of w hite  blood 
cells. In  o rder to  increase the  sensitivity  of the  im m unodetection 
techniques in  use, the  m ononuclear cells w ere isolated from  venous 
periphera l b lood  sam ples.
The isolation of m ononuclear cells from  periphera l b lood sam ples 
w as carried  o u t in  a one step  density  centrifugation  p rocedure. H istopaque- 
1077 (Sigma) is a solution of Ficoll (Pharm acia) an d  sodium  diatrizoate, 
adjusted to a density  of 1.077 ±  0.001 g /m l. A nti-coagulated venous blood 
can be layered  onto  H istopaque-1077. D u rin g  cen trifugation , ery throcytes 
and  granu locy tes are aggregated  b y  Ficoll an d  rap id ly  sedim ent, w hereas, 
lym phocytes an d  o ther m ononuclear cells rem ain  a t the 
p lasm a/H istopaque-1077  interface, (Boyum, 1968).
Sam ples of venous perip h era l b lood  w ere  collected from  healthy  
vo lun teers and  leukaem ic patien ts, in  heparin ised  blood tubes. These w ere 
centrifuged  a t 1,000 rp m  for 10 m in  and  the  plasm a rem oved. The blood 
cells w ere  resu spended  in  5 m l PBS an d  layered  onto  10 m l H istopaque- 
1077. The sam ples w ere  cen trifuged  for 30 m in  at 2000 rpm . A p |s te u r  
p ipette  w as u sed  to aspirate the  m ononuclear cells from  the  interface, 
w here  th ey  fo rm  a "buffy layer". The cell suspension  w as d ilu ted  w ith  an 
equal volum e of PBS and  cen trifuged  a t 1,000 rp m  for 10 m in. The pelletted  
lym phocytes w ere sto red  in  liqu id  n itrogen , as described prev iously  (Section 
3.1.1).
3.9.2 Preparation of Slides:
A H eraeus Sepatech cytocentrifuge w as u sed  to  centrifuge cells onto a 
clean glass slide, in  a single cell layer. Single cell suspensions, of 5 x 10^ 
ce lls /m l in  PBS, w ere  p repared . This w as applied  to  the slides w ith  100 pil 
cell su spension  in  each receptacle. The slides w ere  sp u n  for 2 m in  at 1,000 
rpm . Each sam ple w as checked for m orphological in teg rity  b y  staining, 
u s in g  the  Rapi-D iff triple sta in  set (D iagnostic D evelopm ents), and 
exam ination  u n d e r a  light m icroscope (N ikon SE). Slides of each sam ple 
w ere  sto red  a t 4 °C  fo r im m u n o ch em ica l exam ination .
3.9.3 Immunochemistry:
Im m unocytochem istry  is the use of labelled antibodies as specific 
reagen ts for the  localisation of tissue constituen ts (antigens) in situ. 
Because of the  absolute specificity of an tibody-an tigen  in teractions, positive
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identification of tissue constituents can be achieved. As a result, much of 
the uncertainty has been removed from some aspects of histopathology, 
(Polak & vanNoorden, 1987). The indirect method of staining was adapted 
for use in this instance.
A BF(ab')2 was produced from the G12, anti-CLL, Ab and an anti- 
alkaline phosphatase Ab. The BF(ab')2 was diluted, in 1% (w /v ) BSA in 
PBS, to a concentration of 10 ng/m l. This was applied to the prepared 
cytospins. These were left at room temperature, in a humidified chamber, 
for 2 hrs. The slides were then washed three times by immersion in PBS. 
Alkaline phosphatase (50 n g /m l in PBS) was applied to the cells and 
incubated for 30 min at room temperature, in a humidified chamber. The 
slides were washed three times by immersion in PBS. The substrate BCIP 
was prepared as for ELISAs (Section 3.6.3) and applied to the slides for 30 
min at room temperature, in a humidified chamber. The slides were rinsed 
three times by immersion in PBS. The slides were mounted in glycerol 
jelly. This was prepared by mixing gelatine (1 g), glycerol (7 ml) and water (6 
ml) and heating gently.
3.10 BIOLOGICAL BUFFERS
- Acetate-Acetic B uffer;
Stock solutions of 0.6 M sodium acetate and 0.6 M acetic acid were 
prepared. To 435 ml acetic acid (0.6 M) was added 230 ml sodium acetate (0.6 
M). The solution was adjusted to 1 L with distilled water. This gives a 
buffer of molarity 0.4, pH 4.0.
- Amino M ethyl Propanol B uffer;
150 mg MgCl2-6H20, 0.1 ml Triton X-405 and 1 g N aN 3 were 
dissolved in 30 ml distilled water. This was added to 95.8 ml amino- 
methyl-propanol, while stirring. HC1 (6 M) was used to adjust the pH of the 
solution to 10.25. The solution was left at 4°C  overnight. The pH of the 
solution was checked and readjusted with HC1 (6 M) if necessary, before 
making the solution up to 1 L with distilled water.
- Carbonate-Bicarbonate Buffer;
Stock solutions of 1 M sodium carbonate and 1 M sodium bicarbonate 
were prepared. The carbonate and bicarbonate were mixed in proportions 
1:9 (v /v). The solution was titrated to the correct pH using the stock
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solutions; carbonate to raise the pH, bicarbonate to lower the pH. The buffer 
was diluted to the correct molarity using 0.14 M NaCl in water.
- Citrate Buffer;
Stock solutions of 0.1 M citric acid and 0.1 M sodium dihydrogen 
phosphate were prepared. These solutions were titrated against each other 
to produce the correct pH. For a buffer below pH 5.0 the NaH2PC>4 (0.1 M) 
was added to 100 ml of citric acid (0.1 M). For a buffer above pH 5.0 the citric 
acid was added to 100 ml of NaH2P0 4  (0.1 M). This gives a 0.1 M buffer.
- Glycine-Hydrochloric acid B uffer;
Stock solutions of 0.2 M glycine and 0.2 M HC1 were prepared. Stock 
HC1 was added to 500 ml of stock glycine until the correct pH was reached. 
The solution was made up to 1 L with distilled water. This gives a 0.1 M 
buffer.
-Phosphate Buffered S a lin e;
8 g  NaCl, 0.2 g  KC1, 1.15 g  Na2PC>4 and 0.2 g  KH2PO4 were dissolved 
in 500 ml of distilled water. This solution was made up to 1 L with distilled 
water. This results in a buffer of molarity 0.15, pH 7.4. The buffer can be 
adjusted to another pH if required by adding 6 M HC1 or 6 M NaOH prior to 
adjusting the total volume to 1 L. Alternative molarities can be achieved by 
altering the final volume of the solution.
- Sodium  Phosphate B uffer;
Stock solutions of 0.5 M NaH 2P04 and 0.5 M Na2HPC>4 were 
prepared. The two solutions were titrated to obtain the required pH and the 
final volume adjusted to give the required molarity, e.g. 100 ml of 0.5 M 
N aH 2PC>4 and 100 ml 0.5 M Na2HP04 , mixed together and made up to 1 L, 
result in a 0.1 M buffer of pH 7.5, the mobile phase used in HPLC.
- Tris-Hydrochloric acid B uffer;
Stock solutions of tris [hydroxymethyl] aminomethane (1 M) and HC1 
(1 M) were prepared. The stock Tris was diluted with distilled water to give 
500 ml of Tris solution at twice the required molarity. The solution was 
adjusted to the required pH with the stock HC1. The final volume was 
made up to 1 L with distilled water.
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4.1 OPTIMISATION OF BISPECIFIC ANTIBODY PRODUCTION
PROTOCOLS
Two methods have been described for the production of BF(ab')2s 
(Brennan et a l, 1985; Glennie et a l, 1987). Both of these methods require 
large quantities of IgG as the starting material. Methods for the purification 
of IgG from serum, growth medium or ascites fluid were examined. 
Subsequently, the BF(ab')2 production protocol of Brennan et al. (1985) was 
examined and optimised.
4.1.1 Antibody Purification:
Ab was purified from ascites fluid by precipitation in 50% (w /v)  
saturated ammonium sulphate (Section 32 2 ).  The Ab solution was
checked for purity by HPLC (Section 3.4.2) and shown to contain a number 
of other proteins which may interfere in BF(ab')2 production (Fig. 4.1.1). 
The precipitated Ab was further purified by affinity chromatography using a 
Protein A sepharose column (Section 3.3.3). The Ab purification procedure 
was optimised as follows.
A solution of 'pure' human IgG (Sigma) was made up in ddH2 0 . 
This was diluted 1:1 with binding buffer, supplied with the Protein A 
Sepharose column (Pierce). The IgG was applied to the 1 x  2 cm column 
and washed onto the column with 15 ml binding buffer (Pierce). The eluate 
was collected in 1 ml fractions. The column was washed with 10 ml elution  
buffer (Pierce) and 1 ml fractions collected. The BCA assay (Section 3.5.1) 
was used to determine the presence of protein in each of the fractions and 
to quantitate the protein where present (Fig. 4.1.2), i.e. in fractions 16,17 and 
18, (Fig. 4.1.3). The protein concentration of the human IgG solution, which  
was applied to the Protein A column, was measured at the same time. 
Results indicated that, of the 12.8 m g IgG applied to the column, a total of 
10.34 m g IgG were recovered, which was 80.8% of the total potential 
recovery. Following three separate determinations, the mean recovery was 
found to be 80.4 ±1.1%  of total possible recovery.
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Figure 4.1.2:
The elution profile of 'pure' IgG through a Protein A Sepharose 
column ( 1 x 2  cm), 1 ml fractions were collected. The column was washed 
with binding buffer (Pierce), 15 fractions of which were collected. The buffer 
was changed to elution buffer (Pierce). A further 10 fractions were collected. 
The protein content of the fractions was determined by BCA assay 
(Abs560nm)- This illustrates that a small amount of protein elutes in the 
binding buffer, due to overloading of the column or impurities in the 
sample, while the bulk of the protein (IgG) elutes in fractions 16-18 (the first 
three fractions of elution buffer), which were pooled for future use.
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Figure 4,1.3:
The BCA assay (Section 3.5.1) was used to determine protein 
concentration. The graph shows a sample standard curve produced using 
the BCA assay and a range of BSA standards, with a regression coefficient (r) 
of 0.993.
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In order to show that only IgG was eluting from the Protein A 
column, HPLC (Section 3.4.2) was carried out on the fractions which 
contained protein (Fig. 4.1.1c). It was found that human IgG has a retention 
time on HPLC of 14.4 ±- 0.1 min. HPLC analysis (Section 3.4.2) of fractions 
16,17 and 18 showed two peaks, one at 14.3 ±- 0.1 min, the other at 22 i- 0.1 
min. The identity of the later peak was uncertain but there were two 
possibilities. One was that Protein A was leaching off the column and 
eluting along with the IgG. The other was that the elution buffer interferes 
with the HPLC analysis. In order to establish which of these was the case, 
the Protein A column was run four times more using different elution 
buffers; elution buffer (Pierce), 0.1 M citrate buffer, 0.1 M Glycine buffer and 
0.1 M Tris-HCl buffer. The relevant fractions, 16-18, were assayed by HPLC. 
In all cases the three fractions contained the 22 min peak, as well as the 14.3 
min IgG peak. In which case; (a) all the buffers cause Protein A to leach off 
the column, or (b) the buffers themselves cause a 22 min peak using this 
type of HPLC analysis. A set of blanks were run where buffer alone was 
injected onto the HPLC column. Each of the buffers produced a 22 min 
peak, although the height of the peak varied. The System Gold software 
was used to subtract the 'buffer peak' from the profile obtained from 
fraction 17 eluted from the Protein A column. The second peak was 
eliminated in all cases, indicating that the 22 min peak is a buffer peak, i.e. it 
occurs at the exclusion limit of the column (Fig. 4.1.4).
Purification of the IgG was completed by de-salting on a Sephadex 
G-75 column, from which IgG is totally excluded and elutes in the void 
volume. Fractions 17 and 18 from the Protein A column were pooled and a 
sample applied to the G-75 column (1x10 cm, ddH2 0 ). Up to fifteen 1ml 
fractions were collected and the BCA assay (Section 3.5.1) was carried out on 
each in order to construct an elution profile (Fig. 4.1.5). Those fractions 
containing protein were assayed for protein concentration using the BCA 
assay. From a total of 9.94 m g applied to the column 9.4 mg were recovered, 
which was 94.6% of total potential recovery. Following three separate 
determinations, the mean recovery was found to be 95.1 ±- 0.9% of total 
potential recovery.
IgG purification by this protocol resulted in a recovery of 76.4% of 
total potential yield. Following three separate determinations, the mean 
recovery was found to be 76.5 ±  1% of total potential yield.
The purity of the IgG was confirmed using HPLC (Section 3.4.2) as 
shown (Fig. 4.1.1) and using polyacrylamide gel electrophoresis (PAGE) 
(Section 3.7) as shown (Fig. 4.1.6).
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Figure 4.1.4:
The chromatograms produced following HPLC analysis of the IgG 
eluted from a Protein A column (14 min peak). The superimposed 
chromatograms (a) illustrate that the 22 min peak observed in the IgG 
sample corresponds to that produced when buffer alone is injected onto the 
column. This is confirmed when the system Gold software is used to 
subtract the buffer chromatogram from the IgG chromatogram, as the 22 
min peak is erased (b). HPLC analysis was carried out on a Protein Pak 
300SW size exclusion column, with a sodium phosphate buffer (0.1 M, pH
7.4) mobile phase, at a flow rate of 0.5 m l/m in. The presence of protein was 
determined using a u.v./visible variable wavelength detector set at 280nm. 
(System Gold, Beckman) (AU = Absorbance Units)
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Figure 4.1.5:
The elution profile of pure IgG through a G-75 size exclusion column  
(1 x 1 0  cm), with a PBS (0.1 M, pH 7.4) mobile phase. Fifteen 1 ml fractions 
were collected. The protein content was determined by BCA assay. The 
bulk of the protein (IgG) elutes in fractions 5-8.
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Figure 4.1.6:
This photograph shows the various stages of purification of IgG from 
ascites as determined by PAGE. Lanes A, E and I were loaded with 30 jxl of a 
mixture of six proteins of known molecular weight (Sigma). Lanes B and C 
were loaded with 50 |xl ascitic fluid diluted 1:50 and 1:100, respectively, with 
PBS (0.01 M, pH 7.4). These lanes show the large amount of protein of 
various sizes present in the ascitic fluid. Lanes D and F were loaded with 50 
pil of the solution of IgG precipitated from the ascitic fluid using 
ammonium sulphate (50%, w /v ), diluted 1:10 and 1:20, respectively, with 
PBS (0.01 M, pH 7.4). These lanes show an increase in the relative amount 
of a protein of the same size as IgG, although some impurities still remain. 
Lanes G and H were loaded with 50 nl of the protein containing eluate of 
the Protein A column, diluted 1:10 and 1:20, respectively, with PBS (0.01 M, 
pH 7.4). These lanes show that only one protein, of molecular weight 150 
kDa approximately, is eluted from the Protein A column, i.e. pure IgG. 
PAGE was carried out using an LKB minigel system, with a polyacrylamide 
gel containing 10% SDS, run at a constant current of 25 mA and stained 
with Coomassie blue.
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In an attempt to improve the yield of IgG, a thiophillic 
chromatography column (Affi-T) was set up (Section 3.3.4). A 150 pil sample 
of human IgG was applied to the Affi-T column. The column was washed 
with binding buffer and twenty 1.5 ml fractions were collected. The elution 
buffer was applied and a further twenty 1.5 ml fractions collected. The 
elution buffer contains Tris which interferes with the BCA reaction. Hence, 
the protein concentration of each fraction was estimated by measuring the 
Abs280nm (Fig- 4.1.7). Results indicated that of the 0.975 mg applied to the 
column, 0.825 mg were recovered, which was 84.6% of total potential yield. 
Following three separate determinations, the mean recovery was found to 
be 84.1 ±-1.1% of total potential recovery. Buffer exchange was then carried 
out by extensive dialysis against 0.1 M sodium phosphate buffer (pH 7.4). 
Protein content, as estimated by Abs280nm/ was 0.825 m g before dialysis. A 
total of 0.785mg was recovered after dialysis, which was 95.1% of total 
potential yield. Following three separate determinations, the mean 
recovery was found to be 94.8 ±- 0.7% of total potential recovery.
IgG purification by this protocol resulted in a recovery of 80.4% of 
total potential yield. Following three seperate determinations, the mean 
recovery was found to be 79.7 ±  0.9% of total potential recovery.
From the results (Table 4.1.1) it would appear that the second 
protocol, using Affi-T and dialysis, produces the greater yield. However, the 
Protein A column has a greater capacity to bind IgG, so that fewer column 
runs are necessary and losses are reduced. In light of the relatively large 
quantities of IgG required to produce BF(ab')2, further purifications were 
carried out using the Protein A column and dialysis.
92
Fraction No.
Figure 4.1.7:
The elution profile of 'pure' IgG through an Affi-T affinity colum n. 
Forty 1.5 ml fractions were collected, the buffer was changed, from 
ammonium sulphate (0.75 M) to Tris-HCl (0.05 M, pH 9), after 20 fractions. 
The protein content was determined by measuring the Abs280nm of each 
fraction. This illustrates that a small amount of protein elutes in the 
binding buffer, possibly due to overloading of the column. The bulk of the 
IgG elutes in fractions 25-28 (fractions 5-8 of the elution buffer), which were 
pooled for future use.
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Source Total Protein (mg) Total Protein (% of 
starting material)
Applied to Protein A 12.80 100 !
Recovered from Protein A 10.34 80.3
Applied to G-75 9.94 100
Recovered from G-75 9.40 94.6
Total Recovered 9.8 76.4
Applied to Affi-T 0.97 100
Recovered from Affi-T 0.82 84.6
Applied to Dialysis 0.82 100
Recovered from Dialysis 0.78 95.1
Total Recovered 0.78 80.4
Table 4.1.1:
The recovery of pure IgG from various purification protocols 
following the application of pure IgG. The IgG content was measured by  
estimating the protein concentration, using the BCA assay.
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4.1.2 F(ab')2 Production:
The F(ab')2 fragment was readily produced using digestion with  
pepsin. Two different protocols were used. The procedure used by Brennan  
et at (1985) involved an overnight digestion step (Section 3.8.1). An  
alternative procedure suggested by Runge et al. (1990) involved a 2 hr 
digestion step. Both methods proved equally successful at producing two 
similar peaks on analysis by HPLC (Section 3.4.2). The F(ab')2 fragment 
eluted at 16.1 ±  0.2 min, while the Fc' fragment eluted at 22.5 ±- 0.4 min (Fig.
4.1.8). The first procedure was chosen for future work since gentler 
conditions are used and it gives a more complete digestion.
The Fc' fragment should not interfere with future reactions. 
However, its presence may make interpretation of later chromatograms or 
PAGE gels difficult. Three methods were tried to separate the fragments.
The first method involved an AcA44 Ultrogel column, which was set 
up (1.5 x 30 cm) and equilibrated with 0.1 M sodium phosphate buffer, pH
7.4 (Section 3.4.2). A 0.5 ml sample of F(ab')2 (10 m g/m l) was applied to the 
column and a total of fifty 1 ml fractions were collected. The Abs280nm of 
each fraction was measured and an elution profile constructed. No visible 
peaks emerged in the profile (Fig. 4.1.9). This is possibly due to dilution of 
the sample beyond the detection limit. N o separation could be determined. 
Thus, the AcA44 Ultrogel column is unsuitable for this separation.
The second method involved a Sephacryl S-200 column, which was 
set up (2.6 x 70 cm) and equilibrated with 0.15 M Tris-HCl buffer (pH 8) 
running at 0.4 m l/m in  (Section 3.4.2). A 0.5 ml sample of F(ab')2 (10 
m g/m l) was applied to the column and a total of one hundred 4 ml 
fractions were collected. The Abs280nm of each fraction was measured and 
an elution profile constructed (Fig. 4.1.9). Again it appeared that the protein 
was diluted beyond the detection limit so that no separation could be 
carried out using the Sephacryl S-200 column.
The final method involved a Protein A affinity column, which was 
set up and equilibrated in binding buffer (Section 3.3.3). A 0.5 ml sample of 
F(ab')2 (10 m g/m l) was applied to the column. Fifteen 1 ml fractions of 
binding buffer and five 1 ml fractions of elution buffer were collected. The 
Abs280nm of each fraction was read and an elution profile constructed (Fig.
4.1.9). Two main peaks were present, these were both assayed by HPLC 
(Section 3.4.2) to determine what size of protein molecule was present. Two 
fractions (3 & 18) were assayed and found to contain the same sized protein 
with a retention time of 16.1 min (Fig. 4.1.10). It was concluded that the 
Protein A column used, in this instance, was unsuitable for the purpose 
intended.
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Figure 4.1.8:
The chromatograms produced following HPLC analysis of the F(ab')2 
fragments produced by two different pepsin digestion protocols. Both 
protocols showed two peaks, the F(ab')2 fragment at 16.1 ±- 02  min and the 
Fc' fragment at 22.5 ±  0.4 min. (a) Brennan et al. (1985). (b) Runge et ah, 
(1990). The latter contains two additional features: A shoulder on the 16.1 
min peak indicating the presence of a heavier protein, i.e. undigested IgG. 
A third, smaller peak at 19 ±- 0.1 min corresponds to Rt of pure pepsin. 
HPLC analysis was carried out on a Protein Pak 300SW size exclusion 
column, with a sodium phosphate buffer (0.1 M, pH 7.4) mobile phase, at a 
flow rate of 0.5 m l/m in. The presence of protein was determined using a
u.v./visible variable wavelength detector set at 280nm. (System Gold, 
Beckman) (AU = Absorbance Units)
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Figure 4.1.9:
The elution profiles obtained while 'purifying' the F(ab')2 fragment, 
(a) N o protein could be detected following AcA44 chromatography, (b) No  
separation could be detected following Sephacryl S-200 chromatography, (c) 
Two peaks, one major and one minor, were detected following Protein A 
chromatography, these were further tested to determine their contents.
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Figure 4.1.10:
IgG was subjected to pepsin digestion, the resulting mixture of F(ab')2 
and Fc' was applied to a Protein A sepharose column (Pierce). The F(ab')2 
should elute in the first fractions of binding buffer, Fc' should bind to the 
column until released by the binding buffer. HPLC analysis was carried out 
on the reaction mixture, containing F(ab')2 and Fc' (a). The third fraction of 
binding buffer (b) and the third fraction of elution buffer (c) from the 
Protein A column (Fig. 4.1.9) were also analysed by HPLC. The HPLC 
chromatograms obtained indicate that both fractions contain F(ab')2 only. 
Analysis was carried out using the Beckman System Gold HPLC in 
conjunction with a Protein Pak 300SW column. The sodium phosphate 
buffer (0.1 M, pH 7.4) mobile phase was run at a flow rate of 0.5 ml/m in, the 
variable wavelength detector was set at 280nm for detection of protein. (AU 
= Absorbance Units)
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4.1.3 Fab' Production:
The F(ab')2 fragments were reduced to the Fab' fragments as 
described (Section 3.8.2). dTNB, which reacts with thiol groups, was added 
in order to prevent intrachain disulphide bond formation and stabilise the 
fragments. HPLC was used (Section 3.4.2) to show that the reduction had 
gone to completion and that the resulting molecule was approximately half 
the size of the original F(ab')2 fragment. (Fig. 4.1.11)
It was essential to remove all the unreacted dTNB from the solution. 
This was primarily because dTNB interferes with later stages of BF(ab')2 
production. It was also necessary if the derivatisation of Fab' to Fab'-TNB 
was to be confirmed. This was carried out by extensive dialysis against 1 
mM sodium phosphate buffer (pH 7.4).
A means of detecting dTNB in solution was required if conjugation 
was to be confirmed. dTNB is water soluble, producing a pale yellow  
solution. The absorbance (Abs) of the solution was measured between 
200nm and 500nm, using a Shimadzu UV-160A uv-visible recording 
spectro-photometer. The Xmax was determined to be 325.5nm, (Fig. 4.1.12). 
This solution was allowed to react with cysteine for 3 hrs at 25°C in order to 
form Cys-TNB derivatives. The reaction mixture was dialysed extensively, 
against 1 mM sodium phosphate buffer (pH 7.4), to remove free dTNB. The 
^max of Cys-TNB was found to be 326.6nm, (Fig. 4.1.12). The Xmax of 
cysteine (Xmax 240nm) and human and murine F(ab')2 (Xmax 271.9nm) 
was also measured, (Fig. 4.1.12). Thus, reading the Abs325nm of these 
solutions gives an indication of the amount of dTNB (free and derivatised) 
present, without interference from any protein in solution. This was 
carried out for each step in the production of Fab'-TNB and Fab'-SH.
The Abs325nm of the starting material, F(ab')2, was measured. This 
was then reduced with mercaptoethylamine and allowed to react with 
dTNB (5 mM). The Abs325nm rose considerably. The solution was 
dialysed extensively to remove free dTNB. The Abs325nm of the post­
dialysis solution did not fall significantly compared to the Abs325nm of the 
reaction mixture, indicating that most of the dTNB has been bound to the 
protein. Further reduction of the protein by mercaptoethylamine to Fab'- 
SH released the dTNB into solution. The solution was dialysed extensively 
after which the Abs325nm fell, indicating that the bound dTNB has been 
removed and only Fab'-SH remains. This final reduction was carried out 
on the human Fab'-TNB fragments only, to produce human Fab'-SH 
fragments. The murine fragments were retained as the Fab'-TNB. The 
above results are summarised in Table 4.1.2.
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Figure 4.1.11:
IgG was subjected to pepsin digestion. This mixture containing, 
F(ab')2 and Fc', was analysed by HPLC (a). The mixture was reduced with 
mercaptoethylamine to the Fab'-SH fragment (b). The Fab'-SH has a 
retention time of 18.5 min, which is significantly longer than that of the 
F(ab')2, 16.1 min. This would indicate that the Fab'-SH fragments are 
considerably smaller than the F(ab')2 . Analysis was carried out using the 
Beckman System Gold HPLC in conjunction with a Protein Pak 300SW 
column. The sodium phosphate buffer (0.1 M, pH7.4) mobile phase was 
run at a flow rate of 0.5 ml /m in, the variable wavelength detector was set at 
280nm for detection of protein. (AU = Absorbance Units)
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Figure 4.1.12:
The absorbance spectra of (a) protein (IgG), (b) dTNB and (c) 
cysteine-TNB derivatives, taken on a Shimadzu UV-160A recording 
spectrophotometer.
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Solution Abs325nm ±  SD
F(ab')2 0.166 ±0.008
Fab'-TNB & free dTNB 1.314 ±0.066
Fab'-TNB (post dialysis) 1.251± 0.063
Fab'-SH & free dTNB 1.222 ±0.061
Fab'-SH (post dialysis) 0.255 ±  0.013
Table 4.1.2:
The derivatisation of antibody fragments by dTNB, and its rem oval, 
as illustrated by the measurement of the Abs325nm of the solution. The 
F(ab')2 was reduced and allowed to react with dTNB. This caused the 
Abs325nm to rise sharply. The Abs325nm remains high after dialysis 
indicating that the dTNB has bound to the Fab' (Fab'-TNB). The Fab'-TNB 
is further reduced to the Fab-SH, releasing the dTNB. This is shown by the 
fall in Abs325nm following dialysis. (SD = standard deviation, n = 3)
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4.1.4 BF(ab')2 Production:
The human Fab'-SH and the murine Fab'-TNB were combined 
according to the methods of Brennan et a l  (1985). The mixture was 
subsequently analysed by HPLC (Section 3.4.2). The chromatogram showed 
the presence of large amounts of "Fab1 sized" fragments and trace amounts 
of a larger fragment. The larger fragment had a similar Rt, and hence a 
similar size, to the F(ab')2 fragments previously produced. It appeared that 
association of Fab'-TNB and Fab'-SH fragments to form F(ab')2 fragments 
was limited (Fig. 4.1.13).
In order to increase the formation of F(ab')2 the mixture was set up 
again, this time with the addition of 0.5% (w /v ) hydrogen peroxide. It was 
hoped that the creation of oxidising conditions would increase the number 
of disulphide bonds formed and stabilise the resulting re-formed F(ab')2. 
When this mixture was analysed by HPLC two peaks were evident (Fig. 
4.1.13). In this case, the larger molecule formed 60% of the total protein 
present, as measured by peak area. The Rt of this peak was similar to that of 
the F(ab')2 molecules previously produced, indicating that it may be a 
reformed F(ab')2 fragment or a BF(ab')2-
Five proteins, of known molecular weight, were applied to the HPLC 
(Fig. 4.1.14). From these results a standard curve of Rt vs. Log molecular 
weight was produced (Fig. 4.1.15). The various antibody fragments were 
also analysed on HPLC (Fig. 4.1.16) and the molecular weights calculated 
from the standard curve. The molecular weights of the standards were back 
calculated from the equation of the line. This indicated that the standard 
curve estimated the molecular weight to within 10% of the expected 
molecular weight. The molecular weight of the BF(ab')2 was slightly lower 
than expected, i.e. less than the original F(ab')2 fragment (Table 4.1.3). It 
was, however, twice the weight of a Fab' fragment. This would indicate 
that a F(ab')2 size fragment was formed. It was necessary to determine if 
these fragments were formed by the combination of similar or dissimilar 
Fab' fragments.
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Figure 4.1.13:
Fab'-TNB and Fab'-SH fragments were combined to produce BF(ab')2 
fragments, and analysed by HPLC: (a) In the absence of H2Q2, resulting in 
the production of small amounts of a F(ab')2 sized molecule, Rt = 16.6 ±  0.3 
min. (b) With the addition of 0.5% (w /v ) H2O2, resulting in the 
production of increased quantities of the F(ab')2 sized molecule, up to 75% 
of total potential yield was produced. Analysis was carried out using the 
Beckman System Gold HPLC in conjunction with a Protein Pak 300SW 
column. The sodium phosphate buffer (0.1 M, pH 7.4) mobile phase was 
run at a flow rate of 0.5 m l/m in, the variable wavelength detector was set at 
280nm for detection of protein. (AU = Absorbance Units)
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Figure 4.1.14:
The chromatograms produced as a result of the HPLC analysis of six 
proteins of known molecular weight The proteins elute in order of 
decreasing molecular weight: Blue Dextran, 2 x #  Da, Rt = 9.4 min. 0- 
Amylase, 2 x 10^ Da, Rt = 13.8 min. Alcohol dehydrogenase, 1.5 x 10  ^Da, Rt 
= 15.3 min. Albumin, 6.6 x 104 Da, Rt = 16.9 min. Carbonic anhydrase, 2.9 x 
lC)4Da, Rt = 20.0 min. Cytochrome C, 1.24 x 104Da, Rt = 212  min. Analysis 
was carried out using the Beckman System Gold HPLC in conjunction with 
a Protein Pak 300SW column. The sodium phosphate buffer (0.1 M, pH 7.4) 
mobile phase was run at a flow rate of 0.5 m l/m in, the variable wavelength 
detector was set at 280nm for detection of protein. (AU = Absorbance Units)
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Figure 4.1.15:
The standard curve produced by plotting the retention times, from 
HPLC analysis, of proteins of known molecular weight against the Log 
molecular weight, (r = 0.988) Analysis was carried out using the Beckman 
System Gold HPLC in conjunction with a Protein Pak 300SW column. The 
sodium phosphate buffer (0.1 M, pH 7.4) mobile phase was run at a flow rate 
of 0.5 m l/m in, the variable wavelength detector was set at 280nm for 
detection of protein.
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Figure 4.1.16:
The chromatograms produced following HPLC analysis of the 
antibody fragments formed during the production of BF(ab')2/ illustrating 
that the BF(ab')2 has a similar retention time to the F(ab')2 produced by 
pepsin digestion of the IgG. Analysis was carried out using the Beckman 
System Gold HPLC in conjunction with a Protein Pak 300SW column. The 
sodium phosphate buffer (0.1 M, pH 7.4) mobile phase was run at a flow rate 
of 0.5 ml/min, the variable wavelength detector was set at 280nm for 
detection of protein. (AU = Absorbance Units)
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Protein Rt + SD (min) Mean Molecular 
W eight
Blue Dextran 9.4 ± 0 .3 2,000,000
ß-Amylase 13.8 ± 0 .5 200,000
Alcohol Dehydrogenase 15.3 ±  0.4 150,000
A lbum in 16.9 ± 0 .2 66,000
Carbonic Anhydrase 20.0 ±  0.3 29,000
Cytochrome C 21.2 ±  0.4 12,400
IgG 14.8 ± 0 .3 156,500
F(ab')2 16.1 ±  0.2 96,600
Fab '-SH /  Fab'-TNB 18.5 ±  0.4 40,100
BF(ab')2 16.6 ±  0.3 80,700
Table 4.1.3:
The results of HPLC analysis of standard proteins and antibody 
fragments derived from the production of BF(ab')2, according to the 
method of Brennan et a l. (1985). The retention time (Rt) of each protein 
was determined five times. A standard curve of Rt vs. Log m olecular 
weight was constructed from the proteins of known molecular weight. The 
molecular weight of the antibody fragments was determined from the 
mean Rt.
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A sandwich ELISA was developed to show that the molecule formed 
was in fact composed of a human Fab' and a murine Fab' linked together. 
The wells of a 96-well plate (Nunc) were coated with anti-mouse Fab' 
antibody. Non-specific binding sites were blocked with BSA. BF(ab)2 was 
applied and the murine "half" of the molecule was allowed to bind. The 
secondary antibody was anti-human Fab' antibody labelled with HRE This 
would only bind if the fragments contained a human Fab' "half" (Fig. 
4.1.17). Suitable positive and negative controls were carried out (Table
4.1.4). The Abs4i4nm  of each well was determined. The positive controls 
had a mean reading of 0.597 ±  0.07 (n=4). The negative controls had a mean 
reading of 0.142 ±- 0.03 (n=4). The test wells had a mean reading of 0.578 ±  
0.03 (n=4). These results indicate that the F(ab')2 sized molecule, produced 
in this procedure, was formed by linking a human Fab1 fragment to a 
murine Fab' fragment, i.e. it is a BF(ab')2 fragment. This ELISA was 
repeated five times, each of which confirmed that BF(ab')2 had been 
produced.
A similar ELISA was used to determine the optimum concentration 
of hydrogen peroxide and the optimum incubation period for the 
production of BF(ab')2. A series of vials were set up containing human 
Fab'-SH and murine Fab'-TNB, with H2O2 at concentrations of 0%, 0.1%, 
0.2%, 0.3%, 0.4%, 0.5% and 1.0% (w /v). These were incubated at 37°C. 
Samples were taken from each tube at 0 hr, 1 hr, 2 hr, 4 hr, 6 hr, 8 hr, and 24 
hr intervals. After incubation samples were stored at 4°C. BF(ab')2 
production was estimated using the sandwich ELISA. The results indicate 
that good BF(ab')2 production can be achieved by incubating the Fab' 
fragments at 37°C for 8 hrs with 0.5% (w /v ) H2O2 (Fig. 4.1.18). There was 
very little increase in BF(ab')2 production when the H2O2 concentration 
was doubled to 1% (w /v ) or when the incubation period was increased to 24 
hrs. To maximise BF(ab')2 production, and for convenience, later BF(ab')2 
production runs were carried out in 0.5% (w /v ) H2O2 and incubated 
overnight at 37°C.
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Figure 4.1.17:
An illustration of the ELISA used to determine if the BF(ab')2 
produced was in fact formed from a murine Fab' and a human Fab1. The 
wells of a 96-well plate were coated with anti-mouse Fab' antibody. Non­
specific binding sites were blocked with BSA. BF(ab)2 was applied and the 
murine "half' of the molecule was captured by the bound anti-mouse Fab' 
antibody. The secondary antibody was anti-human Fab' antibody labelled 
with HRE This would only bind if the captured BF(ab')2 contained a 
human Fab' "half1. Thus, on addition of the HRP substrate o-PD, colour 
■will develop only in those wells containing BF(ab')2 .
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Table 4.1.4:
Primary Second Antibody HRP-Labelled Mean Abs405nm
Antibody (Antigen) Antibody ±S.D .
a-M ouse IgG Human IgG a-H um an IgG 0.153 ±  0.021
a-Mouse IgG Human F(ab')2 a-H um an IgG 0.103 ±  0.014
a-Mouse IgG Human Fab' a-H um an IgG 0.114 ±0.025
a-Mouse IgG PBS a-H um an IgG 0.199 ±  0.033
a-Mouse IgG PBS a-M ouse IgG 0.114 ±0.029
Human IgG PBS a-M ouse IgG 0.154 ±0.031
Human F(ab')2 PBS a-M ouse IgG 0.105 ±0.018
Human Fab' PBS a-M ouse IgG 0.146 ±0.031
Mouse IgG PBS a-H um an IgG 0.179 ±  0.042
Mouse F(ab')2 PBS a-H um an IgG 0.141 ±  0.035
Mouse Fab' PBS a-H um an IgG 0.151 ±  0.032
BSA PBS a-M ouse IgG 0.075 ±  0.027
BSA PBS a-H um an IgG 0.077 ±  0.029
a-Mouse IgG Mouse IgG a-M ouse IgG 0.584 + 0.049
a-Mouse IgG Mouse F(ab')2 a-M ouse IgG 0.593 ±  0.031
a-Mouse IgG Mouse Fab1 a-M ouse IgG 0.572 ±  0.040
Human IgG PBS a-H um an IgG 0.627 ±0.037
Human F(ab')2 PBS a-H um an IgG 0.640 ±0.041
Human Fab1 PBS a-H um an IgG 0.640 ±  0.046
Mouse IgG PBS a-M ouse IgG 0.630 ±0.040
Mouse F(ab')2 PBS a-M ouse IgG 0.588 ±  0.036
Mouse Fab' PBS a-M ouse IgG 0.743 ±  0.043
a-Mouse IgG BF(ab')2 a-H um an IgG 0.587 ±  0.038
a-Human IgG BF(ab')2 a-M ouse IgG 0.569 ±0.032
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Figure 4.1.18:
A study was carried out to determine the optimum concentration of 
hydrogen peroxide required for the production of BF(ab')2, as well as the 
optimum incubation period. The results would indicate that incubation of 
the Fab' fragments in 1.0% (w /v ) H2O2, for 24 hrs, at 37°C, create optimum 
conditions for BF(ab')2 production. However, the milder conditions of 
0.5% (w /v ) H2O2, incubated overnight (i.e. 16 hrs) at 37°C, are nearly as 
efficient and were chosen convenient conditions for BF(ab')2 production.
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4.1.5 Summary:
Large quantities of a murine IgG, G12, were purified from ascites 
fluid and used, in conjunction with human IgG, to examine the production 
of BF(ab')2 according to the method of Brennan et a l (1985). From the 
studies in IgG purification it would appear that the Affi-T column produces 
the greater yield of IgG, but the Protein A column has a greater capacity to 
bind IgG. Thus, fewer column runs are necessary with the Protein A 
column and losses are reduced. In light of the relatively large quantities of 
IgG required to produce BF(ab')2, purifications were carried out using the 
Protein A column. The purified IgG was subject to a pepsin digestion to 
produce an F(ab')2 fragment. The method suggested by Brennan et a l 
(1985) was chosen since gentler conditions are used and it gives a more 
complete digestion than the other method tried (Runge et al, 1990). 
Several methods were tested in an attempt to separate the F(ab')2 and Fc' 
fragments (i.e. an AcA44 Ultrogel column, a Sephacryl S-200 column and a 
Protein A affinity column) but none were successful. The F(ab')2 fragments 
were reduced to the Fab' fragment and bound to dTNB to prevent 
intrachain disulphide bond formation. The successful binding of dTNB 
was shown, as was the removal of dTNB from the human IgG molecules. 
The murine Fab'-TNB and the human Fab'-SH were allowed to re-associate 
according to the method of Brennan et a l (1985), the recombinant molecule 
produced formed less than 10% of the total protein present in solution, as 
measured by HPLC. The addition of 0.5% (w /v ) H2O2 increased this yield to 
60%. The HPLC analysis also indicated that the molecule formed is twice 
the weight of a Fab' fragment, but slightly lower than that of the original 
F(ab')2 fragment. This may be due to the degree of error in the standard 
curve. Alternatively, it may be caused by the altered three dimensional 
structure of the fragments compared to the parental antibodies. This, as 
well as their molecular weight, effects the rate at which the fragments pass 
through the HPLC column. The results of the ELISA indicate that the 
F(ab')2 sized molecule, produced in this procedure, was formed by linking a 
human Fab' fragment to a murine Fab' fragment, ie. it is a BF(ab')2 
fragment.
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4.2 A MODEL SYSTEM FOR BISPECIFIC ANTIBODY APPLICATION
In the previous section (4.1) a method for the production of BF(ab')2 
was optimised. It was necessary to determine if the BF(ab')2 produced 
retained the binding activity of the parental Igs, and, if so, to what extent 
that activity was retained. To this end a model system was developed for 
BF(ab')2 application. Two IgGs were readily available, i.e. a polyclonal, 
rabbit anti-BSA Ab and a monoclonal murine anti-CLL Ab (G12). The cell 
line K562, to which G12 binds, was readily available. A detectable substrate 
for the anti-BSA Ab was required. A BSA-HRP conjugate was produced to 
fulfill this role. The model system was set up by coating an ELISA plate 
with K562 cells, applying the anti-BSA X G12 BF(ab')2 and HRP-BSA 
conjugate and developing the colour using the HRP substrate o-PD.
4.2.1 Conjugation o f Horse Radish Peroxidase to BSA:
The enzyme Horse Radish Peroxidase (HRP) was conjugated to the 
protein Bovine Serum Albumin (BSA) using the periodate method of 
conjugation (Section 3.5.2).
HPLC analysis was carried out on the 'HRP-BSA conjugate' and on 
HRP and BSA individually (Section 3.4.2). Monitoring the eluent at 280nm 
indicated that the HRP-BSA sample contained a protein which appeared to 
be larger than either HRP (45 kDa) or BSA (66 kDa) (Fig. 4.2.1). In order to 
confirm this a total of five injectons of each of HRIJ BSA and HRP-BSA 
were made onto the HPLC. The mean Rt for HRP the smallest protein was 
17.76 ±  0.14 min. BSA is larger with a mean Rt of 16.36 ±- 0.06 min. The 
mean Rt for the HRP-BSA peak was 15.90 ±  0.04 min. A one-tailed, paired 
Student t test was used to show that the Rt of BSA and the Rt of HRP are 
significantly longer than the Rt of HRP-BSA, within 99% confidence limits. 
This would indicate that a conjugated protein was produced which was 
significantly larger than the parent proteins.
During the HPLC analysis, fractions were collected at 1 min intervals. 
The relevant, protein-containing fractions were assayed for the presence of 
HRP The HRP substrate o-PD was prepared as for ELISA. To the wells of a 
96-well plate was added 100 jd substrate solution and 50 jxl of each fraction 
from the HPLC analysis of BSA, HRP and HRP-BSA. After 30 min at room 
temperature, the Abs405nm was determined. A plot of absorbance vs. 
fraction number (Fig. 4.2.2) showed that the HRP-BSA solution consisted of 
two HRP-containing peaks. These peaks corresponded in Rt with the HRP 
peak and the conjugated protein peak in the HRP-BSA solution.
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Figure 4.2.1:
The chromatograms produced following HPLC analysis of (a) HRP 
(Rt = 17.764 ±  0.141 min), (b) BSA (Rt = 16.363 ±  0.060 min) and (c) HRP-BSA 
conjugate (Rt = 15.905 ±- 0.046 min), illustrating that the conjugate protein is 
significantly larger than either of the parent proteins. HPLC analysis was 
carried out on a Protein Pak 300SW size exclusion column, with a sodium 
phosphate (0.1 M, pH 7.4) mobile phase, run at a flow rate of 0.5 ml/min. 
The variable wavelength detector was set at 280nm for determination of 
protein. (System Gold, Beckman) (AU = Absorbance Unit)
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Figure 4.2.2:
HRR BSA and HRP-BSA were each applied to HPLC (Fig. 4.2.1). 
Fractions of eluent were collected every minute (i.e. 0.5 ml each). Each 
fraction was analysed for the presence of active HRR 50 |xl of each fraction 
was added to 100 jaI of o-PD in citrate buffer (0.1 M, pH 4.5). Colour 
development was measured at 405nm and was proportional to HRP 
activity. The elution profiles were constructed. The eluent from the HPLC 
analysis of BSA showed no HRP activity, as was expected. The eluent from 
the HPLC analysis of HRP showed a broad band of HRP activity, visible in 
fractions 16-20. The eluent from the HPLC analysis of HRP-BSA conjugate 
showed two peaks of HRP activity. The main peak of HRP activity occurs in  
fractions 17-19, corresponding to the peak seen in the HRP analysis. A 
minor peak of HRP activity occurs in fraction 14. This indicates the 
presence of a protein with HRP activity but with a greater molecular weight 
than HRIJ i.e. a HRP-BSA conjugate.
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This would indicate that, as a result of the conjugation procedure, a 
conjugated protein was produced which was larger than the parent 
proteins. One of the parent proteins, HRIJ forms a part of the conjugated 
protein and retains its enzymatic activity.
The conjugated protein was purified from the HRP-BSA solution by 
the use of two affinity chromatography columns. In the first, the rabbit 
anti-HRP Ab was coupled to CNBr-activated Sepharose. In the second, the 
rabbit anti-BSA Ab was coupled to CNBr-activated sepharose (Section 3.3.1). 
The purpose of the former was to remove free BSA from solution, and of 
the latter to remove free HRP from solution. To the anti-HRP-column was 
applied HRI? BSA and HRP-BSA. The 1 ml fractions collected were assayed 
for protein using the BCA assay (Section 3.5.1), and for HRP as described 
above. Free BSA elutes in the wash buffer, while HRP and HRP conugates 
adsorb onto the column and elute only when dissociation buffer is applied 
(Fig. 4.2.3). To the anti-BSA-column was applied HRR BSA and those 
fractions of HRP-BSA eluted from the first column which were shown to 
contain HRP Fractions collected from this column were assayed for protein 
and HRP as before. Free HRP elutes in the wash buffer, while BSA and BSA 
conjugates adsorb onto the column and elute only when dissociation buffer 
is applied. It was shown that a protein, with HRP activity, elutes in the 
dissociation buffer from the second column (Fig.4.2.4). This could only be a 
conjugate protein having both BSA and HRP sub-units.
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Figure 4.2.3:
Three proteins were applied to an affinity column, CNBr-activated Sepharose 
coupled to anti-HRP Ab (0.5 x 5 cm). The binding buffer w as PBS (0.02 M, pH 7.1), of which 
15 x 1 ml fractions were collected, and the elution buffer was 0.1 M glycine /HC1 buffer (pH 
2.5), of which 10 x 1 ml fractions were collected. Each fraction w as assayed for protein, using 
the BCA assay (Abs560nm)/ and active HRR by testing for the conversion of the substrate o- 
FD to a measurable coloured product (Abs405nm)- BSA (a) did not bind to the column but 
eluted in the binding buffer (Abs5 6 0 nm), no HRP activity w as detected (Abs405nm)- HRP (b) 
bound to the column and eluted in the elution buffer (Abs405nm)/ the amount of protein 
present was below  the limit of detection (Abs5 6 Qnm)- In the sample containing HRP-BSA 
conjugate (c) all the HRI’ free and conjugated, bound to the column and eluted in the elution 
buffer (Abs405nm)- Protein eluted in the binding buffer (Abs560nm)/ representing free BSA, 
and in the elution buffer, representing conjugated BSA.
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Figure 4.2.4:
Three proteins were applied to an affinity column, CNBr-activated Sepharose 
coupled to anti-BSA Ab (0.5 x 5 cm). The binding buffer was PBS (0.02 M, pH 7.1), of which 15 
x 1 ml fractions were collected, and the elution buffer was 0.1 M glycine/HC1 buffer (pH 2.5), 
of which 10 x 1 ml fractions were collected. Each fraction was assayed for protein, using the 
BCA assay (Abs56Qnm)/ and active HRP by testing for the conversion of the substrate o-PD to 
a measurable coloured product (Abs405nm). BSA (a) bound to the column and eluted in the 
elution buffer (AbssgOnm)/ no HRP activity was detected (Abs405nm)- HRP (b) did not bind 
to the column and eluted in the binding buffer (Abs405nm)/ the amount of protein present was 
below  the limit of detection (Abssgonm)- In the sample containing HRP-BSA conjugate (c) 
free HRP eluted in the binding buffer (Abs405nm)/ while that in the elution buffer, 
represented HRP conjugated to BSA. All the BSA bound to the column and eluted in the 
elution buffer (AbssgQnm)- Fractions 16-18, in which the protein and HRP concentrations are 
highest, contain pure HRP-BSA conjugate.
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4.2.2 Developm ent of a M odel ELISA System:
A BF(ab')2 was produced from a rabbit, polyclonal anti-BSA Ab 
(Sigma) and a murine, monoclonal anti-CLL Ab (G12). A series of ELISAs 
were carried out to illustrate the bispecificity of the BF(ab')2 produced and 
determine its activity compared to the parental IgGs. In the first of these it 
was shown that the BF(ab')2 produced was in fact formed by the coming  
together of a murine Fab' and a rabbit Fab' (Fig. 4.2.5a). The plate was coated 
with an anti-mouse Fab' Ab and blocked with 1% (w /v ) gelatin in PBS (0.1 
M, pH 9) (Section 3.6.2). BF(ab')2 was applied to the wells at a concentration 
of 0.1 m g/m l in PBS. A HRP-labelled goat anti-rabbit IgG Ab was then 
applied. The colour was developed in the plate using the HRP substrate o- 
PD (Section 3.6.3). The positive control wells were coated with rabbit IgG; 
these had a mean Abs405nm of 0.418 ±- 0.031. The negative control wells 
did not have BF(ab')2 applied; these had a mean Abs405nm of 0.050 ±- 0.007. 
The absorbance of the test wells, mean of 0.350 ±- 0.023, was considerably 
higher than for the negative control wells. This would indicate that a 
BF(ab')2 had been formed.
The next two ELISAs were carried out to determine whether or not 
each seperate Fab' had retained binding activity for the specified Ags. In the 
first of these, the plate was coated with BSA and blocked with 1% (w /v)  
gelatin in PBS (0.1 M, pH 9) (Section 3.6.2). BF(ab')2 was applied to the wells 
at a concentration of 0.1 m g/m l in PBS. A HRP-labelled goat anti-mouse 
IgG Ab was then applied (Fig. 4.2.5b). The colour was developed in the plate 
using the HRP substrate o-PD (Section 3.6.3). The positive control wells 
were coated with mouse IgG; these had a mean Abs405nm of 0.328 ±- 0.035. 
The negative control wells did not have BF(ab')2 applied; these had a mean 
Abs405nm of 0.041 ±  0.010. The absorbance of the test wells, mean of 0.286 ±  
0.031, was considerably higher than for the negative control wells. This 
would indicate that the rabbit Fab' retains Ag binding activity when 
forming part of a BF(ab')2- In the second ELISA, the plate was coated with 
K562 cells and blocked with 1% (w /v ) gelatin in PBS (0.1 M, pH9) (Section 
3.6.1). BF(ab')2 was applied to the wells at a concentration of 0.1 m g/m l in 
PBS. A HRP-labelled goat anti-rabbit IgG Ab was then applied (Fig. 4.2.5c). 
The colour was developed in the plate using the HRP substrate o-PD 
(Section 3.6.3). The positive control wells were coated with rabbit IgG, these 
had a mean Abs405nm of 0.298 ±  0.033. The negative control wells did not 
have BF(ab')2 applied, these had a mean Abs405nm of 0.037 ±- 0.013. The 
absorbance of the test wells, mean of 0.259 ±  0.037, was considerably higher 
than for the negative control wells. This would indicate that the mouse 
Fab' retains Ag binding activity when forming part of a BF(ab')2-
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Figure 4.2.5:
An illustration of the series of ELISA formats used to assess the 
bifunctionality of the BF(ab')2- Each was run with suitable positive and 
negative controls and blank wells. The test wells were deemed to be 
positive if the absorbance was at least 150% of the negative control wells. 
Each of the illustrated test wells gave positive results in the ELISAs 
indicating that: (a) the BF(ab')2 is formed from two different Fab'
fragments; (b) the rabbit anti-BSA Fab', which forms half of the BF(ab')2, 
retains its binding activity; (c) the murine anti-K562 Fab', which forms the 
other half of the BF(ab')2, retains its binding activity; (d) the BF(ab')2 can be 
used successfully in a one-step enzyme immunoassay for K562 cells.
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The final ELISA utilizes the binding activity of both halves of the 
BF(ab')2. The plate was coated with K562 cells and blocked with 1% (w /v )  
gelatin in 0.1 M PBS, pH 9 (Section 3.6.1). BF(ab')2 was applied to the wells 
at a concentration of 0.1 m g/m l in PBS. The HRP-BSA conjugate was 
applied at the same time as the BF(ab')2 at a concentration of 0.1 m g/m l in 
PBS (Fig. 4.2.5d). The colour was developed in the plate using the HRP 
substrate o-PD (Section 3.6.3). The positive control wells were developed 
with HRP-linked anti-rabbit IgG; these had a mean Abs405nm of 0.214 ±- 
0.025. The negative control wells did not have BF(ab')2 applied; these had a 
mean Abs405nm of 0.045 ±  0.005. The absorbance of the test wells, mean of 
0.134 ±- 0.020, was considerably higher than for the negative control wells. 
This would indicate that both the mouse Fab1 and the rabbit Fab' retain 
their Ag binding activity when forming part of a BF(ab')2 and that the 
BF(ab')2 can be used successfully in a one-step enzyme immunoassay for 
K562 cells.
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4.2.3 Measurement of BF(ab')2 Activity:
A series of ELISAs was carried out to determine if the BF(ab')2 
retained the binding affinity and specificity of the parental IgG molecules. 
The BF(ab')2 to be tested was purified using double affinity 
chromatography. In the first column, an anti-rabbit Fab' Ab was coupled to 
CNBr-activated Sepharose. In the second column, an anti-mouse Fab' Ab 
was coupled to CNBr-activated sepharose (Section 3.3.1). The purpose of 
the former was to remove free murine Fab' from solution, and the purpose 
of the latter to remove free rabbit Fab' from solution.
The first ELISAs were set up to determine if the BF(ab')2 had retained 
the specificity of the parental IgG molecules. A 96-well plate was coated 
with K562 cells and blocked with 1% (w /v ) gelatin in PBS (0.1 M, pH 9) 
(Section 3.6.1). NSO cells, suspended in PBS, were diluted to give eight cell 
suspensions with a concentration range of 0-10  ^ cells/m l. Each of these 
suspensions was applied in triplicate to wells of the plate. Murine IgG (G12) 
was applied to each of these wells at a concentration of 0.1 m g/m l in PBS. 
The cells and Ab fragments were incubated together for 1 hr at 37°C, then 
washed out. A HRP-labelled goat anti-mouse Fab' Ab was then applied. 
The colour was developed in the plate using the HRP substrate o-PD 
(Section 3.6.3). This procedure was carried out simultaneously using G12 
F(ab')2, Fab' and BF(ab')2- The specificity of each Ab fragment was 
determined by the degree to which the NSO cells interfere with the binding 
of the fragment to the adsorbed K562 cells. A graph was drawn of 
Abs405nm vs. concentration of NSO cells (Fig. 4.2.6). This shows that the 
binding of the IgG is slightly affected by the presence of NSO cells. The 
Abs405nm fell from 0.268 ±  0.014, in the absence of NSO cells, to 0.200 ±  
0.018 in the presence of 10  ^ cells/m l. The binding of the BF(ab')2 was also 
affected by the presence of NSO cells. The Abs405nm fell from 0.171 ±  0.012, 
in the absence of NSO cells, to 0.098 ±  0.013 in the presence of 10  ^ cells/m l. 
Both the IgG and the BF(ab')2 were inhibited to the same extent by the 
presence of the NSO cells. This would indicate that formation of the 
BF(ab')2 does not affect the specificity of the Ab fragments used. This ELISA 
was carried out a further three times to confirm this result.
Another 96-well plate was coated with BSA and blocked with 1% 
(w /v ) gelatin in PBS (0.1 M, pH 9) (Section 3.6.1). A serial dilution was 
carried out on a solution of ovalbumin (OVA) in PBS to give eight 
solutions with a concentration range of 0-10 m g/m l. Each of these dilutions 
was applied in triplicate to wells of the plate. Rabbit anti-BSA IgG was 
applied to each of these wells at a concentration of 0.1 m g/m l in PBS.
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Concentration of NSO Cells (Cells/ml)
Figure 4.2.6:
The results of an ELISA to determine the extent to which NSO cells 
interfere with the the anti-K562 IgG's and BF(ab')2 's ability to bind to a plate 
coated with K562. Large numbers of NSOs do cause some inhibition of 
binding. The extent of the inhibition is the same for both IgG and BF(ab')2 .
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The OVA and Ab fragments were incubated together for 1 hr at 37°C, then 
washed out. A HRP-labelled goat anti-rabbit Fab' Ab was then applied. The 
colour was developed in the plate using the HRP substrate o-PD (Section 
3.6.3). This procedure was carried out simultaneously using rabbit anti- 
BSA F(ab')2, Fab' and the BF(ab')2 . The specificity of each Ab fragment was 
determined by the degree to which the OVA interferes with the binding of 
the fragment to the adsorbed BSA. A graph was drawn of Abs405nm vs. 
concentration of OVA (Fig. 4.2.7). This shows that the binding of the IgG is 
affected by the presence of OVA. The Abs405nm fell from 0.542 ±  0.026, in 
the absence of OVA, to 0.321 ±  0.031 in the presence of 10 m g/m l. The
binding of the BF(ab')2 was also affected by the presence of OVA. The
Abs405nm fell from 0.487 ±  0.022, in the absence of OVA, to 0.271 ±  0.023 in 
the presence of 10 m g/m l. Both the IgG and the BF(ab')2 were inhibited to 
the same extent by the presence of the OVA. This would indicate that 
formation of a BF(ab')2 does not affect the specificity of the Ab fragments 
used. This ELISA was carried out a further three times to confirm this 
result.
From both these graphs (Figs. 4.2.6 & 4.2.7), it would appear that the 
binding affinity of the Fab'fragments involved in BF(ab')2 production is 
somewhat reduced compared to the parental IgGs. In both cases the 
absorbances of the BF(ab')2 fragment are lower than that of the IgG. The
loss of binding affinity appears to be more pronounced for the murine than
for the rabbit Fab'.
4.2.4 Summary:
A HRP-BSA conjugate was successfully produced, as shown by HPLC 
and double affinity chromatography. An anti-BSA X anti-K562 BF(ab')2 was 
successfully produced, as shown by HPLC and ELISA. A series of ELISAs 
were used to show that both the Fab' fragments used in the production of 
the BF(ab')2 retained the binding activity and specificity of the parental IgG, 
although some of the affinity is lost. The BF(ab')2 was used successfully in a 
one-step enzyme immunoassay for K562 cells.
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Figure 4.2.7:
The results of an ELISA to determine the extent to which ovalbumin 
interferes with the the anti-BSA IgG's and BF(ab')2 's ability to bind to a 
plate coated with BSA. Large concentrations of ovalbumin do cause some 
inhibition of binding. The extent of the inhibition is the same with both 
IgG and BF(ab')2 .
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BF(ab')2s have been used to develop a model system for the detection 
of the cell line K562. This system can be improved upon and applied to the 
detection of chronic lymphocytic leukaemia (CLL) in patient blood samples. 
A rabbit polyclonal anti-alkaline phosphatase (AP) Ab was produced to 
replace the anti-BSA Ab used previously. The anti-K562 Ab (G12) binds to 
B-CLL lymphocytes, via a 69.2 kDa cell surface Ag. A G12 X anti-AP BF(ab')2 
was produced which was used to develop two enzyme immuno-assays and 
an immuno-chemical method for the detection of CLL.
4.3.1 Production o f an Anti-Alkaline Phosphatase Antibody:
Polyclonal antibodies were raised against the enzyme alkaline 
phosphatase (AP) in order to develop a detection system for CLL using 
BF(ab')2s. The enzyme, molecular weight 100 kDa, is large enough to be 
immunogenic so that no conjugation or carrier proteins were required. An 
immunisation schedule was set up (Section 3.2.1). Following six cycles of 
immunisation an ELISA was set up to determine the serum titre. A serial 
dilution of the serum was carried out in the range 1:102-1:10®. AP was 
coated onto the 96-well plate and non-specific binding sites blocked with 
BSA (Section 3.6.2). The serial dilutions were applied in triplicate to the 
wells of the plate and allowed to bind for 1 hr at 37°C. The secondary Ab, 
HRP-labelled goat anti-rabbit IgG (Sigma), was applied after the plate had 
been washed. Colour was developed in the plates by the addition of the 
HRP substrate o-PD (Section 3.6.3). Maximum colour developm ent 
occurred at the lowest dilution (1:100), with an Abs405nm of 0.588 ±- 0.029. 
The negative control, to which a 1:100 dilution of serum from an un­
immunised rabbit was added, gave an Abs405nm of 0.068 ±  0.015. The 
highest dilution of serum from the immunised rabbit to give a strong 
positive reaction was found to be 1:10 /^ with an Abs405nm of 0.315 ±- 0.018. 
Serum from this, and subsequent, immunisations were pooled and stored 
at -20°C prior to purification of the IgG.
4.3 DETECTION OF CHRONIC LYMPHOCYTIC LEUKAEMIA USING
BISPECIFIC ANTIBODIES
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4.3.2 ELISA Development:
A BF(ab')2 was produced using the methods described, (Sections 3.8.2 
& 3.8.3). The parental Abs were rabbit polyclonal anti-AP Ab and the 
murine, monoclonal anti-CLL Ab (G12) which also binds to the K562 cell 
line. A chequerboard ELISA was carried out to determine the optimum  
concentrations of BF(ab')2 and AP required for the detection of the human 
leukaemic cell line, K562. The wells of a 96-well ELISA plate were coated 
with K562 cells and blocked with BSA (Section 3.6.1). In developing the 
ELISA, two variables were taken into consideration; concentration of 
BF(ab')2 and concentration of AE To each blocked and washed well was 
added 50 pil BF(ab')2 (in the range 0-50 pig/ml) and 50 pil AP (in the range 0- 
500 pig/ml). (Fig. 4.3.1) These were incubated for 1 hr at 37°C. The plate was 
washed three times with PBS. Colour was developed in the wells using the 
AP substrate BCIP (Section 3.6.3). The lowest concentrations of AP and 
BF(ab')2 to give a strongly positive result were chosen for future use. These 
were AP at 100 pig/ml and BF(ab')2 at 1 pig/ml (Table 4.3.1). These 
concentrations, of AP and BF(ab')2, were found to be optimum and were 
independent of the method of production of BF(ab')2-
A suspension ELISA was also developed. This was carried out in 1.8 
ml, conical centrifuge tubes. Non-specific binding sites on the plastic were 
blocked by filling the tubes with 1% (w /v ) BSA in PBS, and storing them at 
4°C for a minimum of 12 hr before use. K562 cells were harvested from 
culture vessels (Section 3.1.2) and suspended in PBS. In developing the 
ELISA, three variables were taken into consideration; concentration of K562 
cells, concentration of BF(ab')2 and concentration of AE To each blocked 
and washed tube was added 200 pil K562 cells (in the range 10^-10® cells/m l), 
50 pil BF(ab')2 (in the range 0-50 pig/ml) and 50 pil AP (in the range 0-500 
pig/ml). These were incubated for 1 hr at 37°C. The cells were pelletted by 
centrifugation at 6,000 rpm for 3 min. The cells were washed with PBS and 
pelletted as before. This was repeated twice. The cells were re-suspended in 
1 ml of the AP substrate BCIIJ 1 m g/m l in amino methyl propanol buffer, 
and incubated for 30 min at 37°C (Section 3.6.3). The cells were pelletted as 
before and the Abs620nm of the supernatants determined on a 
spectrophotometer (Table 4.3.2). Good results were achieved at a K562 
concentration of 10  ^ cells/m l, a BF(ab')2 concentration of 50 pig/ml and an 
AP concentration of 50 pig/ml.
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1 2 3 4 5 6 7 8 9 10 11 12
A 10 9 8 8 7 7 6 6 5 5 4 0
B 9 8 8 7 7 6 6 5 5 4 4 0
C 8 8 7 7 6 6 5 5 4 4 3 0
D 8 7 7 6 6 5 5 4 4 3 3 0
E 7 7 6 6 5 5 4 4 3 3 2 0
F 7 6 6 5 5 4 4 3 3 2 2 0
G 6 6 5 5 4 4 3 3 2 2 1 o ;
H 0 0 0 0 0 0 0 0 0 0 0 0
Figure 4.3.1:
A schematic diagram of a chequerboard ELISA plate. To each well in 
column 1 (1A-1H) was applied 50 jxl of the highest concentration of BF(ab')2 
(2 m g/m l), i.e. PBS. To each well in column 12 (12A-12H) was applied 50 |xl 
of the lowest concentration of BF(ab')2 (0 m g/m l). To each well of the 
columns in between (2A-2H, 3A-3H, etc.) was applied 50 jxl of one of a serial 
dilution of BF(ab')2 . In a similar manner, to each well of row A (A1-A12) 
was applied 50 fxl of the highest concentration of AP (500 pig/ml). To each 
well in row H (H1-H12) was applied 50 pil of the lowest concentration of AP 
(0 ng/m l). To each well of the rows in between (B1-B12, C1-C12, etc.) was 
applied 50 pil of one of various dilutions of AP When colour was 
developed in the wells, well H 12 acted as a blank, since no AP or BF(ab')2 
were applied to this well (numbers 0-10 indicate colour intensity). 
Maximum colour development occured in well A l, since the maximum  
concentration of both AP and BF(ab')2 were applied to this well. The colour 
development increased diagonally across the plate as the concentrations of 
AP and BF(ab')2 increased. At some point in the plate (e.g. D5) a strong 
colour development is achieved using the minimum amount of reagents.
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AP BF(ab')2 (pig/ml)
M-g/ 2 x l x 2 x 1 X 2 x l x 2 x lx 2 x lx 2 x 0.0
ml 103 103 102 102 101 101 10° 10° 10“1 10"1 10-2
500 0.28 0.26 0.26 0.25 0.23 0.23 0.21 0.20 0.19 0.11 0.09 0.03
100 0.25 0.25 0.24 0.22 0.21 0.20 0.20 0.18 0.15 0.09 0.07 0.02
50 0.26 0.24 0.19 0.17 0.16 0.16 0.15 0.13 0.10 0.07 0.05 0.02
10 0.23 0.17 0.15 0.13 0.12 0.11 0.11 0.09 0.06 0.04 0.04 0.03
5 0.13 0.11 0.09 0.08 0.07 0.07 0.08 0.06 0.04 0.03 0.03 0.01
1 0.07 0.05 0.04 0.04 0.04 0.03 0.04 0.03 0.02 0.01 0.01 0.02
0.5 0.02 0.02 0.02 0.01 0.02 0.01 0.01 0.00 0.01 0.00 0.01 0.01
0 0.01 0.01 0.02 0.01 0.02 0.01 0.00 0.01 0.00 0.01 0.01 0.00
Table 4.3.1:
The results (shown as Abs620nm) of one of a series of five 
chequerboard ELISAs carried out to optimise the conditions to be used in an 
ELISA for the detection of K562 cells using BF(ab')2- A 96-well plate was 
coated with K562 cells and blocked with BSA. Alkaline phosphatase and 
BF(ab')2 were added simultaneously in the concentrations indicated. The 
lowest concentrations of alkaline phosphatase and BF(ab')2 to consistently 
give a strongly positive result were chosen for future use. In this case, as in 
each of the ELISAs, these were alkaline phosphatase at 100 pig/ml and 
BF(ab')2 at 1 pig/ml.
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AP BF(ab')2 (pig/ml)
jig/m l 50 10 5 1 0.5 0.1 0.05 0.0
500 0.787 ±  
0.139
0.730 + 
0.105
0.721 ±  
0.093
0.646 + 
0.121
0.576 ±  
0.089
0.537 + 
0.098
0.444 + 
0.079
0.036 ±  
0.011
100 0.539 ±  
0.031
0.398 ±  
0.024
0.325 ±  
0.018
0.256 ±  
0.013
0.174 ±  
0.009
0.122 ±  
0.006
0.095 ±  
0.006
0.049 ±  
0.003
50 0.253 ±  
0.011
0.147 ±  
0.008
0.128 ±  
0.007
0.135 ±  
0.007
0.116 ±  
0.005
0.091 ±  
0.005
0.073 ±  
0.004
0.054 ±  
0.002
10 0.101 ±  
0.005
0.096 ±  
0.005
0.089 ±  
0.005
0.075 ±  
0.004
0.081 ±  
0.003
0.069 ±  
0.004
0.058 ±  
0.003
0.055 ±  
0.003
1 0.044 ±  
0.002
0.063 ±  
0.003
0.060 ±  
0.003
0.057 + 
0.003
0.045 + 
0.002
0.038 ±  
0.002
0.034 ±  
0.002
0.039 ±  
0.002
0 0.044 + 
0.003
0.059 + 
0.003
0.039 ±  
0.002
0.063 ±  
0.003
0.060 + 
0.003
0.043 ±  
0.002
0.030 + 
0.001
0.008 ±  
0.001
Table 4.3.2:
The results of one of a series of three suspension ELISAs carried out 
to optimise the conditions to be used in an ELISA for the detection of K562 
cells using BF(ab')2 . A number of 1.8 ml conical centrifuge tubes were 
blocked with BSA. K562 cells were added at a concentration of 10^ cells/m l, 
along with alkaline phosphatase and BF(ab')2 in the concentrations 
indicated. Each combination was carried out in triplicate, the results are 
shown as Abs620nm — standard deviation. The tubes which contained 500 
pig/ml alkaline phosphatase showed erratic colour development due to the 
formation of precipitate in the substrate solution. This assay was repeated 
three times with similar results. The lowest concentrations of alkaline 
phosphatase and BF(ab')2 to give a consistently strong positive result were 
chosen for future use. In this case, as in all three ELISAs, these were 
alkaline phosphatase at 50 pig/111! and BF(ab')2 at 50 pig/ml. The other two 
ELISAs in the series were carried out with K562 at 10  ^ and 10  ^ cells/ml. 
With the former, precipitate formed in the substrate of nearly all the tubes. 
In the latter, low  absorbances were recorded even at the highest 
concentrations of alkaline phosphatase and BF(ab')2 (i.e. Abs620nm of 0.098 
±  0.004).
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4.3.3 Measurement o f BF(ab')2 Activity:
A BF(ab')2 was produced using the methods described, (Sections 3.8.2 
& 3.8.3). The parental Abs were rabbit polyclonal anti-AP Ab and the 
murine, monoclonal anti-CLL Ab (G12) which also binds to the K562 cell 
line. The presence of the BF(ab')2 was determined by HPLC (Section 3.4.2) 
(Fig. 4.3.2), PAGE (Section 3.7) (Fig. 4.3.3) and ELISA. A 96-well plate was 
coated with goat anti-mouse IgG Ab and blocked with BSA (Section 3.6.2). 
After washing, the BF(ab')2 were applied (10 pig/ml), for 1 hr at 37°C. The 
secondary Ab was HRP-labelled anti-rabbit IgG (Section 3.6.3). Colour was 
developed in the plate using the substrate o-PD. Test wells, containing 
BF(ab')2 had a mean Abs405nm of 0.437 ±  0.021 (n=5). This compared well 
with control wells, to which no BF(ab')2 was added, which had a mean 
Abs405nm of 0.084 ±  0.005 (n=5). The BF(ab')2 was purified using two  
affinity chromatography steps (Section 3.3.2). The first column was 
prepared using CNBr-activated Sepharose and anti-rabbit IgG Ab, the 
second using CNBr-activated Sepharose and anti-mouse IgG Ab. The 
purified BF(ab')2 were concentrated by dialysis on a sucrose bed and stored 
at4°C , until their binding activity could be determined.
The specific activity of AP was determined, in order that the amount 
of AP bound to Ab fragment can be estimated. A serial dilution of AP was 
carried out in the range 0-1 m g/m l. To 25 pil of AP solution was added 0.5 
ml of the substrate BCIR 1 m g/m l in amino-methyl-propanol buffer, in 1.8 
ml, conical centrifuge tubes. These were incubated for 30 min at 37° C. The 
Abs620nm was then determined and a graph of Abs620nm vs concentration 
(pig) constructed. The specific activity of the AP was calculated from the 
graph to be 1.868 AU/jxg.
The binding activities of the parental IgG and F(ab')2, the Fab'-B and 
BF(ab')2-B (produced by the method of Brennan et a l, 1985) and the Fab'-G 
and BF(ab')2-G (produced by the method of Glennie et a l, 1987) were 
determined against AP This was carried out in 1.8 ml, conical centrifuge 
tubes. Non-specific binding sites on the plastic were blocked by filling the 
tubes with BSA (1% w /v , in PBS) and storing them at 4°C for a minimum 
of 12 hr before use. A serial dilution of AP was made up in the range 0-1 
m g/m l. Each concentration was dispensed, in 50 jxl aliquots, into twelve 
blocked and washed tubes. To each tube was added 25 pil of a 5 ¡xg/ml 
solution of one of rabbit IgG, F(ab')2/ Fab'-B, Fab'-G, BF(ab')2-B or BF(ab')2- 
G. Each combination (i.e. AP concentration and Ig fragment) was carried 
out in duplicate. The tubes were incubated for 1 hr at 37°C.
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Figure 4.3.2:
The chromatograms produced following HPLC analysis of the 
antibody fragments formed during production of BF(ab')2. The antibodies 
were applied to a Protein Pak 300SW size exclusion column in a sodium  
phosphate buffer (0.1 M, pH 7.4) mobile phase, 0.5 m l/m in, and detected at 
280nm. The samples were: (a) IgG with a retention time (Rt) of 14.8 min. 
(b) F(ab')2 with a Rt of 162 min. (c) Fab1 with a Rt of 18.7 m in  (d) BF(ab')2 
with a Rt of 16.5 min. This would indicate that the BF(ab')2 produced was 
of a similar size to the parental F(ab')2- It will not be exactly the same since 
the BF(ab')2 derives from two separate species of IgG.
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Figure 4.3.3:
A photograph of the gel produced following PAGE analysis of the 
antibody fragments formed during production of BF(ab')2s. The lanes 
contained: (a & g) molecular weight markers, (b) IgG. (c) F(ab')2- (d) 
Fab', (e) BF(ab')2, produced by the method of Brennan et al. (1985). (f) 
BF(ab')2, produced by the method of Glennie et a l (1987). This would  
indicate that the BF(ab')2 produced was of a similar size to the parental 
F(ab')2, it will not be exactly the same since the BF(ab')2 derives from two 
different species of IgG.
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To each tube was added 0.425 ml PBS and 0.5ml ammonium sulphate (100% 
w /v ). The tubes were incubated for 15 min at 4°C and then centrifuged for 
5 min at 10,000 rpm. In control studies, two tubes containing 2 m g/m l AP 
but no Ig were subjected to the same ammonium sulphate precipitation. 
These indicated that this procedure precipitated the Ig fragments and any 
bound AIJ but not free AP The proteins were resuspended in 500 ml BCIP 
(lm g/m l in amino methyl propanol buffer) and incubated for 30 min at 
37°C. The Abs620nm was determined for each solution. The results were 
used to determine the amount of AP bound in each tube. From this the 
amount of AP bound per mole of Ab fragment was calculated (Table 4.3.3). 
The results indicated that 25% of the binding activity of the parental IgG 
was lost following pepsin digestion. The binding activity of the Fab' 
fragments fell to 20-30% of the parental IgG. Some activity was restored on 
formation of the BF(ab')2, returning to 43% of the parental IgG.
The binding activity of the same set of murine Ab fragments was 
determined against the cell line K562. The K562 cells were grown in culture 
in DMEM.S5. These were suspended in PBS and a serial dilution carried 
out to give concentrations in the range 0-10? cells/m l. These were 
dispensed in twelve 50 pil aliquots into BSA blocked 1.8 ml, conical 
centrifuge tubes. To each tube was added 25 pil of a 5 jxg/ml solution of one 
of IgG, F(ab')2, Fab'-B, Fab’-G, BF(ab')2-B or BF(ab')2-G. Each combination 
was carried out in duplicate. The tubes were incubated for 1 hr at 37°C. The 
cells were centrifuged for 5 min at 5,000 rpm, and suspended in PBS before 
being centrifuged again. The cells were resuspended in 200 pil of a solution 
of HRP linked-anti-mouse Fab' Ab, in PBS, for 1 hr at 37°C. The cells were 
centrifuged and washed as before. The cells were resuspended in 500 pil o- 
PD in citrate buffer (pH 4) and incubated at room temperature for 30min. 
The Abs405nm was determined. In an ELISA where the Fab' fragments 
were bound to the wells of a 96-well plate, it was determined that the HRP- 
linked, anti-mouse Fab' Ab resulted in 0.321 AU/pig mouse Fab', while the 
HRP-linked, anti-rabbit Fab' Ab resulted in 0.167 AU/pig rabbit Fab'. This 
information was used to quantify the amount of Ab fragment bound to 10  ^
cells. From this the average number of cells bound per mole of Ab 
fragment was determined (Table 4.3.4). The results indicated that 33% of 
the binding activity of the parental IgG was lost following pepsin digestion. 
The binding activity of the Fab' fell to 25% of the parental IgG. Following 
BF(ab')2 production, binding activity was returned to 94% of that of the 
parental F(ab')2-
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Anti-AP AP
(ng)
AP/Ab
(jxg/pig)
AP/Ab  
(m ol/m ol)
Binding % 
of IgG
Binding %
ofF(ab')2
IgG 0.032 0.256 0.379 100.0 132.5
F(ab')2 0.037 0.296 0.286 75.5 100.0
Fab'-B 0.025 0.200 0.080 21.1 30.0
Fab'-G 0.038 0.304 0.122 32.2 42.7
BF(ab')2-B 0.025 0.200 0.161 42.5 56.3
BF(ab')2-G 0.026 0.204 0.165 43.4 57.5
Table 4.3.3:
The results of an ELISA used to measure the binding activity of the 
Ab fragments against alkaline phosphatase (AP). From the ELISA, the total 
amount of AP (pig) bound by each Ab fragment was calculated. This 
information was used to determine the amount of AP (pig) bound per pig Ab 
fragment. This was converted to a molar ratio. From this the binding 
activity of each Ab fragment was calculated as a percentage of the parental 
IgG and F(ab')2 binding activity. These results show that the BF(ab')2 
retains 43% of the binding activity of the parental IgG and 57% of the 
binding activity of the parental F(ab')2- (Fab'-B= Fab' fragment produced 
using the method of Brennan et ah, 1985; Fab'-G= Fab' fragment produced 
using the method of Glennie et at, 1987.)
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Anti-K562 Ab
(W?)
Ab (pimol/ 
106 cells)
Cells x l0l 2 
/  mol Ab
Binding % 
oflgG
Binding % 
of F(ab')2
IgG 0.588 3.7 0.27 100.0 150.0
F(ab')2 0.547 5.6 0.18 66.6 100.0
Fab'-B 0.572 14.2 0.07 25.9 38.9
Fab'-G 0.559 13.9 0.07 25.9 38.9
BF(ab')2-B 0.461 5.7 0.17 63.0 94.4
BF(ab')2-G 0.479 5.9 0.17 63.0 94.4
Table 4.3.4:
The results of an ELISA used to measure the binding activity of the 
Ab fragments against the leukaemic cell line K562. From the ELISA, the 
total amount of Ab (pig) bound by 10  ^cells was calculated. This information  
was used to determine the amount of Ab (pimol) bound to 10  ^ cells. This 
was converted to number of cells per mole of Ab. From this the binding 
activity of each Ab fragment was calculated as a percentage of the parental 
IgG and F(ab')2 binding activity. These results show that the BF(ab')2 
retains 63% of the binding activity of the parental IgG and 94.4% of the 
binding activity of the parental F(ab')2-
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4.3.4 Assay of Clinical Samples by ELISA:
Two ELISAs, capable of differentiating a leukaemic cell line, K562, 
from non-leukaemic cell lines, i.e. NSO, EJ and NRK, had been developed. 
These assays were further tested to see if they could differentiate normal 
blood from that of leukaemic patients. Samples of venous peripheral blood 
were collected from patients known to be suffering from CLL (samples from 
the Mater Hospital) and from healthy volunteers (ABG, DCU), in 
heparinised blood tubes. The lymphocytes were isolated from thirteen of 
the twenty samples (Section 3.9.1). For a small, random number of samples 
both red and white blood cells were retained. The blood samples were 
coded and stored in liquid nitrogen.
On four different days, blood samples for the same set of patients 
were thawed and assayed by both ELISA protocols. The samples were tested 
in  conjunction with positive controls (K562), negative controls (NSO & 
normal PBL) and a blank (BSA). The results of one days testing are shown  
in detail, along with overall results (Table 4.3.5). Any sample with 
Abs620nm greater than 150% of the negative control samples was taken as a 
positive test result. Using the plate ELISA, seventeen of the twenty samples 
tested were consistently diagnosed as CLL samples. Following four 
repetitions, 84% of known CLL patients tested positive by this assay. Assay 
of isolated PBLs by this method resulted in the positive diagnosis of 84.6% 
of CLL patients. Assay of un-treated blood cells, i.e. red and white cells 
together, by this method resulted in the positive diagnosis of 82.1% of CLL 
patients. Using the suspension ELISA, twenty of the twenty samples tested 
were consistently diagnosed as CLL samples. Following four repetitions, 
92.5% of known CLL patients tested positive by this assay. With the use of 
isolated PBLs the rate of diagnosis was 92.8%, which was not significantly 
different from the overall rate. Similarly, with the use of a mixed 
population of cells the rate of diagnosis, at 92.3%, remained close to the 
overall rate.
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Table 4.3.5:
Sample Cells Plate
ELISA
Positive/ 4 
ELISAs
Susp.
ELISA
Positive/ 4 
ELISAs
Im m uno-
chemistry
K562 - 0.620±0.10 4 0.773 4 ++++ +
NSO - 0.125+0.02 0 0.156 0 +
LC W 0.116+0.03 1 0.147 0 +
BSA - 0.084+0.01 0 0.022 0 -
JoBII w 0.244+0.03 3 0.437 4 ++ +
N H w 0.218±-0.02 3 0.206 3 + +
ToS II w 0.216+0.02 3 0.402 3 + +
ToS w 0.182+0.01 2 0.395 3 + +
PB w 0.206+0.01 4 0.382 4 + +++
M L n w 0.234+0.03 4 0.409 4 + + +
PG w 0.200± 0.02 3 0.418 4 ++ +
JH w 0.228±-0.01 4 0.500 4 ++ + +
MS w 0.208+0.02 4 0.428 4 ++++
EG w 0.202+0.02 3 0.487 3 ++ +
JoB III w 0.244+0.01 4 0.467 4 ++ +
ML IV w 0.212± 0.02 4 0.623 4 ++ +
M oCII w 0.208±0.02 3 0.678 4 + +
PK R/W 0.246±0.02 4 0.544 4 ND
JoB R/W 0.226±0.02 4 0.531 4 ND
MoC R/W 0.110+0.01 3 0.570 4 ND
JoB R/W 0.234±-0.02 4 0.554 4 ND
HH R/W 0.204±0.01 3 0.564 4 ND
HH R/W 0.200± 0.02 2 0.564 3 ND
PmH R/W 0.184±0.02 2 0.726 3 ND
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4.3.5 Immunocytochemistry of Clinical Samples:
Cytospins were prepared from the same blood samples that were 
tested by ELISA (Section 3.9.2). This included CLL samples, K562 cells, NSO 
cells and normal PBL. Some slides were stained with Rapi-Diff stain 
(Section 3.9.2) to ensure structural integrity. The cultured cells appear to be 
more robust than the PBLs (Fig. 4.3.4). The remainder of the slides were 
subjected to immunocytochemical analysis (Section 3.9.3). A clear 
difference in staining intensity exists between the positive and negative 
controls (Fig. 4.3.5). Most of the CLL samples were strongly positive, 9 out 
of 13 graded +++ or higher (Fig. 4.3.6). A few CLL samples were only weakly 
positive (4 out of 13 graded only ++). The intensity of the staining varied 
greatly with CLL samples, in most instances this corresponded to the 
response of each particular sample to the ELISAs (Table 4.3.5).
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Figure 4.3.4:
Cytospin preparations: (a) K562 cells, (b) Lyrriphocytes from a patient 
suffering from CLL. Both slides were stained with Rapi-Diff stain, this 
colours the nucleus purple and the cytoplasm pink Although both slides 
were prepared using the same protocol, K562 cells adhere to the slide in 
higher density, and are less damaged, than the CLL cells.
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Figure 4.3.5:
Cytospin preparations stained using immunochemical techniques. 
Both slides were treated with an anti-CLL X anti alkaline phosphatase BAb 
(50(j,g/ml) and alkaline phosphatase (50pig/ml). Colour was developed in 
the slides using the substrate BCIE (a) K562 cells, positive control, stain 
darkly blue (graded +++++). (b) NSO cells, negative control, do not stain 
(graded +).
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Figure 4.3.6:
Cytospin preparations of peripheral blood lymphocytes from CLL 
patients. Both slides were treated with an anti-CLL X anti-alkaline 
phosphatase BAb (50pig/ml) and alkaline phosphatase (50|xg/ml). Colour 
was developed in the slides using the substrate BCIP. The strong blue 
staining indicates that both samples test positive for CLL. (a) Sample JOB, 
graded +++. (b) Sample EG, graded +++.
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4.3.6 Summary:
The enzyme alkaline phosphase was used to raise polyclonal Abs in a 
rabbit. It has a molecular weight of 100 kDa and a specific activity of 1.868 
AU/pig. An anti-AP X anti-CLL BF(ab')2 was produced and used to optimise 
a plate ELISA for the detection of CLL cells. Best results were achieved 
when AP and BF(ab')2 were added together at concentrations of 100 pig/ml 
AP and 1 pig/ml BF(ab')2, for 1 hr at 37°C. This concentration of BF(ab')2 
was found to be optimum whether the BF(ab')2 was produced by the 
method of Brennan et al. (1985) or Glennie et al. (1987). A suspension 
ELISA was also developed to be carried out in 1.8 ml conical centrifuge 
tubes. Best results were achieved at a K562 concentration of 10^ cells/ml, a 
BF(ab')2 concentration of 50 pig/ml and an AP concentration of 50 pig/ml.
An ELISA was carried out to estimate the binding activity of the 
rabbit anti-AP IgG, F(ab')2, Fab' and BF(ab')2. The results indicated that 25% 
of the binding activity of the parental IgG was lost following pepsin 
digestion. The binding activity of the Fab' fragments fell to 20-30% of the 
parental IgG. Some activity was restored on formation of the BF(ab’)2, 
returning to 43% of the parental IgG. A second ELISA was carried out to 
estimate the binding activity of the mouse anti-CLL IgG, F(ab')2, Fab1 and 
BF(ab')2. The results indicated that 33% of the binding activity of the 
parental IgG was lost following pepsin digestion. The binding activity of 
the Fab' fell to 25% of the parental IgG. Following BF(ab')2 production, 
binding activity was returned to 94% of that of the parental F(ab')2-
The ELISAs and an immunochemical method, which were 
developed using the BF(ab')2, were used to detect CLL cells in patient blood 
samples. 83.75% of known CLL patients tested positive using the plate 
ELISA. Assay of isolated PBLs by this method resulted in the positive 
diagnosis of 84.6% of CLL patients. Assay of un-treated blood cells, i.e. red 
and white cells together, by this method resulted in the positive diagnosis 
of 82.1% of CLL patients. 92.5% of known CLL patients tested positive using 
the suspension ELISA. The use of isolated PBLs did not significantly 
improve this rate of diagnosis, 92.8%. Similarly, the use of un-treated cells 
did not affect the rate of diagnosis, 92.3%. When immuno-chemistry was 
used, the intensity of the staining varied greatly with CLL samples, in most 
instances this reflected the results of the ELISAs.
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4.4 DETECTION OF 7-HYDROXYCOUMARIN USING BISPECIFIC
ANTIBODIES
An ELISA was developed for the detection of a cell line and diseased 
tissue, using a BF(ab')2- The following describes the production of a 
BF(ab')2 using the anti-alkaline phosphatase Ab and a rabbit polyclonal 
anti-7-hydroxy-coumarin (7-OHC) Ab. It was hoped that this BF(ab')2 could 
be used to develop an ELISA for the detection of 7-OHC in solution and in 
clinical samples.
4.4.1 Analysis of BF(ab')2 Production by HPLC:
A BF(ab')2 was produced from two rabbit polyclonal Abs. The first 
was the anti-alkaline phosphatase (AP) Ab, described previously (Section
4.3.1). The second was an anti-7-hydroxycoumarin (70HC) Ab (donated by 
D. Bogan, DCU). This anti-serum had a titre of 1:5,000 when tested by 
competitive ELISA. The anti-AP and anti-70HC Abs were used for the 
production of anti-AP X anti-70HC BF(ab')2 using the methods of Brennan 
et al. (1985) (Section 3.8.2) and Glennie et al. (1987) (Section 3.8.3). HPLC 
analysis was carried out at each stage of BF(ab’)2 production (Fig. 4.4.1). 
Analysis was carried out under the conditions described (Section 3.4.2) 
except that the flow rate used was 0.75 m l/min.
Five proteins, of known molecular weight, were applied to HPLC and 
a standard curve of Log molecular weight vs. Rt produced (Fig. 4.4.2). The 
moleular weights of the standards were back calculated from the equation 
of the line. This indicated that the standard curve estimated the molecular 
weight correct to within 12.6% of the expected molecular weight. The 
molecular weights of the various antibody fragments were also calculated 
from the standard curve (Table 4.4.1). The BF(ab')2 formed was found to be 
similar in size to the parental F(ab')2 fragments. This was confirmed by 
PAGE of the same fragments (Fig. 4.4.3). Using the method of Brennan et 
al. (1985) the BF(ab')2 formed 79% of the total protein present, as measured 
by peak area. Using the method of Glennie et al. (1987) the BF(ab')2 formed 
51% of the total protein present, as measured by peak area. Both the 
BF(ab')2 produced were purified by affinity chromatography. The columns 
were prepared by binding the antigens, AP or 70H C, to CNBr-activated 
sepharose (Section 3.3.1). The relevant BF(ab')2 containing fractions were 
pooled and concentrated in dialysis bags on a bed of sucrose. The BF(ab')2 
were stored at 4°C for future use.
147
10 20
Rt (min)
Figure 4.4.1:
The chromatograms produced following HPLC analysis of the Ab 
fragments produced using the method of Glennie et al. (1987) for the 
production of BF(ab')2. HPLC was carried out on a Protein Pak 300SW 
series column, with 0.1 M sodium phosphate buffer (pH 7.4), at a flow rate 
of 0.75 ml/min.
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Figure 4.4.2:
The standard curve produced by plotting the retention times, from 
HPLC analysis, of proteins of known molecular weight against the log 
molecular weight (r = 0.987). HPLC was carried out on a Protein Pak 300SW 
series column, with 0.1 M sodium phosphate buffer (pH 7.4), at a flow rate 
of 0.75 m l/m in. The proteins elute in order of decreasing molecular 
weight: fi-Amylase, 2x10  ^ Da, Rt = 11.23 min. Alcohol dehydrogenase, 
1.5x10^ Da, Rt = 12.04 min. Albumin, 6.6x10  ^Da, Rt = 14.50 min. Carbonic 
anhydrase, 2.9x104 Da, Rt = 15.68 min. Cytochrome c, 1.24x10^ Da, Rt = 17.07 
min.
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Protein Rt (min) Molecular Weight
Blue Dextran 7.65 ±-0.3 2,000,000
ß-Amylase 11.23 ± 0 .5 200,000
Alcohol Dehydrogenase 12.04 ±  0.4 150,000
A lbum in 14.50 ±  0.2 66,000
Carbonic Anhydrase 15.68 ±  0.3 29,000
Cytochrome C 17.07 ±  0.4 12,400
IgG 12.42 ±  0.3 128,915
F(ab')2 13.78 ±  0.2 68,549
Fab'-SH/ Fab'-mal 14.97 ± 0 .4 39,387
BF(ab')2 13.83 ±  0.3 66,922
Table 4.4.1:
The results of HPLC analysis of standard proteins and antibody 
fragments derived from the production of BF(ab')2s, according to the 
method of Glennie et a l (1987). HPLC was carried out on a Protein Pak 
300SW series column, with 0.1 M sodium phosphate buffer (pH 7.4), at a 
flow rate of 0.75 m l/m in. The Rt of each protein was determined five 
times. A standard curve of Log molecular weight vs. Rt was constructed 
from the proteins of known molecular weight. The molecular weight of 
the antibody fragments was determined from the mean Rt.
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Figure 4.4.3:
A photograph of the gel produced following PAGE analysis of the 
antibody fragments formed during production of BF(ab')2. The lanes 
contained: (a & g) molecular weight markers, (b) IgG. (c) F(ab')2 and Fc'- 
(d) Fab', (e) BF(ab')2, produced by the method of Brennan et al. (1985). (f) 
BF(ab')2, produced by the method of Glennie et al. (1987). This would  
indicate that the BF(ab')2 produced was of a similar size to the parental 
F(ab')2, approximately 70 kDa.
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4.4.2 Measurement of BF(ab')2 Activity:
The IODOGEN reagent has been used to label Ab fragments with 
radioactive iodine prior to their use in BF(ab')2 production (Glennie et a l, 
1987). IODOGEN was used to label the Ab fragments with non-radioactive 
iodine (Section 3.5.3). These were; the anti-70HC IgG, F(ab')2, Fab'-B (from 
the method of Brennan et al., 1985) and Fab'-G (from the method of 
Glennie et al., 1987). The reaction mixtures were dialysed extensively 
against PBS to remove free iodine. The concentration of protein and iodine 
present in these samples was measured using the BCA assay (Section 3.5.1) 
and the Sandell-Kolthoff assay (Section 3.5.4), respectively. From this the 
amount of iodine bound to each Ab fragment was calculated (Table 4.4.2).
BF(ab')2s were produced using the methods of Brennan et al. (1985) 
and Glennie et al. (1987). One set of BF(ab')2s was produced using 
unlabelled anti-AP Fab' and iodine-labelled anti-70HC Fab'. Another set of 
BF(ab')2s was produced using unlabelled anti-70HC Fab' and iodine- 
labelled anti-AP Fab'. These BF(ab')2s, along with the iodine labelled Ab 
fragments, were used to determine approximate affinity values for the IgG, 
F(ab')2, Fab’-B, Fab'-G and BF(ab’)2-
A 96-well plate was coated with 1 pig AP per well and blocked with 
BSA (Section 3.6.2). To each well was applied one of the following; iodine- 
labelled anti-AP IgG, iodine-labelled anti-AP F(ab')2, iodine-labelled anti-AP 
Fab'-B, iodine-labelled anti-AP Fab'-G, BF(ab')2s made by both methods 
from unlabelled anti-AP Fab' and iodine-labelled anti-70HC Fab' (Fig. 
4.4.4b). Each labelled Ab fragment or labelled BF(ab')2 was applied in the 
concentration range 0.001-100 pig/well and each concentration was applied 
to three wells. The amount of iodine bound in each well was measured, 
from a standard curve (Fig. 4.4.5), using the Sandell-Kolthoff assay. The 
quantity of Ab fragment bound to the plate was then calculated (Table 4.4.3).
Since 70H C does not bind strongly to 96-well plates, the second 96- 
well plate was coated with a 10 pig/ml solution of 70HC-BSA conjugate, in 
PBS, per well (donated by D. Bogan, DCU) and blocked with BSA (Section
3.6.2). To each well was applied one of the following; iodine-labelled anti- 
70H C IgG, iodine-labelled anti-70HC F(ab')2, iodine-labelled anti-70HC  
Fab'-B, iodine-labelled anti-70HC Fab'-G, BF(ab')2s made by both methods 
from unlabelled anti-70HC Fab' and iodine-labelled anti-AP Fab' (Fig. 
4.4.4a). Each labelled Ab fragment or labelled BF(ab')2 was applied in the 
concentration range 0.001-100 pig/well. Each concentration of Ab fragment 
was applied to three wells. The amount of iodine bound in each well was 
measured, from a standard curve (Fig. 4.4.5), using a Sandell-Kolthoff assay. 
The quantity of Ab fragment bound to the plate was calculated (Table 4.4.3).
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Sample Protein
(m g/m l)
Iodine
(M-g/ml)
Iodine/Protein  
(M-g/mg)
a-A P IgG 1.01 10.4 10
a-A P  F(ab')2 1.25 9.7 8
a -A P  Fab'-B 1.20 7.2 6
a -A P  Fab'-G 1.29 9.3 7
a -7 0 H C  IgG 1.01 10.1 10
a -7 0 H C  F(ab')2 1.15 9.5 8
a -7 0 H C  Fab'-B 0.74 8.6 12
a -7 0 H C  Fab'-G 0.74 8.2 11
Table 4.4.2:
The BCA assay and Sandell-Kolthoff reaction were used to measure 
the amount of protein and iodine present in each sample. From this the 
level of non-radioactive iodine bound to each Ab fragment following 
iodination using the IODOGEN reagent was calculated, (a = anti-)
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Figure 4.4.4:
An illustration of the ELISA set up to determine approximate affinity 
values for various IgG, F(ab')2, Fab' and BF(ab')2 fragments, (a) The anti-7- 
hydroxy-coumarin antibody was tested in a 96-well plate coated with 7- 
hydroxy-coumarin. To each well was applied one of the antibody fragments 
to be tested, which had been pre-labelled with iodine (I). In the case of the 
BF(ab')2 only the anti-alkaline phosphatase half of the molecule was 
labelled, (b) The anti-alkaline phosphatase antibody was tested in a 96-well 
plate coated with alkaline phosphatase. To each well was applied one of the 
antibody fragments to be tested, which had been pre-labelled with iodine (I). 
In the case of the BF(ab')2 only the anti-7-hydroxy-coumarin half of the 
molecule was labelled. The presence of iodine was detected using the 
Sandell-Kolthoff reaction. (AP = alkaline phosphatase, 7-OHC = 7-hydroxy 
coumarin, I = iodine)
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Figure 4.4.5:
A sample standard curve produced using the Sandell-Kolthoff 
reaction in a micro-assay and a range of KI standards, with a regression 
coefficient (r) of 0.996. From this the amount of iodine-conjugated Ab 
fragment bound to each plate was calculated.
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Sample Iodine
fag)
Ab
(mg)
Ab
(moles)
Ag/Ab  
(m ol/m ol)
a-A P IgG 0.83 0.083 5 x10-1° 2.800
a -A P  F(ab')2 0.71 0.089 12x10-10 1.167
a -A P  Fab'-B 0.88 0.143 36x10-10 0.389
a -A P  Fab’-G 0.85 0.121 31 x 10-10 0.452
BF(ab')2-B 0.41 0.034 8 x10-1° 1.750
BF(ab’)2-G 0.55 0.050 12x10-1° 1.167
a -7 0 H C  IgG 0.50 0.050 3 x 10-1° 4.667
a -7 0 H C  F(ab’)2 0.85 0.106 14x10-1° 1.000
a -7 0 H C  Fab'-B 0.28 0.023 5x10-1° 2.800
a -7 0 H C  Fab'-G 0.33 0.030 7x10-10 2.000
BF(ab')2-B 0.89 0.148 37x10-10 0.378
BF(ab')2-G 0.55 0.078 20x10-1° 0.700
Table 4.4.3:
The results of assays to determine the binding affinity of various Ab 
derivatives for their respective Ags. The plates were coated with a known 
amount of Ag and the Ab fragments allowed to bind. The amount of 
iodine in each well was measured and, hence, the amount of Ab fragment 
bound was calculated. The amount of Ag bound per mole of Ab was 
determined. The results indicate that much of the binding activity is lost 
following the pepsin digestion. Some further activity may be lost following 
reduction to the Fab1 fragment, although this is not always the case, (a = 
anti-; -B = produced by the method fo Brennan et ah, 1985; -G = produced 
by the method of Glennie et al, 1987)
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4.4.3 Development of a Competitive ELISA for 70HC:
A checkerboard ELISA was carried out to determine the optimum  
concentrations of BF(ab')2 and AP required for the detection of 70HC. The 
wells of a 96-well ELISA plate were coated with 70HC-BSA conjugate and 
blocked with BSA (Section 3.6.2). To each column of wells (1-12) was 
applied increasing concentrations of BF(ab')2 in the range 0-2 m g/m l, 50 
^il/well. To each row of wells (A-H) was applied increasing concentrations 
of AP in the range 0-500 ng/m l, 50 ^1/well. (Fig. 4.3.1) These were incubated 
for 2 hr at 37° C. The plate was washed three times in PBS. Colour was 
developed in the wells using the AP substrate BCIP (Section 3.6.3). The 
lowest concentrations of AP and BF(ab')2 to give a strongly positive result 
were chosen for future use. These were AP at 100fxg/ml and BF(ab')2 at 20 
|xg/ml. These concentrations of BF(ab')2 and AP were found to be 
optimum, independent of method of production.
A competitive ELISA was set up to produce a standard curve for 
70HC concentration. The plates were coated with 70HC-BSA conjugate 
and blocked with BSA as before. To the eight wells of each column (1-12) 
was added one of a serial dilution of 70H C, in the range 0-20 n g / ml, 50 ¡xl 
per well. To each well was added 50 jil BF(ab')2, at 20 [xg/ml, and 50 jxl AP, 
at 100 |xg/ml. The plate was then incubated at 37°C for 2 hr or overnight. 
The plates were developed using BCIP as before. This was carried out using 
BF(ab')2 produced by the method of Brennan et al. (1985) (Fig. 4.4.6, a & c) 
and those produced by the method of Glennie et al. (1987) (Fig. 4.4.7, a & c). 
In both cases the ELISA s were repeated five times and, although the 
standard curves produced were straight lines with good regression co­
efficients, the small difference in Abs620nm between top and bottom 
standard (0.033 ±  0.003 AU) prohibited their use in 70H C quantitation.
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Figure 4.4.6:
Standard curves produced following the analysis by competitive 
ELISA of 7-hydroxycoumarin. ELISA plates were coated with 7-OHC-BSA 
conjugate. Standards of 7-OHC were incubated in the presence of BF(ab')2 
produced by the method of Brennan et al. (1985) and alkaline phosphatase 
(a) for 2 hr (r = 0.958) and (c) overnight (r = 0.964). The same standards and 
BF(ab')2 were incubated without AP (b) for 2 hr (r = 0.959) and (d) overnight 
(r = 0.956), AP was subsequently applied for 1 hr. Each concentration of 
7-OHC was measured in quadruplicate.
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Figure 4.4.7:
Standard curves produced following the analysis by competitive 
ELISA of 7-hydroxycoumarin. ELISA plates were coated with 7-OHC-BSA 
conjugate. Standards of 7-OHC were incubated in the presence of BF(ab')2 
produced by the method of Glennie et al. (1987) and alkaline phosphatase 
(a) for 2 hr (r = 0.991) and (c) overnight (r = 0.984). The same standards and 
BF(ab')2 were incubated without AP (b) for 2 hr (r = 0.991) and (d) overnight 
(r = 0.997), AP was subsequently applied for 1 hr. Each concentration of 
7-OHC was measured in quadruplicate.
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The competitive ELISA was repeated, with the exception that the AP 
was left out of the initial incubation. AP was applied as before but after the 
unbound BF(ab')2 and 70H C had been washed out. The plate was 
incubated for a further 1 hr at 37°C. Each ELISA was carried out five times. 
This was carried out using BF(ab')2 produced by the method of Glennie et 
al. (1987) (Fig. 4.4.7, b & d), as before, the small difference in Abs620nm  
between top and bottom standard (0.030 ±  0.004 AU) prohibit their use in 
70H C quantitation. This was also carried out using BF(ab')2 produced by 
the method of Brennan et al. (1985) (Fig. 4.4.6, b & d). In this case, the plate 
which was incubated with BF(ab')2 and 70H C  for 2 hr showed some 
improvement in the top to bottom standard Abs620nm difference (0.100 ±-
0.004 AU). The second plate, which was incubated with BF(ab')2 and 70H C  
overnight and with AP for 1 hr, had the greatest difference in Abs620nm 
between top and bottom standard (0.230 ±- 0.006 AU) and appears to offer the 
best route for development of the desired assay. However, since this 
protocol offers no significant improvement on previous methods, either in 
detection of 7-OHC or speed of the assay, it was not examined further.
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4.4.4 Summary:
An anti-AP X anti-70HC BF(ab')2 was produced as shown by HPLC. 
Using the method of Brennan et al. (1985) the BF(ab')2 formed 79% of the 
total protein present, as measured by peak area. Using the method of 
Glennie et al. (1987) the BF(ab')2 formed 51% of the total protein present. 
IODOGEN was used to label the Ab fragments and the Sandell-Kolthoff 
reaction was used in a micro-assay to assess the binding activity of each of 
the labelled Ab fragments. The results indicate that much of the binding 
activity is lost following the pepsin digestion. Some further activity may be 
lost following reduction to the Fab' fragment, although this is not always 
the case.
In order to develop an ELISA for the detection of 7-OHC, a 
checkerboard ELISA was carried out to find the optimum concentrations of 
AP and BF(ab')2- These were found to be AP at 100 (xg/ml and BF(ab')2 at 20 
[Ag/ml. This concentration of BF(ab')2 was found to be optimum whether 
the BF(ab')2 was produced by the method of Brennan et al. (1985) or Glennie 
et al. (1987). These conditions were used in several competitive ELISAs to 
detect 7-OHC in the concentration range 0-20 ng/m l. The standard curves 
produced were straight lines with good regression co-efficients, the small 
difference in Abs620nm between top and bottom standard (0.033 ±- 0.003 
AU) prohibited their use in 70H C  quantitation. One plate, which was 
incubated with BF(ab')2 and 70H C  overnight and then with AP for 1 hr, 
had the greatest difference in Abs620nm between top and bottom standard 
(0.230 ±  0.006 AU). This protocol was not developed since it offered no 
significant improvement on methods already available.
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Bispecific antibodies (BAb) are antibody-derived molecules capable of 
monovalently binding to two distinct antigens (Fig. 5.1). BAbs use the 
specificity of monoclonal antibodies (MAb) to join together molecules or 
cells to mediate a desired effect. Such molecules can bind enzymes, 
therapeutic agents or radioactive labels to a target without the need for 
chemical modification. MAbs must be chemically conjugated to these 
active agents, a procedure which may alter the affinity and/or activity of 
either the MAb or the active agent. This would indicate that BAbs may 
have several advantages over MAbs in diagnostic and therapeutic 
procedures (Section 1.1.2). In addition to replacing MAb conjugates, the 
unique properties of BAbs suggest the possibility of a range of novel 
immunoassays. These areas have been reviewed recently by a number of 
workers (Reading & Bator, 1988; Songsivilia & Lachmann, 1990; Fanger et 
a l,  1992; Nolan & O'Kennedy, 1992).
Since their inception, a number of methods have been used to 
produce BAbs, with varying degrees of success. BAbs have been created by 
the fusion of Ab-producing cells, by chemical cross-linking of two Abs or by 
molecular genetic approaches. Each of these approaches has its limitations, 
and a major problem in establishing trials with BAbs is the procurement of 
sufficient amounts of clinical-grade material necessary to carry out studies 
in their entirety. The production of hybrid-hybridomas is a time 
consuming and uncertain process, and, once produced, the high nuclear 
content of the cell causes a high level of genetic instability. Yields of BAb by 
this method have been shown to be approximately 34% of total Ig 
production (Wong & Colvin, 1987; Tada et a l, 1989). The BAb must then  
be extracted in a multi-step purification involving dialysis, salt 
precipitation, affinity chromatography and HPLC (Staerz & Bevan, 1986; 
Takahashi & Fuller, 1988; Barr et a l, 1989; Tada et a l, 1989). Chemical BAb 
production methods offer several advantages over biological BAb 
production, primarily, the speed and ease with which they can be carried 
out. The starting material for these procedures is purified IgG of defined 
specificity. Purification of the desired BAb is simplified since only IgG 
fragments are present in a buffered solution compared to hybrid-hybridoma 
products which must be isolated from growth medium or ascitic fluid. 
Most commonly, chemically produced BAbs are bispecific F(ab')2 fragments 
[BF(ab')2] (Brennan et al., 1985; Glennie et a l, 1987), they can thus be 
separated from the larger parental IgG, and smaller Fab' fragments on the 
basis of size.
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Figure 5.1:
A diagramatic representation of a bispecific antibody. Bispecific 
antibodies are antibody-derived molecules capable of monovalently binding  
to two distinct antigens. When produced by hybrid-hybridomas, bispecific 
antibodies are IgG sized molecules, consisting of one light and one heavy 
chain from each parental IgG. When produced chemically, bispecific 
antibodies are F(ab')2 sized molecules, consisting of one light chain and part 
of the heavy chain (the section containing the variable region and hinge 
region) from each parental IgG.
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Yields of BF(ab')2 produced by chemical m ethods have been show n to be 
approximately 60% of total potential yields (Brennan et al., 1985; Glennie et 
a l ,  1987; N itta et a l,  1989). Two protocols for the chemical production of 
BF(ab')2s w ere examined. Of these the m ethod of Brennan et al. (1985) 
appears to offer the advantage of having BF(ab')2 as the sole product, 
compared to the m ethod of Glennie et al. (1987) in which heterodimers 
occur. For this reason the m ethod of Brennan et al. (1985) w as examined 
initially.
Large quantities of a m urine IgG, G12, w ere purified from  ascitic fluid 
and used, in  conjunction w ith hum an IgG (Sigma), for the production of a 
BAb. Precipitation of the Ig using am m onium  sulphate is a quick and easy 
method of extracting Ig from  solution (Section 3.2.2). However, the level of 
purity  achieved by this m ethod w as insufficient and further purification 
steps w ere necessary (Section 4.1.1). From the studies on IgG purification, it 
w ould appear that the Affi-T colum n produces the greater yield of IgG, but 
the Protein A colum n has a greater capacity to bind IgG. Thus, fewer 
column runs are necessary w ith  the Protein A column and losses are 
reduced. In  light of the relatively large quantities of IgG required to produce 
BF(ab')2s, purifications w ere carried out using the Protein A column. The 
purified IgG w as subject to a pepsin digestion to produce an F(ab')2 
fragment. The m ethod of Brennan et al. (1985) was chosen since it used 
gentler conditions and  gave a m ore complete digestion than  the method of 
Runge et al. (1990) (Section 4.1.2). The F(ab')2 fragm ents w ere reduced to 
the Fab' fragm ent and conjugated to dTNB to prevent intrachain 
disulphide bond form ation, (Fig. 5.2). The successful conjugation of dTNB 
was show n using spectrophotom etric analysis, as w as the removal of dTNB 
from  the hum an IgG molecules (Section 4.1.3) (Fig. 5.3).
The m urine Fab'-TNB and the hum an Fab'-SH were allowed to re­
associate according to the m ethod of Brennan et al. (1985). The recom binant 
molecule produced form ed less than  10% of the total protein present in 
solution, as m easured by HPLC (Section 4.1.4). This yield was im proved by 
the addition of an  oxidising agent, such as hydrogen peroxide, although  this 
also increases the risk  of hom ologous pairing of Fab' fragments. For this 
reason, an ELISA w as carried out to determ ine which, of several, 
concentrations of H 2O2  w ould m axim ise BF(ab')2 production while 
m inimising the am ount of H 2O2 required. The addition of 0.5% (w /v) 
H 2O2 was found to increase the yield of BF(ab')2 to 60% of total potential 
yield, as m easured b y  HPLC (Section 4.1.4) (Fig. 5.3).
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Preparation of Blspeclflc Antibodies (I)
IgG In 0.1 M Sodium Acetate, pH 4.5
Pepsin overnight 0  37 °C
Fiab^ In 1 mM Phosphate buffer
2-Mercaptoethylamlne, 1mM 
Sodium Arsenite, 10mM 
EDTA, 1mM 
overnight G 25°C
Ellmans Reagent, 5mM 
3hrs 9  25V
Stable Fab1 - NB In 1 mM Phosphate buffer
Figure 5.2:
A n illustration of the first part of the production protocol for 
bispecific antibodies, which was adapted from the m ethod of Brennan et al. 
(1985). The conditions given are those optimised for use in our laboratory.
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Preparation of Bispecific Antibodies (II)
Fab a - NB In 1mM Phosphate buffer
2-Mercaptoethylamine, 10mM 
Sodium Arsenfte, 10mM 
EDTA, 1mM 
30min G 25° C
Stable Fab a  - SH in 1 mM Phosphate buffer
- S  NB 
• S - N B  
■ S • NB
Fab'e - NB in 1 mM Phosphate buffer
EDTA, 1mM
Hydrogen Peroxide, 0.5% 
overnight 0  37 °C
Bispedfic Antibody
Figure 5.3:
A n illustration of the second part of the production protocol for 
bispecific antibodies, w hich was adapted from the m ethod of Brennan et al. 
(1985). The conditions given are those optimised for use in our laboratory.
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The HPLC analysis also indicated that the molecule formed is twice the 
weight of a Fab' fragm ent, bu t slightly low er than  that of the original F(ab')2 
fragment. This m ay occur for tw o distinct reasons. Firstly, the species 
differences in  parental IgG m ean that any recom binant F(ab')2 cannot equal 
either of the parental molecules in size. Secondly, the m ethod of analysis 
used produced a standard curve which estim ated molecular w eight correct 
to w ithin 10% of actual molecular weight. Thus, the accuracy of molecular 
w eight prediction by  this m ethod is reduced at very  high molecular 
weights. In addition, proteins of the same molecular weight, bu t w ith 
different 3-dimensional structure, will differ som ew hat in retention time 
on the Protein Pak 300SW column. W hen these factors are taken into 
consideration, the recom binant F(ab')2 produced falls well w ithin the size 
param eters of a F(ab')2 fragm ent. This w as confirmed by  electrophoretic 
analysis of the various Ig fragm ents produced (Section 4.1.4). The results of 
the ELISA indicate that the ’F(ab')2-sized' molecule, produced in this 
procedure, w as form ed by  linking a hum an Fab' fragm ent to a m urine Fab' 
fragment, ie. it is a BF(ab')2 fragment.
It had been suggested that BF(ab')2 showed no loss of activity 
compared to the parental IgG (Glennie et a l, 1987). This was tested by the 
production of a functional BF(ab')2. A HRP-BSA conjugate was produced, 
as show n by HPLC and double affinity chrom atography (Section 4.2.1). An 
anti-BSA X anti-K562 BF(ab')2 w as successfully produced, as show n by HPLC 
and ELISA (Section 4.2.2). A series of ELISAs w ere used to show that bo th  
the Fab' fragments, used in  the production of the BF(ab')2, m aintained the 
binding activity and specificity of the parental IgG, although some of the 
affinity is lost. In  a comparative test, the affinity of the anti-K562 Fab' 
appeared to fall by  70% com pared to parental IgG, while that of the anti-BSA 
Fab' fell by approximately 50%. M uch of this affinity was lost as a result of 
the pepsin digestion (Section 4.2.3), an  indication of the importance of the 
Fc' fragm ent in stabilising the IgG molecule. The BF(ab')2 was used 
successfully in a one-step enzyme im m unoassay for K562 cells which 
served as a model system  for later trials.
Two further BAbs w ere produced and  used to study the applicability 
of BAbs to enzym e im m unoassay and immunochemical studies. A 
num ber of novel approaches have been suggested (Paulus, 1985; Gorog et 
a l ,  1989). However, the m ain advantage of BAbs, at the moment, is in the 
im provem ent of conventional systems. Primarily, the sim ultaneous 
addition of reagents to an assay reduces the time required for the assay, 
while increasing the reproducibility (Suresh et al., 1986; Gorog et al, 1989; 
Tada et a l,  1989; Bugari et a l,  1990; Stratieva-Taneeva et al, 1993). This
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concept was pu t to the test. The enzyme alkaline phosphase (AP) was used 
to raise polyclonal Ab in a rabbit. The serum  had an anti-AP titre of 1 in 
10,000 (Section 4.3.1). AP has a molecular w eight of 100 kDa and a specific 
activity of 1.868 A U /ng. An anti-AP X anti-CLL BF(ab')2 was produced and 
used to optimise a microtitre-plate, based ELISA for the detection of CLL 
cells. Best results w ere achieved w hen AP and BF(ab')2 w ere added together 
at concentrations of 100 ¡xg/ml AP and 1 [xg/ml BF(ab')2, for 1 h r at 37°C. 
These concentrations of BF(ab')2 and AP w ere found to be optim um  and 
independent of the m ethod of production of the BF(ab')2 (Section 4.3.2). A 
suspension ELISA w as developed in  1.8 ml conical centrifuge tubes. These 
ELISAs are faster than plate ELISAs, since the cells do not have to be 
adsorbed onto PVC plates. Thus, the entire sample is analysed and not just 
those cells that 'stick' well to PVC. Their accuracy and usefulness in the 
detection of CLL w as tested here. Best results w ere achieved at a K562 
concentration of 10^ cells/m l, a BF(ab')2 concentration of 50 |xg/m l and an 
AP concentration of 50 n g /m l (Section 4.3.2). Again these concentrations of 
BF(ab')2 and AP w ere found to be optimal and independent of the method 
of production of the BF(ab')2- For both  the plate ELISA and the suspension 
ELISA the concentration of AR in particular, and BF(ab')2 were som ew hat 
higher than desirable. However, since fairly small volum es of those 
particular reagents are used in  the assays, these high concentrations were 
tolerated.
ELISAs using BAbs, that have been developed and reported, have 
used enzyme and BAb concentrations in the range 1-10 Mg/ml (Gorog et al, 
1989; Tada et al., 1989; Stratieva-Taneeva et a l,  1993). Each of these was for 
the detection of a soluble, rather than  a m em brane-bound, protein Ag (i.e. 
CEA, lymphotoxin and 11-2, respectively). Standard curves w ere produced 
using pure analyte-Ag to coat the 96-well plate. Thus, a known, high 
quantity  of analyte-Ag is available for b inding to the BAb, and low 
concentrations of BAb and developing enzyme will be sufficient to detect 
the presence of analyte-Ag. W hen the analyte-Ag is m em brane-bound the 
entire cell m ust be adsorded onto the 96-well plate. Levels of expression oi: 
the analyte-Ag on the cell surface will vary  greatly and the surface of the 
wells of the plate will be coated w ith  large am ounts of membrane lipo­
proteins and non-antigenic m em brane proteins as well as the analyte-Ag. 
W ith the relatively small am ounts of analyte-Ag available for binding, 
larger quantities of BAb and developing enzyme are required for the 
detection of the analyte-Ag. There are no reports available w ith evidence of 
ELISAs, using BAbs, directed against cells or m em brane-bound Ags. Thus,
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there is no basis of comparison w ith  w hich to determ ine the efficiency of 
the conditions used here.
An ELISA was carried ou t to estimate the binding activity of the 
rabbit anti-AP IgG, F(ab')2, Fab1 and BF(ab')2. The results indicated that 25% 
of the binding activity of the parental IgG was lost following pepsin 
digestion. The binding activity of the Fab' fragm ents fell to 20-30% of the 
parental IgG. Some activity w as restored on form ation of the BF(ab')2, 
returning to 43% of the parental IgG (56% of the parental F(ab')2). A second 
ELISA was carried out to estimate the binding activity of the mouse anti- 
CLLIgG, F(ab')2/ Fab' and BF(ab')2 The results indicated that 33% of the 
binding activity of the parental IgG w as lost following pepsin digestion. 
The binding activity of the Fab' fell to 25% of the parental IgG. Following 
BF(ab')2 production, binding activity was retu rned  to 63% of the parental 
IgG (94% of the parental F(ab')2). These alterations in  binding activity are 
independent of m ethod of production of BF(ab')2 used. The loss of activity 
appears to be greater for the rabbit, polyclonal, anti-AP Ab than for the 
mouse, monoclonal, anti-K562 Ab. This appears to contradict the earlier 
test, in w hich the same m urine, anti-K562 Ab lost m ore of its binding 
activity than the rabbit, anti-BSA Ab. This w ould seem to indicate that 
effects on binding activity depend on the combination of parental Abs used, 
rather than on the m ethod of production of the BF(ab')2- This makes it 
difficult to predict, in  advance, the probable efficiency of a BF(ab')2-
It is interesting to note the effects of the manipulations involved in  
BAb production have on the various Ab fragm ents produced. The reduced 
activity of the F(ab')2, com pared to the whole molecule, emphasises the 
stabilising role of the Fc1 portion w ithin the IgG molecule. The activity of 
the Fab' was less than  half that of the parental F(ab')2- This was, in part, 
expected since the Fab' molecule has only one Ag-binding site compared to 
tw o on the F(ab')2 molecule. The recovery of this activity on form ation of 
the BF(ab')2 molecule w as not anticipated, although it w as duplicated w ith 
BF(ab')2 produced later in  this project, and w ith  BAbs produced by o ther 
w orkers in  this laboratory (Quinlan, 1994). It is possible that this is due to 
the conformational changes w hich occur w hen  the two Fao' fragments are 
bound together. The fact that recovery of activity is incomplete, i.e. the 
activity of the BF(ab')2 does not equal that of the parental F(ab')2, is probably 
due to the added strains placed on the molecules w hen Fab' from  tw o 
different species are joined together.
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The ELISAs and an im m unochem ical m ethod, which were 
developed using the BF(ab')2, w ere used to detect CLL cells in  patient blood 
samples. 83.75% of know n CLL patients tested positive using the plate 
ELISA (Section 4.3.4). Assay of isolated PBLs by this m ethod resulted in the 
positive diagnosis of 84.6% of CLL patients. Assay of untreated blood cells, 
i.e. red and white cells together, b y  this m ethod resulted in the positive 
diagnosis of 82.1% of CLL patients. 92.5% of know n CLL patients tested 
positive using the suspension ELISA (Section 4.3.4). The use of isolated 
PBLs did not significantly im prove this rate of diagnosis, (92.8%). Similarly, 
the use of untreated cells did not affect the rate of diagnosis, (92.3%). It was 
thought that use of isolated PBLs w ould concentrate the the num ber of Ag 
positive cells and, hence, am plify the signal, compared to a mixed 
population of red and w hite blood cells. This w as show n not to be the case. 
Cell counts w ere carried out prior to each ELISA. Since these were counts of 
PBL population, rather than total cell counts, the same num ber of PBL were 
present in  the assay w hether the PBL are isolated or not. Since the G12 Ab 
does not bind to red blood cells, their presence does not interfere w ith the 
assay, or the results obtained. Thus, there was no significant difference in 
the rate of diagnosis of CLL w hen isolated PBLs w ere used, compared to 
w hen a mixed population of red and white blood cells w ere used.
An im m uno-chemical m ethod w as developed, in which the BF(ab')2 
and AP w ere applied sim ultaneously to a cytospin preparation of K562 cells 
or isolated lymphocytes (Section 3.9.3). W hen this was used, the intensity 
of the staining varied greatly w ith  CLL samples; in most instances th is 
corresponded to the response of each particular sample to the ELISAs 
(Section 4.3.5). This w ould indicate that the intensity of the staining is a 
function of the binding activity of the G12 part of the BF(ab')2- This m ay be 
related to expression of Ag on the cell surface, which can alter w ith 
progression of the disease and treatm ent regimen. This information was 
not available and correlations could not be m ade for the blood samples 
tested. All the slides were m ade w ith isolated PBL from the same patients 
assayed in  the ELISAs. Of those samples examined, 9 out of 13 (69%) gave a 
strongly positive diagnosis, while 4 out of 13 (30%) gave a weakly positive 
diagnosis. All these slides show ed a definite positive reaction compared to 
controls (normal PBL).
The rates of diagnosis achieved w ith the ELISAs and  im m uno­
chemical m ethod are consistent w ith  incidence of the disease. About 90- 
95% of persons w ith CLL have the m ature B-cell type, the rem ainder have 
T-cell, hairy cell or other less well defined types of leukaemia (Finch & 
Linet, 1992). CLL B-cells express a 69 kDa glycoprotein not expressed on
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norm al or other leukaemic blood cells. It is thought that this glycoprotein 
m ay be the Ag for the G12 Ab (Lannon et a l,  1988; Dighiero et a l, 1991). 
Thus, assays for CLL based on binding w ith G12, or G12 derived BF(ab')2s/ 
will positively diagnose a m axim um  of 95% of patients. In addition to a 
symptomatic approach, diagnosis of CLL w ould norm ally involve detailed 
histopathological examination, including identification of the following: 
sustained lymphocytosis, lymphocytes w ith  atypical m orphology, 
chromosomal abnormality, surface m em brane Ig and other cell surface 
m arkers (Dighiero et al., 1991; Finch & Linet, 1992). The assays developed 
here are quicker and require less expertise than  traditional h istopathological 
techniques. They will require more strenuous testing, against larger 
num bers of fresh clinical samples, before their true value can be accurately 
predicted. It is proposed that these tests could then form part of a battery of 
tests to determine the diagnosis and progress of the disease.
A second BAb was produced in order to develop an assay for the 
drug, 7-hydroxycoumarin (7-OHC). A rabbit anti-AP X anti-70H C BF(ab')2 
w as produced as show n by HPLC. Using the m ethod of Brennan et al. 
(1985) the BF(ab')2 form ed 79% of the total protein present, as m easured by 
peak area. Using the m ethod of Glennie et al. (1987) the BF(ab')2 formed 
51% of the total protein present, as m easured by peak area. (Section 4.4.1) 
The high yields in the form er m ethod make it the m ethod of choice in this 
instance. They are a clear indication that using parental IgG from the same 
species improves Fab'-Fab' re-association, and, hence, overall yields. The 
HPLC m ethod used in this analysis w as changed slightly from that used 
previously. The flow rate of the mobile phase was increased in an attempt 
to sharpen the peaks and speed up analysis times. The retention times of 
the Ab fragm ents were shortened, bu t the chrom atography was not 
significantly im proved. The standard curve of molecular weight vs. 
retention time estim ated molecular weight correct to w ithin 12.6% of the 
actual molecular weight. This represented a decrease in accuracy compared 
to the earlier method.
IODOGEN was used to label the Ab fragm ents (Glennie et al, 1987) 
and the Sandell-Kolthoff reaction was used in  a micro-assay to assess the 
binding activity of each of the labelled Ab fragments (O'Kennedy et a l, 
1989). The results indicate that m uch of the binding activity is lost 
following the pepsin digestion. Activity m ay fall by  as m uch as 60% 
compared to parental IgG (Section 4.4.2). Some further activity m ay be lost 
following reduction to the Fab1 fragment. In the case of the anti-AP Ab, the 
activity of the Fab1 fell sharply compared to the parental IgG. Most of this 
w as recovered on form ation of the BF(ab')2, w hich had the same activity as
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the parental F(ab')2. This same pattern, of loss and recovery of activity, 
occurs w ith  all previous BF(ab')2 molecules. A different pattern  occurs 
w ith  the anti-7-OHC Ab. In  this case, activity is lost following form ation of 
the BF(ab')2 w hen com pared to IgG, F(ab')2 or Fab1. This m ay indicate that 
the anti-7-OHC Ab is not as stable as those used previously and  m ay not be 
entirely suitable for the types of m anipulations necessary in BF(ab)2 
p roduction .
In order to develop an ELISA for the detection of 7-GHC, a 
checkerboard ELISA w as carried out to find the optim um  concentrations of 
AP and BF(ab')2 (Section 4.4.3). These w ere found to be AP at 100 ;ag/m l 
and BF(ab')2 at 20 ng /m l. These concentrations, of BF(ab')2 and AT} were 
found to be optim um , independent of the m ethod of production of 
BF(ab')2. These conditions w ere used in several competitive ELISAs to 
detect 7-OHC in  the concentration range 0-20 jxg/ml. This w as chosen as it 
is the range of m ost clinical significance. The standard curves produced 
w ere straight lines w ith  good regression co-efficients. How ever, the small 
difference in  Abs620nm  betw een top and bottom  standard (0.033 ±  0.003 
AU) prohibited their use in 70H C  quantitation. One plate, which was 
incubated w ith  BF(ab')2 and 70H C  overnight and then w ith AP for 1 hr, 
had the greatest difference in A bs620nm  betw een top and bottom  standard 
(0.230 ±- 0.006 AU) and appears to offer the best route for developm ent of the 
desired assay. The am ount of AP or BF(ab')2 applied to the plate could be 
increased to im prove the signal. An amplification system could be used, 
e.g. a tri-specific Ab w hich binds tw o AP for every 7-OHC. The most likely 
route for im proving the assay, however, is to use a more suitable parental 
anti-7-OHC Ab. The Ab that w as used had a high level of specificity, but a 
low titre (1:5,000) com pared to the parental anti-AP Ab (1:100,000; and poor 
stability. The ELISA that was developed, using these anti-7-CHC and antl- 
AP Abs, for the detection of 7-OHC does not represent an improvement on 
detection techniques already available. It is neither as fast nor as acciuare as 
conventional competitive ELISA or HPLC m ethods. These methods have 
been used to analyse large num bers of samples in  the space of a day and are 
accurate in  the concentration range 5-100 |xg/m l (Egan, 199S). The assay 
developed using BF(ab')2 required overnight incubation and was useful in 
the narrow er concentration range of 0-20 n g /m l only (Section 4.4.3).
Overall, the results of these studies indicate that BAbs can be 
extremely useful in  developm ent of immunoassays. They can greatly 
increase the speed w ith  which the assays are carried out without, any gre.jc 
loss of detection. This is, how ever entirely dependent on the parental IgG 
used. Some species of IgG m ay not be stable enough to withstand the
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various reduction steps, resulting in  loss of activity. This is possibly due to 
loss of the light chain, since in m ost cases the BF(ab')2 w as som ew hat 
lighter than the parental F(ab')2. A num ber of polyclonal Abs w ere used for 
tw o m ain reasons. Firstly, they are m ore easily produced than MAbs. 
Secondly, it is possible that the application of a num ber of Abs, with 
specificity for m ore than one epitope on the target Ag, m ay act in synergy co 
im prove both  the specificity and the signal to noise ratio of the assay. 
Polyclonal Abs contain large quantities of Abs, specific to several epitopes 
on the one Ag. Parental IgG from  the same species will result in higher 
yields of BAb and, w ith  less strain placed on the reform ed molecule, should 
be more stable and of higher activity than those produced using IgG from 
different species. ELISAs and other novel im m unoassays m ay be im proved 
by the use of in-built amplification systems, such as the use of tri-speciiic 
Abs.
BAbs can be produced in high yield and purity  w ith relative ease 
using the m ethods described. It is probable that, in  the future, genetic 
m anipulations will take over as a m eans for producing BAbs. A lthough 
currently yields are low by  these m ethods, techniques are im proving all the 
time. Such "designer" molecules offer m any potential im provem ents over 
w hat is currently available, particularly in the field of immuno- 
therapeutics.
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